

BMJ Open

Multi-institution Case-control and Cohort Study of Risk Factors for the Development and Mortality of Clostridium difficile Infections in Japan

Journal:	BMJ Open
Manuscript ID:	bmjopen-2014-005665
Article Type:	Research
Date Submitted by the Author:	09-May-2014
Complete List of Authors:	Takahashi, Masahiko; NHO Tokyo Medical Center, Mori, Nobuaki; National Hospital Organization Tokyo Medical Center, General internal medicine Bito, Seiji; National Hospital Organization Tokyo Medical Center, General internal medicine
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Epidemiology
Keywords:	Gastrointestinal infections < GASTROENTEROLOGY, Epidemiology < INFECTIOUS DISEASES, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

Title

Multi-institution Case-control and Cohort Study of Risk Factors for the Development and Mortality of *Clostridium difficile* Infections in Japan

Corresponding author

Masahiko Takahashi

Chief Director, Department of Gastroenterology

National Hospital Organization Tokyo Medical Center

2-5-1 Higashigaoka, Meguro-Ku, Tokyo 152-8902, Japan

Phone number: +81-3-3411-0111

Fax number: +81-3-3412-9811

matakaha@ntmc.hosp.go.jp

Authors

Masahiko Takahashi ^{1*}, Nobuaki Mori ², Seiji Bito ³.

Author Affiliations

- ¹ Chief Director of Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
- ² Medical staff of Department of General internal medicine and Infectious diseases physician, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
- ³ Chief Director of Department of General internal medicine and epidemiologist, National Hospital Organization Tokyo

Medical Center, Tokyo, Japan

For peer review only

1 Abstract

2
3
4 **Objective:** To examine risk factors for *Clostridium difficile* infection (CDI) morbidity and mortality in Japan.

5
6
7 **Design:** Multi-method investigation including a case-control study and cohort study.

8
9
10 **Setting:** Forty-seven participating facilities of the National Hospital Organization (NHO).

11
12
13 **Participants:** One thousand twenty six CDI patients and 878 patients in control group over the age of 18 years admitted to
14
15 the subject NHO facilities from November 2010 to October 2011.

16
17
18 **Main Outcome Measures:** In case-control study, we identify risk factors for CDI development. Next, in cohort study, we
19
20 identify risk factors for all-cause mortality within 30 days following CDI onset.

21
22
23 **Results:** A total of 1,026 cases of CDI meeting the definitions of this investigation were identified, encompassing 878 patients
24
25 at 42 of the 47 subject facilities. In the case-control study, we identified, compared with no antibiotics use, use of first- and
26
27 second-generation cephem antibiotics (odds ratio[OR], 1.44; 95% confidence interval [CI], 1.10 to 1.87), use of third- and
28
29 fourth-generation cephem antibiotics(OR, 1.86; 95%CI, 1.48 to 2.33), and use of carbapenem antibiotics (OR, 1.87; 95%CI,
30
31 1.44 to 2.42) were risk factors for CDI development. However, use of penicillin was not identified as risk factors. In the
32
33 cohort study, sufficient data for analysis was available for 924 CDI cases; 102 of them (11.0%) resulted in death within 30
34
35 days of CDI onset. Compared with no anti-CDI drug use, use of vancomycin was associated with reduced risk of mortality
36
37 (OR, 0.43; 95%CI, 0.25 to 0.75) whereas metronidazole was not.

38
39
40 **Conclusions:** The findings mirror those of previous studies from Europe and North America, identifying the administration of
41
42 broad-spectrum antibiotics as a risk factor for CDI development. The use of vancomycin is associated with a decreased risk of
43
44 mortality.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This study is the first large-scale nationwide multi-center CDI investigation in Japan.
- Most of the epidemiological data of CDI has been limited in the North America and Europe. Our data plays a role of completion of the missing data in Asia.
- Use of β -lactam antibiotics except penicillin was the risk factor for CDI development in the first Japanese large-scale investigation. Appropriate antibiotic use is necessary in order to control the incidence of CDI.
- Vancomycin administration for CDI was associated with decreased risk of mortality. Although the cost-effective treatment of CDI may necessitate the appropriate use of less-expensive metronidazole, vancomycin should be administered in case expected to become severe or life-threatening.
- The most salient limitation of the case-control study phase is the existence of many confounding factors. In particular, probiotic use, which was recently shown to be correlated with CDI prevention, was not included in the predictive model of this study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Clostridium difficile is the main causative pathogen of antibiotic-associated colitis. Since 2000, outbreaks of BI/NAP1/027 strain *C. difficile* infections (CDI) have been reported in North American and European hospitals and elder care facilities. The numbers of CDI patients as well as severe and intractable cases have increased simultaneously. Consequently, epidemiological surveillance systems have been set up in several countries. However, very few countries have implemented such national-level measures.

In Japan, the Ministry of Health, Welfare, and Labor’s Japan Nosocomial Infection Surveillance program investigates the incidence rates of a variety of drug-resistant bacteria; however, this program does not monitor the incidence rate of *C. difficile* (<http://www.nih-janis.jp/index.asp>). Therefore, CDI epidemiological studies in Japan to date have been based on scattered data from individual medical facilities. Consequently, the phenomenon of CDI in Japan is not sufficiently understood. Reports of BI/NAP1/027 infections are limited, and conditions in Japan possibly differ from those in Europe and North America.

Previous studies report that antibiotic administration is the largest risk factor for CDI development. Other risk factors include advanced age and proton pump inhibitor use.[1, 2] CDI mortality rates differ depending on the presence or absence of an outbreak as well as the relevant definitions of epidemiological surveillance. Furthermore, it is especially difficult to objectively determine precise CDI-related mortality rates because of factors such as underlying patient conditions.[3]

This report documents a case–control study of CDI in Japan based on data from the National Hospital Organization (NHO), which is Japan’s largest group of hospitals and includes facilities located nationwide. In addition, a cohort investigation of mortality among CDI cases was conducted.

Materials and Methods

Research Design

This multicenter study is a collaborative effort of the 47 facilities that met our facility standards from among the 143 NHO facilities in Japan. The study was planned as a part of the NHO's "National Hospital Organization Multi-Center Clinical Research for Evidence-Based Medicine" project. This study was conducted with the approval of the Central Ethics Committee of the NHO. The CDI group in this study included in principal all newly diagnosed CDI cases among patients hospitalized from November 1, 2010 to October 31, 2011; cases were registered continuously.

In the case-control study of CDI development, CDI cases newly diagnosed during the investigation period were registered in the CDI group; meanwhile, age-, sex-, and underlying disease-matched patients in the same facilities were registered to the control group. In addition, a prospective cohort study of CDI group patients who died within 30 days of CDI development was conducted. This investigation is a multi-method study using standard case-control and cohort study designs.

Definition of CDI

CDI was defined as the presence of any gastrointestinal symptoms accompanied by a clinical suspicion of CDI as well as a positive result for *C. difficile* toxins from rapid stool testing or *C. difficile* isolation from stool cultures or both. Final determinations were made by the attending physician or the facility's infection control team.

Enzyme immunoassay testing kits for *C. difficile* toxins A and B were used as the rapid testing method (Immunocard CD toxin A&B, Meridian Bioscience Inc., Cincinnati, OH, USA; C. Diff Quik Chek, Alere Medical Co. Ltd., Tokyo, Japan; Tox A/B Quik Chek, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan; X/pect Toxin A/B, Kanto Chemical Co Ltd., Tokyo, Japan). Cycloserine-cefoxitin mannitol agar (Nissui-pure-to CCMA baichi EX, Nissui Pharmaceutical Co. Ltd., Tokyo, Japan), cycloserine-cefoxitin fructose agar (CCFA baichi, Becton, Dickinson and Company Co. Ltd., Tokyo, Japan; Poamedhia[®] CCFA[®] kairyoubaiichi, Eiken Chemical Co., Ltd., Tokyo, Japan), and brucella HK agar (RS) (brucella HK agar (RS), Kyokuto Pharmaceutical Industrial Co. Ltd., Tokyo, Japan) were used in the *C. difficile* isolation cultures.

1 **Case–Control Study of CDI Development**

2
3
4 No additional information besides age, sex, and date of diagnosis was gathered when new patients were registered in the
5
6
7 CDI group. After the end of the study registration period, additional patient clinical data were gathered, including clinical
8
9
10 department, underlying diseases, dates of hospital admittance and discharge, and medical treatments administered for ≥ 3
11
12
13 days between admittance and CDI development. Recorded treatments included disruption of feeding, parenteral nutrition,
14
15 enteral feeding, surgery with general anesthetic, cancer drugs, antibiotics (excluding external-use antibiotics), proton pump
16
17 inhibitors (oral or intravenous). We also collected data regarding the use of intravenous antibiotics including penicillins,
18
19 first- and second-generation cepheems, third- and fourth-generation cepheems, carbapenems, fluoroquinolones,
20
21 clindamycin/lincomycin, anti–Methicillin-resistant *Staphylococcus aureus* (MRSA) drugs, and anti-fungal drugs, and others.
22
23
24 Finally, we collected data regarding the use of oral antibiotics including cepheems, fluoroquinolones, and others.
25
26
27

28
29
30 The control group was divided into three subgroups according to age: ≤ 74 , 75–84, and ≥ 85 years. The control patients
31
32 were selected from among patients at the same facilities who did not contract CDI and were matched to the CDI patients
33
34 with respect to age, sex, underlying disease, and hospital stays of ≥ 5 days within the same month as a counterpart’s CDI
35
36 diagnosis. We strove to ensure that the CDI and control groups were as matched as possible. The same data were collected
37
38 from both groups. The control patients were registered, and relevant patient data were gathered after the end of the CDI
39
40 group study registration period.
41
42
43

44
45
46
47 **Cohort Study on Mortality among CDI Patients**

48
49
50 The prospective cohort study of registered CDI group patients from the case–control study examined all-cause mortality
51
52 within 30 days as the primary outcome. The following data were collected: whether the underlying disease was infectious
53
54 and whether comorbidities were related to malignant tumors (i.e., gastrointestinal, respiratory, blood/lymph, gynecologic,
55
56 urological, or other tumors including cancers of the ear, nose, and throat), diabetes, renal failure, heart failure, respiratory
57
58
59
60

failure, or cirrhosis. We also considered patient nutritional status including whether the patient was subjected to parenteral nutrition or enteral feeding as well as serum albumin levels measured within 30 days prior to CDI development (i.e., ≥ 3.5 , 2.7–3.4, or ≤ 2.6 g/dL). In addition, we examined CDI treatment factors including whether antibiotic use was halted, probiotic use, and the type of anti-CDI drugs used (i.e., vancomycin and metronidazole). All patient data for the cohort investigation were collected after the end of the registration period.

Data Management and Statistical Analysis

The study coordinator established independent data management centers within the NHO facilities for data collection. All input data were verified by a designated study data manager. Data from each facility were entered directly into a web-based case report form and subsequently encrypted for security. The data management center was responsible for confirming any missing data and directly inquiring the relevant facilities as necessary. After the end of the study period, the data were finalized and subsequently transferred to the Research Coordinator's office.

During the case-control phase of the study, CDI development was treated as the outcome and odds ratios (ORs) were calculated from bivariate analysis comparing the use of different types of antibiotics as outcome causes. For each type of antibiotic, those used for ≥ 3 days were designated "used" while all others were designated "unused." A dummy variable regression was subsequently performed. Statistical significance in the bivariate analysis was tested by the chi-square test. Logistic regression analysis was performed using the individual patient characteristics and other assumed confounding variables as independent variables. The 95% confidence intervals (CIs) for each variable were used to determine the relationships between the various predictive variables and outcomes.

In the cohort study, gastrointestinal perforations, toxic megacolon, CDI-related surgeries, and the all-cause in-hospital mortality of patients within 30 days of CDI development were recorded. The clinical outcome of mortality within 30 days was set as the dependent variable, and the relationships among the underlying diseases, nutritional status, probiotic use, and

types of anti-CDI drugs used were subjected to bivariate and multivariate analyses. Like the case-control phase, bivariate analysis were conducted using the chi-square test, and the multivariate analysis was conducted using logistic regression. The significance level for all analyses was set at $p < 0.05$. We used IBM SPSS Statistics version 20 for statistical analysis.

Ethics Committee Approval and Informed Consent

This study was conducted with the approval of the Central Ethics Committee of the NHO. In principle, individual patients who met the inclusion criteria were not given direct explanations of the study, and no direct consent was sought. Information about the study was made public through postings on facility notice boards and webpages. Patients and their representative agents had the right to refuse study participation.

Results

Participating Facilities

Among the 47 facilities, a total of 1,026 CDI cases were registered at 42 facilities throughout Japan, from Hokkaido in the north to Okinawa in the south. No CDI cases were recorded at the remaining 5 participating facilities, more than 280 patient beds. The regional locations of the 47 facilities were as follows: 5 in Hokkaido and Tohoku, 10 in Kanto and Koshinetsu, 2 in Tokai and Hokuriku, 9 in Kinki, 10 in Chugoku and Shikoku, and 11 in Kyushu and Okinawa (Table 1).

Table 1. Number of registered cases of CDI and characteristics of hospitals included in the surveillance of CDI in the NHO (from november 2010 through october 2011)

Region	No. patient beds	No. patient days	No. patients registered		30-day all-cause mortality		Bacteriological survey	
			CDI group	Control group			EIA detection: toxins A and B	Culture
Hokkaido, tohoku	698	208,388	55	55	3 (5%)		+	+
	500	150,603	42	32	1 (2%)		+	+
	310	82,687	28	19	2 (7%)			+
	310	72,144	17	12	2 (12%)		+	+
	220	76,539	1	1	0 (0%)		+	+
Kanto, koshinetsu	780	238,420	124	121	15 (12%)		+	+
	455	151,622	36	36	3 (8%)		+	
	560	158,921	35	30	4 (11%)		+	+
	243	60,155	34	34	6 (18%)		+	+
	350	109,025	22	22	4 (18%)		+	+
	500	159,432	15	14	1 (7%)		+	
	510	166,668	4	4	0 (0%)		+	
	380	109,482	3	2	0 (0%)		+	+
	455	132,483	3	1	0 (0%)		+	
	429	104,802	0	0	— (—)		+	
Tokai, hokuriku	430	195,209	42	26	10 (24%)		+	+
	280	56,475	0	0	— (—)		+	
Kinki	316	103,677	24	22	1 (4%)		+	
	220	47,354	23	23	1 (4%)		+	+
	600	191,041	20	20	3 (15%)		+	
	494	70,455	15	15	6 (40%)		+	+
	520	145,299	13	9	1 (8%)		+	
	500	142,409	6	6	1 (17%)		+	
	180	55,721	3	3	1 (33%)		+	
	346	118,014	2	2	0 (0%)		+	
Chugoku, shikoku	370	94,722	0	0	— (—)		+	
	388	99,728	54	49	5 (9%)		+	+
	700	211,595	49	48	4 (8%)		+	+
	506	119,356	33	8	1 (3%)		+	+
	400	122,846	30	30	5 (17%)		+	
	401	108,303	26	0	2 (8%)		+	+
	250	80,558	21	21	0 (0%)		+	
	424	128,868	12	10	0 (0%)		+	
	365	125,645	10	10	3 (30%)		+	+
	300	87,061	0	0	— (—)			+
Kyushu, okinawa	459	66,454	0	0	— (—)		+	
	424	137,827	46	22	5 (11%)		+	
	702	239,448	38	37	1 (3%)		+	
	190	54,038	33	31	9 (27%)		+	
	550	189,417	27	26	3 (11%)		+	
	285	58,185	25	25	3 (12%)		+	
	500	140,371	24	23	2 (8%)		+	
	300	90,457	14	14	4 (29%)		+	
	320	103,315	6	5	1 (17%)		+	+
	280	79,580	4	4	2 (50%)		+	
	366	112,906	4	4	0 (0%)		+	
	368	89,195	3	2	2 (67%)		+	
Total	19,486	5,592,077	1,026	878	117 (11%)		45	20

1 **Patient Grouping**

2
3
4 A total of 1,026 CDI cases that met the study definitions were recorded at the various institutions. We were unable to
5
6
7 collect clinical records regarding medical treatments for 1 case; therefore, this case was excluded from the case-control
8
9
10 study, and the remaining 1,025 cases were analyzed. A total of 962 patients (93.9%) developed CDI within 48 hours after
11
12 hospital admittance. The control group comprised 878 patients who were selected from 41 of the 42 facilities. In the cohort
13
14
15 study, we analyzed the data from 924 of the 1,025 CDI group patients, excluding 101 patients with no available recent
16
17
18 serum albumin level data (i.e., within 30 days prior to CDI development (Figure 1).
19

20
21 **Case-Control Study of CDI Development**

22
23
24 The mean ages of the CDI and control groups were 75.8 and 75.4 years, respectively. The majority of the subjects were of
25
26
27 advanced age: 64.0% and 62.5% of the CDI and control group patients were aged ≥ 75 years, respectively. No significant
28
29
30 differences were identified between the CDI and control groups in the univariate analysis of age distribution, sex differences,
31
32
33 or underlying disease (Table 2). Among the medical treatments administered before CDI development, the following were
34
35
36 significantly more prevalent in the CDI group than the control group: disruption of feeding (48.6% vs. 30.4%), parenteral
37
38
39 nutrition (24.7% vs. 10.3%), and enteral feeding (24.8% vs. 9.1%). Antibiotics were used prior to CDI development in
40
41
42 85.8% of cases. The use of all types of intravenous antibiotics was significantly more prevalent in the CDI group. No
43
44
45 significant differences were identified between the 2 groups with respect to oral antibiotic use. Meanwhile, in the univariate
46
47
48 analysis, proton pump inhibitor use was significantly more prevalent in the CDI group than the control group (40.3% vs.
49
50 31.2%).
51

52
53 We used logistic regression analysis to determine the risk factors for CDI development. The following medical treatments
54
55
56 prior to CDI development were identified as significant risk factors in comparison to the control group: disruption of
57
58
59 feeding (odds ratio[OR], 1.31; 95% confidence interval[CI], 1.05 to 1.64), parenteral nutrition (OR, 1.63; 95%CI, 1.21 to
60

2.20) and enteral feeding (OR, 2.16; 95%CI, 1.60 to 2.92). The following intravenous antibiotics were also identified as statistically significant risk factors for CDI development: first- and second-generation cepheems (OR, 1.44; 95%CI, 1.10 to 1.87), third- and fourth-generation cepheems (OR, 1.86; 95%CI, 1.48 to 2.33), and carbapenems (OR, 1.87; 95%CI, 1.44 to 2.42). However, penicillin (OR, 1.04; 95%CI, 0.82 to 1.33), fluoroquinolones (OR, 1.16; 95%CI, 0.74 to 1.83), clindamycin/lincomycin (OR, 1.35; 95%CI, 0.81 to 2.26), and proton pump inhibitor use (OR, 1.17; 95%CI, 0.95 to 1.44) were not identified as risk factors.

Table 2. Univariate and multivariate analyses of CDI development-related risk factors

Characteristics	CDI group	Control group	Univariate analysis	Multivariate analysis	
	%	%	P value	Odds ratio (95% CI)	P value
All	(1,025)	(878)	—	—	—
Age					
≤74 years	36.0 (369)	37.5 (329)	0.67	Ref.	—
75–84 years	37.0 (379)	37.2 (327)		1.02 (0.81 to 1.28)	0.88
≥85 years	27.0 (277)	25.3 (222)		1.09 (0.84 to 1.41)	0.52
Sex					
Women	43.0 (441)	42.6 (374)	0.85	1.11 (0.91 to 1.36)	0.28
Underlying disease					
Respiratory infections	15.8 (162)	17.5 (154)	0.14	—	—
Other infectious conditions	16.9 (173)	14.2 (125)		—	—
Gastrointestinal conditions	8.1 (83)	9.0 (79)		—	—
Malignant tumors	22.6 (232)	24.3 (213)		—	—
Cardiovascular conditions	7.7 (79)	9.8 (86)		—	—
Other conditions	28.9 (296)	25.2 (221)		—	—
Medical treatment prior to CDI development					
Disruption of feeding	48.6 (498)	30.4 (267)	<0.001	1.31 (1.05 to 1.64)	<0.05
Parenteral nutrition	24.7 (253)	10.3 (90)	<0.001	1.63 (1.21 to 2.20)	<0.01
Enteral feeding	24.8 (254)	9.1 (80)	<0.001	2.16 (1.60 to 2.92)	<0.001
Surgery with general anesthetic	18.2 (187)	15.6 (137)	0.14	0.89 (0.67 to 1.18)	0.41
Cancer drugs	11.3 (116)	14.2 (125)	0.06	0.86 (0.62 to 1.18)	0.35
Antibiotics use	85.8 (879)	66.5 (584)	<0.001	—	—
Intravenous					
Penicillins	27.6 (283)	21.0 (184)	<0.01	1.04 (0.82 to 1.33)	0.75
First/second-generation cephe	22.7 (233)	15.6 (137)	<0.001	1.44 (1.10 to 1.87)	<0.01
Third/fourth-generation cephe	35.2 (361)	19.9 (175)	<0.001	1.86 (1.48 to 2.33)	<0.001
Carbapenems	31.8 (326)	15.0 (132)	<0.001	1.87 (1.44 to 2.42)	<0.001
fluoroquinolones	7.5 (77)	4.0 (35)	<0.01	1.16 (0.74 to 1.83)	0.52
Clindamycin/lincomycin	6.5 (67)	2.8 (25)	<0.001	1.35 (0.81 to 2.26)	0.25
MRSA drugs	10.7 (110)	4.3 (38)	<0.001	1.10 (0.71 to 1.72)	0.66
Anti-fungal drugs	6.9 (71)	3.2 (28)	<0.001	1.01 (0.60 to 1.70)	0.96
Others(aminoglycosides, monobactam,etc.)	8.5 (87)	5.9 (52)	<0.05	1.19 (0.80 to 1.77)	0.39
Oral					
Cephems	5.6 (57)	4.4 (39)	0.29	1.49 (0.95 to 2.32)	0.08
fluoroquinolones	14.5 (149)	11.5 (101)	0.06	1.11 (0.82 to 1.51)	0.49
Others (macrolides, penicillins, etc.)	14.0 (144)	13.9 (122)	0.95	0.84 (0.63 to 1.13)	0.26
Proton pump inhibitors	40.3 (413)	31.2 (274)	<0.001	1.17 (0.95 to 1.44)	0.14

Cohort Study on Mortality among Patients with CDI

The cohort study examined mortality among the 924 patients from the 1,025 CDI group patients in the case-control study for whom serum albumin level data before CDI development were available.

Among the 924 patients, 102 (11.0%) died within 30 days of developing CDI. Among those cases, the cause of death was attributed to CDI in 11 cases (1.2%). The mean age of the 102 patients who died during the study was 80.1 ± 8.3 years. Patients ≥ 75 years old were especially prevalent in this subgroup, accounting for 77.5% (79/102) of the cases.

Some patients developed severe complications within 30 days of CDI development, including gastrointestinal perforation in 1 patient (0.1%) and toxic megacolon in 2 patients (0.2%); 1 patient (0.1%) underwent a CDI-related surgery. Among the 714 cases in which CDI was treated directly, recurrence within 30 days was observed in 34 cases (4.8%).

The univariate analysis indicated that comorbidities of heart and respiratory failure were significantly more prevalent among CDI patients. In addition, lower serum albumin levels were significantly associated with mortality. Among CDI treatments, mortality was significantly lower among cases in which probiotics were administered.

A logistic regression analysis of the 102 cases in which the patients died within 30 days of CDI development was performed to identify the factors associated with the risk of mortality. Compared to patients ≤ 74 years old, the odds ratio of mortality among patients aged 75–84 years was 2.08 (95%CI, 1.19 to 3.62). Among underlying diseases, heart failure (OR, 2.12; 95%CI, 1.26 to 3.55) and respiratory failure (OR, 1.98; 95%CI, 1.19 to 3.32) were identified as risk factors for mortality within 30 days of CDI development. Regarding nutritional status, neither parenteral nutrition nor enteral nutrition was identified as a risk factor for mortality. However, low serum albumin level (i.e., ≤ 2.6 g/dL) was identified as a significant risk factor for mortality (OR, 3.50; 95%CI, 1.33 to 9.22). Among CDI treatments, probiotic use (OR, 0.66; 95%CI, 0.42 to 1.04) was not identified as a risk factor for mortality. However, compared to cases in which no anti-CDI drugs were administered, vancomycin administration yielded an odds ratio of 0.43 (95%CI, 0.25 to 0.75), indicating a

1 significantly lowered risk of mortality in the CDI group. Meanwhile, no such lowered mortality was observed in cases
2
3
4 treated with metronidazole (OR, 0.85; 95%CI, 0.48 to 1.51).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Univariate and multivariate analyses of all-cause mortality in CDI patients

Characteristics	All-cause mortality rate %	Univariate analysis P value	Multivariate analysis	
			Odds ratio (95% CI)	P value
All	11.0 (102/924)	—	—	—
Age				
74 years	7.1 (23/326)	<0.05	Ref.	
75–84 years	13.3 (47/353)		2.08 (1.19 to 3.62)	<0.05
85 years	13.1 (32/245)		1.86 (0.98 to 3.55)	0.06
Sex				
Men	12.2 (64/524)	0.21	Ref.	
Women	9.5 (38/400)		0.78 (0.49 to 1.24)	0.29
Underlying disease				
Non-infectious	10.3 (64/619)	0.37	Ref.	
Infectious	12.5 (38/305)		0.99 (0.60 to 1.62)	0.97
Comorbidities				
Malignant tumors				
Not present	10.6 (67/630)	0.57	Ref.	
Present	11.9 (35/294)		1.54 (0.94 to 2.53)	0.09
Diabetes				
Not present	11.6 (89/765)	0.27	Ref.	
Present	8.2 (13/159)		0.71 (0.37 to 1.35)	0.29
Renal failure				
Not present	10.7 (84/784)	0.46	Ref.	
Present	12.9 (18/140)		0.90 (0.49 to 1.65)	0.73
Heart failure				
Not present	9.3 (70/756)	<0.01	Ref.	
Present	19.0 (32/168)		2.12 (1.26 to 3.55)	<0.01
Respiratory failure				
Not present	9.2 (69/754)	<0.001	Ref.	
Present	19.4 (33/170)		1.98 (1.19 to 3.32)	<0.01
Cirrhosis				
Not present	11.2 (100/895)	0.76	Ref.	
Present	6.9 (2/29)		0.61 (0.13 to 2.83)	0.53
Indicators of nutritional status				
Parenteral nutrition or enteral feeding				
Not present	9.4 (53/563)	0.05	Ref.	
Present	13.6 (49/361)		1.16 (0.73 to 1.84)	0.53
Serum albumin (g/dL)				
≥3.5	4.0 (5/124)	<0.001	Ref.	
2.7–3.4	7.2 (27/376)		1.55 (0.57 to 4.21)	0.39
≤2.6	16.5 (70/424)		3.50 (1.33 to 9.22)	<0.05
CDI treatments				
Cessation of antibiotics				
Not present	12.5 (65/519)	0.11	Ref.	
Present	9.1 (37/405)		0.77 (0.48 to 1.22)	0.26
Probiotics (for intestine treatment)				
Not present	13.8 (52/378)	<0.05	Ref.	
Present	9.2 (50/546)		0.66 (0.42 to 1.04)	0.08
Anti-CDI drugs				
Not present	15.2 (32/210)	<0.05	Ref.	
Vancomycin	7.4 (32/433)		0.43 (0.25 to 0.75)	<0.01
Metronidazole	13.5 (32/237)		0.85 (0.48 to 1.51)	0.59
Vancomycin and metronidazole	13.6 (6/44)		0.75 (0.27 to 2.08)	0.57

1 **Discussion**

2
3
4 This is the first large-scale clinical study of CDI in Japan. This study examined 1,026 cases of CDI recorded over 1 year
5
6
7 at the nationwide facilities of Japan’s largest hospital group. The findings of this investigation are similar to those reported
8
9
10 in previous studies conducted in Europe, North America, and Australia with respect to the identification of several risk
11
12 factors for CDI development, including age, severity of the underlying condition, and artificial feeding.[2, 4, 5] Antibiotic
13
14 use is a known risk factor for CDI development.[6] The present case-control study confirms that intravenous cephe-
15
16 m and carbapenems are important risk factors. Some studies report a low risk of CDI development owing to intravenous penicillin
17
18 administration.[7, 8] Concordantly, penicillin use was not identified as a risk factor in the present study. Although proton
19
20 pump inhibitor use was indicated as a risk factor for CDI development in previous studies[9, 10] it was not identified as a
21
22 risk factor in the present logistic regression analysis. This finding might be influenced by the relatively high *Helicobacter*
23
24 *pylori* infection rate in elderly Japanese people; proton pump inhibitors might produce smaller changes in pH levels in such
25
26 patients than American and European patients.[11]

27
28
29
30 In this study, 11.0 % of CDI patients died within 30days. In comparison, higher 30-day mortality rates have been reported
31
32
33 in previous outbreaks: 24.8% in the ribotype 027 strain outbreak in Canada, and 36.7% in an examination of a single
34
35 intensive care unit in the USA.[12, 13] However, reports of non-outbreak conditions indicate mortality rates of 13%, similar
36
37 to the findings of the present study.[14] Some reports state that the CDI-associated mortality rate has increased 2.5 fold,
38
39 possibly indicating that CDI cases are more severe and contribute more significantly to mortality than previously though.[3,
40
41 14] The mortality rate of CDI patients is reported to increase with age.[15] Concordantly, the present study also found a
42
43 significantly elevated risk of death in patients ≥ 75 years old.

44
45
46 The findings of this study indicate that the mortality risk of CDI patients was not reduced as a result of metronidazole
47
48 treatment but was reduced with vancomycin treatment, corroborating the existing recommendation.[16] It is worth noting
49
50
51
52
53
54
55
56
57
58
59
60

that metronidazole is less expensive than vancomycin, making it economically advantageous. a patient's condition must be carefully evaluated when selecting anti-CDI drugs. In particular, for patients in the present study who had conditions associated with a greater mortality risk, including advanced age (i.e., ≥ 75 years), heart or respiratory failure, or malnutrition as determined by low serum albumin levels, the use of vancomycin rather than metronidazole for treatment appears to have provided better outcomes.

Regardless, this study has also several methodological limitations. The most salient limitation of the case-control study phase is the existence of many confounding factors. In particular, probiotic use, which was recently shown to be correlated with CDI prevention, was not included in the predictive model of this study.[17] When interpreting the findings of this study, it is necessary to consider the influence of confounding factors that were not included in the analytical models. Regarding antibiotic use, the present analyses included independent explanatory variables for each antibiotic. However, actual antibiotic use is more complicated. Therefore, it is difficult to clearly determine the roles of individual antibiotics as risk factors for CDI development. In addition, although data for the control group were analyzed during the entire study period until hospital discharge, only data from the period prior to CDI development were analyzed in the CDI group. Therefore, the risks might be underestimated, because the control group had a longer period of exposure risk than the CDI group. Confounding factors that were not included in the present analyses also represent a limitation of the cohort study phase. Furthermore, issues of data quality among the facilities affect all aspects of this study. More than 40 different facilities participated in this study. While some facilities registered nearly all of their CDI patients, other facilities registered smaller proportions of patients. Finally, there might have been differences with regard to individual researchers' understanding of the outcome definitions.

As the Japanese population continues to age, the number of elderly patients suffering from multiple ailments is increasing as well. As the number of patients requiring intravenous administration of broad-spectrum antibiotics has increased, close

1 and careful monitoring of CDI epidemiology is necessary. In order to ensure appropriate antibiotic use and control the
2
3
4 incidence of CDI, it is important to create institutional measures such as infection control teams and to not limit such
5
6
7 controls to the efforts of individual doctors. The cost-effective treatment of CDI may necessitate the appropriate use of
8
9
10 less-expensive metronidazole. However, in cases expected to become severe or life-threatening, the more expensive drug
11
12
13 vancomycin should be administered. In countries facing an aging population, CDI is one of many issues concerning
14
15
16 medicine and medical treatment costs. Accordingly, further and more proactive research into CDI epidemiology is needed.

21 **Acknowledgements**

22
23
24 The authors would like to express their sincere gratitude to Dr. Haru Kato and the Department of Bacteriology II,
25
26
27 National Institute of Infectious Diseases, Tokyo, Japan for their expert advice regarding CDI and the provision of CDI
28
29
30 training to the participating facilities.

31
32
33 We also wish to thank the participating institutions in the CD-NHO study Group for their collaboration with data and
34
35
36 sample collection: Hisaji Oshima (NHO Tokyo Medical Center); Hiroshi Miki (NHO Sendai Medical Center); Keisei
37
38
39 Shimoe (NHO Fukuyama Medical Center); Harumi Tominaga (NHO Kure Medical Center); Toyomitsu Sawai and Eisuke
40
41
42 Sasaki (NHO Ureshino Medical Center); Shie Nishijima and Naoko Maeda (NHO Shizuoka Medical Center); Masaru
43
44
45 Amishima (NHO Hokkaido Medical Center); Miki Odawara (NHO Kyushu Medical Center); Mitsuhiko Kamimura (NHO
46
47
48 National Disaster Medical Center); Hideaki Nagai (NHO Tokyo National Hospital); Kiyoshi Furuta (NHO Matsumoto
49
50
51 Medical Center, Matsumoto Hospital); Tohru Yamanaka (NHO Kumamoto Minami Hospital); Ikuko Mizouchi (NHO
52
53
54 Minimi-Okayama Medical Center); Yutaka Sato (NHO Kanmon Medical Center); Keita Ato and Hiroki Saito (NHO
55
56
57 Asahikawa Medical Center); Yoshio Haga (NHO Kumamoto Medical Center); Isao Murakami (NHO Higashihiroshima
58
59
60 Medical Center); Takeshi Yamaryo (NHO Nagasaki Kawatana Medical Center); Hiroyuki Akiyama and Yukino Yoshikura

(NHO Minami Wakayama Medical Center); Akiko Muratake (NHO Beppu Medical Center); Masato Hasegawa (NHO Higashi-Ohmi General Medical Center); Isamu Kamimaki (NHO Saitama National Hospital); Tomoaki Kosyoubu (NHO Yonago Medical Center); Takao Odagaki (NHO Kyoto Medical Center); Nozomu Iwashiro (NHO Hakodate National Hospital); Hiroyasu Ishida (NHO Mito Medical Center); Hiroshi Komatsu (NHO Maizuru Medical Center); Kaoru Nakama (NHO Oita Medical Center); Yoshiko Yamamoto (NHO Osaka Minami Medical Center); Yoshihito Iwahara (NHO Kochi National Hospital); Fumiko Okino (NHO Yamaguchi-Ube Medical Center); Daisuke Higuchi (NHO Okinawa National Hospital); Kazuhiro Satonaka (NHO Hyogo-Chuo National Hospital); Takayoshi Soga and Haruko Ideguchi (NHO Yokohama Medical Center); Mayuko Watanabe (NHO Kagoshima Medical Center); Kozaburo Hiramatsu (NHO Nagasaki National Hospital); Mitsugu Saito (NHO Awara National Hospital); Morio Sawamura (NHO Nishigunma National Hospital); Satoru Kaneda (NHO Chiba Medical Center); Kenji Okada (NHO Fukuoka National Hospital); Katsuhiro Suzuki (NHO Kinki-Chuo Chest Medical Center); Tetsuko Chiba and Keiji Chida (NHO Iwate National Hospital); Akihiko Tamura (NHO Tochigi Medical Center); Shunji Matsuda (NHO Ehime Medical Center); Takaya Maruyama (NHO Mie National Hospital); Shigeaki Kimura (NHO Tokushima National Hospital); Shin Oguri (NHO Minami Kyoto National Hospital)

Contributors

MT conceived the idea for the study, designed the study, developed the protocol, was responsible for study management and data collection, interpreted the findings, and drafted the paper. NM interpreted the findings and drafted the paper. SB designed this study, developed the protocol, performed data analysis, and interpreted findings.

Funding

This study was supported by a grant from the National Hospital Organization (multi-center clinical studies for

1 evidenced-based medicine).

7 **Competing interests**

10 None.

16 **Ethics approval**

18 The Central Ethics Committee of the NHO.

24 **Provenance and peer review**

27 Not commissioned; externally peer reviewed.

33 **Data sharing statement**

36 No additional data are available.

42 **Contributorship Statement**

44 All authors had full access to all of the data and can take responsibility for the integrity of the data and the accuracy of the
46 data analysis. The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being
48 reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned
50 have been explained.

References

- 1 Rupnik M, Wilcox MH, Gerding DN. *Clostridium difficile* infection: new developments in epidemiology and pathogenesis. *Nat Rev Microbiol* 2009;**7**:526-36.
- 2 Cohen SH, Gerding DN, Johnson S, *et al*. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;**31**:431-55.
- 3 Mitchell BG, Gardner A. Mortality and *Clostridium difficile* infection: a review. *Antimicrob Resist Infect Control* 2012;**1**:20.
- 4 Freeman J, Bauer MP, Baines SD, *et al*. The changing epidemiology of *Clostridium difficile* infections. *Clin Microbiol Rev* 2010;**23**:529-49.
- 5 Bliss DZ, Johnson S, Savik K, *et al*. Acquisition of *Clostridium difficile* and *Clostridium difficile*-associated diarrhea in hospitalized patients receiving tube feeding. *Ann Intern Med* 1998;**129**:1012-9.
- 6 Owens RC, Jr., Donskey CJ, Gaynes RP, *et al*. Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clin Infect Dis* 2008;**46 Suppl 1**:S19-31.
- 7 Brown KA, Khanafer N, Daneman N, *et al*. Meta-analysis of antibiotics and the risk of community-associated *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2013;**57**:2326-32.
- 8 Deshpande A, Pasupuleti V, Thota P, *et al*. Community-associated *Clostridium difficile* infection and antibiotics: a meta-analysis. *J Antimicrob Chemother* 2013;**68**:1951-61.
- 9 Dial S, Delaney JA, Barkun AN, *et al*. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA* 2005;**294**:2989-95.
- 10 Kwok CS, Arthur AK, Anibueze CI, *et al*. Risk of *Clostridium difficile* infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol* 2012;**107**:1011-9.
- 11 Asaka M, Kimura T, Kudo M, *et al*. Relationship of *Helicobacter pylori* to serum pepsinogens in an asymptomatic Japanese population. *Gastroenterology* 1992;**102**:760-6.
- 12 Loo VG, Poirier L, Miller MA, *et al*. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005;**353**:2442-9.
- 13 Kenneally C, Rosini JM, Skrupky LP, *et al*. Analysis of 30-day mortality for *clostridium difficile*-associated disease in the ICU setting. *Chest* 2007;**132**:418-24.
- 14 Hensgens MP, Goorhuis A, Dekkers OM, *et al*. All-cause and disease-specific mortality in hospitalized patients with *Clostridium difficile* infection: a multicenter cohort study. *Clin Infect Dis* 2013;**56**:1108-16.
- 15 Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in *Clostridium difficile* infection in the general hospital population: a systematic review. *J Hosp Infect* 2012;**82**:1-12.
- 16 Zar FA, Bakkanagari SR, Moorthi KM, *et al*. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007;**45**:302-7.
- 17 Johnston BC, Ma SS, Goldenberg JZ, *et al*. Probiotics for the prevention of *Clostridium difficile*-associated diarrhea: a systematic review and meta-analysis. *Ann Intern Med* 2013;**157**:878-88.




Figure 1. Study populations for the analysis of patients with *Clostridium difficile* infection (CDI) and controls.

190x254mm (96 x 96 DPI)

TAKAHASHI et. al.

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls (b) For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how matching of cases and controls was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Other analyses	✓	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	✓8	Summarise key results with reference to study objectives
Limitations	✓19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	✓20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	✓21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	✓22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

TAKAHASHI et al.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	✓	Explain the scientific background and rationale for the investigation being reported
Objectives	✓	State specific objectives, including any prespecified hypotheses
Methods		
Study design	✓	Present key elements of study design early in the paper
Setting	✓	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	✓	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	✓	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Other analyses	✓17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	✓18	Summarise key results with reference to study objectives
Limitations	✓19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	✓20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	✓21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	✓22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Multi-institution Case-control and Cohort Study of Risk Factors for the Development and Mortality of Clostridium difficile Infections in Japan

Journal:	BMJ Open
Manuscript ID:	bmjopen-2014-005665.R1
Article Type:	Research
Date Submitted by the Author:	10-Jul-2014
Complete List of Authors:	Takahashi, Masahiko; NHO Tokyo Medical Center, Mori, Nobuaki; National Hospital Organization Tokyo Medical Center, General internal medicine Bito, Seiji; National Hospital Organization Tokyo Medical Center, General internal medicine
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Epidemiology
Keywords:	Gastrointestinal infections < GASTROENTEROLOGY, Epidemiology < INFECTIOUS DISEASES, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

1 1 **Title**

2

3

4 2 Multi-institution Case-control and Cohort Study of Risk Factors for the Development and Mortality of *Clostridium difficile*

5

6

7 3 Infections in Japan

8

9

10 4

11

12 5 **Corresponding author**

13

14

15 6 Masahiko Takahashi

16

17

18 7 Chief Director, Department of Gastroenterology

19

20

21 8 National Hospital Organization Tokyo Medical Center

22

23

24 9 2-5-1 Higashigaoka, Meguro-Ku, Tokyo 152-8902, Japan

25

26

27 10 Phone number: +81-3-3411-0111

28

29

30 11 Fax number: +81-3-3412-9811

31

32

33 12 matakaha@ntmc.hosp.go.jp

34

35

36 13 **Authors**

37

38 14 Masahiko Takahashi ^{1*}, Nobuaki Mori ², Seiji Bito ³.

39

40

41 15 **Author Affiliations**

42

43

44 16 ¹ Chief Director of Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo,

45

46

47 17 Japan

48

49

50 18 ² Medical staff of Department of General internal medicine and Infectious diseases physician, National Hospital

51

52

53 19 Organization Tokyo Medical Center, Tokyo, Japan

54

55

56 20 ³ Chief Director of Department of General internal medicine and epidemiologist, National Hospital Organization Tokyo

57

58

59 21 Medical Center, Tokyo, Japan

60

Abstract

Objective: To examine risk factors for *Clostridium difficile* infection (CDI) morbidity and mortality in Japan.

Design: Multi-method investigation including a case-control study and cohort study.

Setting: Forty-seven participating facilities of the National Hospital Organization (NHO).

Participants: One thousand twenty six CDI patients and 878 patients in control group over the age of 18 years admitted to the subject NHO facilities from November 2010 to October 2011.

Main Outcome Measures: In case-control study, we identify risk factors for CDI development. Next, in cohort study, we identify risk factors for all-cause mortality within 30 days following CDI onset.

Results: A total of 1,026 cases of CDI meeting the definitions of this investigation were identified, encompassing 878 patients at 42 of the 47 subject facilities. In the case-control study, we identified, compared with no antibiotics use, use of first- and second-generation cephem antibiotics (odds ratio[OR], 1.44; 95% confidence interval [CI], 1.10 to 1.87), use of third- and fourth-generation cephem antibiotics(OR, 1.86; 95%CI, 1.48 to 2.33), and use of carbapenem antibiotics (OR, 1.87; 95%CI, 1.44 to 2.42) were risk factors for CDI development. However, use of penicillin was not identified as risk factors. In the cohort study, sufficient data for analysis was available for 924 CDI cases; 102 of them (11.0%) resulted in death within 30 days of CDI onset. Compared with no anti-CDI drug use, use of vancomycin was associated with reduced risk of mortality (OR, 0.43; 95%CI, 0.25 to 0.75) whereas metronidazole was not.

Conclusions: The findings mirror those of previous studies from Europe and North America, identifying the administration of broad-spectrum antibiotics as a risk factor for CDI development. The use of vancomycin is associated with a decreased risk of mortality.

1 41
2
3 42
4 43
5
6 44
7
8 45
9 46
10 47
11 48
12 49
13 50
14 51
15 52
16 53
17
18
19
20
21 54
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This study is the first large-scale nationwide multi-center CDI investigation in Japan.
- Most of the epidemiological data of CDI has been limited in the North America and Europe. Our data plays a role of completion of the missing data in Asia.
- Use of β -lactam antibiotics except penicillin was the risk factor for CDI development in the first Japanese large-scale investigation. Appropriate antibiotic use is necessary in order to control the incidence of CDI.
- Vancomycin administration for CDI was associated with decreased risk of mortality. Although the cost-effective treatment of CDI may necessitate the appropriate use of less-expensive metronidazole, vancomycin should be administered in case expected to become severe or life-threatening.
- The limitation of this study is the low number of registered CDI cases from quite a few participants and the existence of many confounding factors.

Introduction

Clostridium difficile is the main causative pathogen of antibiotic-associated colitis. Since 2000, outbreaks of BI/NAP1/027 strain *C. difficile* infections (CDI) have been reported in North American and European hospitals and elder care facilities. The numbers of CDI patients as well as severe and intractable cases have increased simultaneously. Consequently, epidemiological surveillance systems have been set up in several countries. However, very few countries have implemented such national-level measures.

CDI epidemiological studies in Japan to date have been based on scattered data from individual medical facilities. Consequently, the phenomenon of CDI in Japan is not sufficiently understood, including *C. difficile* typing.[1, 2, 3, 4, 5, 6, 7, 8, 9]

Previous studies report that antibiotic administration is the largest risk factor for CDI development. Other risk factors include advanced age and proton pump inhibitor use. [10, 11] CDI mortality rates differ depending on the presence or absence of an outbreak as well as the relevant definitions of epidemiological surveillance. Furthermore, it is especially difficult to objectively determine precise CDI-related mortality rates because of factors such as underlying patient conditions. [12]

This report documents a case-control study of CDI in Japan based on data from the National Hospital Organization (NHO), which is Japan's largest group of hospitals and includes facilities located nationwide. In addition, a cohort investigation of mortality among CDI cases was conducted.

Materials and Methods

Research Design

This multicenter study is a collaborative effort of the 47 facilities that met our facility standards from among the 143 NHO facilities in Japan. The study was planned as a part of the NHO's "National Hospital Organization Multi-Center

1 76 Clinical Research for Evidence-Based Medicine” project. This study was conducted with the approval of the Central Ethics
2
3
4 77 Committee of the NHO. The CDI group in this study included in principal all newly diagnosed CDI cases among patients
5
6
7 78 hospitalized from November 1, 2010 to October 31, 2011; cases were registered continuously.

8
9
10 79 In the case-control study of CDI development, CDI cases newly diagnosed during the investigation period were
11
12
13 80 registered in the CDI group; meanwhile, age-, sex-, and underlying disease-matched patients in the same facilities were
14
15
16 81 registered to the control group. In addition, a prospective cohort study of CDI group patients who died within 30 days of
17
18
19 82 CDI development was conducted. This investigation is a multi-method study using standard case-control and cohort study
20
21
22 83 designs.

23
24 84 **Definition of CDI**

25
26
27 85 CDI was defined as the presence of any gastrointestinal symptoms accompanied by a clinical suspicion of CDI as well as
28
29
30 86 a positive result for *C. difficile* toxins from rapid stool testing or *C. difficile* isolation from stool cultures or both. Final
31
32
33 87 determinations were made by the attending physician or the facility’s infection control team.

34
35
36 88 Enzyme immunoassay testing kits for *C. difficile* toxins A and B were used as the rapid testing method (Immunocard CD
37
38
39 89 toxin A&B, Meridian Bioscience Inc., Cincinnati, OH, USA; C. Diff Quik Chek, Alere Medical Co. Ltd., Tokyo, Japan; Tox
40
41
42 90 A/B Quik Chek, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan; X/pect Toxin A/B, Kanto Chemical Co Ltd., Tokyo, Japan).
43
44
45 91 Cycloserine-cefoxitin mannitol agar (Nissui-pure-to CCMA baichi EX, Nissui Pharmaceutical Co. Ltd., Tokyo, Japan),
46
47
48 92 cycloserine-cefoxitin fructose agar (CCFA baichi, Becton, Dickinson and Company Co. Ltd., Tokyo, Japan; Poamedhia®
49
50
51 93 CCFA® kairyoubaichi, Eiken Chemical Co., Ltd., Tokyo, Japan), and brucella HK agar (RS) (brucella HK agar (RS),
52
53
54 94 Kyokuto Pharmaceutical Industrial Co. Ltd., Tokyo, Japan) were used in the *C. difficile* isolation cultures.

55
56 95 **Case-Control Study of CDI Development**

57
58
59 96 No additional information besides age, sex, and date of diagnosis was gathered when new patients were registered in the
60

CDI group. After the end of the study registration period, additional patient clinical data were gathered, including clinical department, underlying diseases, dates of hospital admittance and discharge, and medical treatments administered for ≥ 3 days between admittance and CDI development. Recorded treatments included disruption of feeding, parenteral nutrition, enteral feeding, surgery with general anesthetic, cancer drugs, antibiotics (excluding external-use antibiotics), proton pump inhibitors (oral or intravenous). We also collected data regarding the use of intravenous antibiotics including penicillins, first- and second-generation cepheems, third- and fourth-generation cepheems, carbapenems, fluoroquinolones, clindamycin/lincomycin, anti-Methicillin-resistant *Staphylococcus aureus* (MRSA) drugs, and anti-fungal drugs, and others. Finally, we collected data regarding the use of oral antibiotics including cepheems, fluoroquinolones, and others.

The control group was divided into three subgroups according to age: ≤ 74 , 75–84, and ≥ 85 years. The control patients were selected from among patients at the same facilities who did not contract CDI and were matched to the CDI patients with respect to age, sex, underlying disease, and hospital stays of ≥ 5 days within the same month as a counterpart's CDI diagnosis. The control group cases were selected regardless of gastrointestinal symptoms such as diarrhea. We strove to ensure that the CDI and control groups were as matched as possible. The same data were collected from both groups. The control patients were registered, and relevant patient data were gathered after the end of the CDI group study registration period.

Cohort Study on Mortality among CDI Patients

The prospective cohort study of registered CDI group patients from the case-control study examined all-cause mortality within 30 days as the primary outcome. Clinical outcomes of patients who discharged within 30 days of CDI development were not investigated in this study. The following data were collected: whether the underlying disease was infectious and whether comorbidities were related to malignant tumors (i.e., gastrointestinal, respiratory, blood/lymph, gynecologic, urological, or other tumors including cancers of the ear, nose, and throat), diabetes, renal failure, heart failure,

1 118 respiratory failure, or cirrhosis. We also considered patient nutritional status including whether the patient was subjected to
2
3
4 119 parenteral nutrition or enteral feeding as well as serum albumin levels measured within 30 days prior to CDI development
5
6
7 120 (i.e., ≥ 3.5 , 2.7–3.4, or ≤ 2.6 g/dL). In addition, we examined CDI treatment factors including whether antibiotic use was
8
9
10 121 halted, probiotic use, and the type of anti-CDI drugs used (i.e., vancomycin and metronidazole). All patient data for the
11
12
13 122 cohort investigation were collected after the end of the registration period.

15 123 **Data Management and Statistical Analysis**

18 124 All input data were verified by a designated study data manager. Data from each facility were entered directly into a
19
20
21 125 web-based case report form and subsequently encrypted for security. The data management center was responsible for
22
23
24 126 confirming any missing data and directly inquiring the relevant facilities as necessary.

27 127 During the case–control phase of the study, CDI development was treated as the outcome and odds ratios (ORs) were
28
29
30 128 calculated from bivariate analysis comparing the use of different types of antibiotics as outcome causes. For each type of
31
32
33 129 antibiotic, those used for ≥ 3 days were designated “used” while all others were designated “unused.” A dummy variable
34
35
36 130 regression was subsequently performed. Statistical significance in the bivariate analysis was tested by the chi-square test.
37
38
39 131 Logistic regression analysis was performed using the individual patient characteristics and other assumed confounding
40
41
42 132 variables as independent variables. The 95% confidence intervals (CIs) for each variable were used to determine the
43
44
45 133 relationships between the various predictive variables and outcomes.

47 134 In the cohort study, gastrointestinal perforations, toxic megacolon, CDI-related surgeries, and the all-cause in-hospital
48
49
50 135 mortality of patients within 30 days of CDI development were recorded. The clinical outcome of mortality within 30 days
51
52
53 136 was set as the dependent variable, and the relationships among the underlying diseases, nutritional status, probiotic use, and
54
55
56 137 types of anti-CDI drugs used were subjected to bivariate and multivariate analyses. Like the case–control phase, bivariate
57
58
59 138 analysis were conducted using the chi-square test, and the multivariate analysis was conducted using logistic regression.

60

The significance level for all analyses was set at $p < 0.05$. We used IBM SPSS Statistics version 20 for statistical analysis.

Ethics Committee Approval and Informed Consent

This study was conducted with the approval of the Central Ethics Committee of the NHO. In principle, individual patients who met the inclusion criteria were not given direct explanations of the study, and no direct consent was sought. Information about the study was made public through postings on facility notice boards and webpages. Patients and their representative agents had the right to refuse study participation.

Results

Participating Facilities

Among the 47 facilities, a total of 1,026 CDI cases were registered at 42 facilities throughout Japan, from Hokkaido in the north to Okinawa in the south. No CDI cases were recorded at the remaining 5 participating facilities, more than 280 patient beds (Table 1).

152 Table 1. Number of registered cases of CDI and characteristics of hospitals included in the surveillance of
153 CDI in the NHO (from november 2010 through october 2011)

Region	No. patient beds	No. patient days	No. patients registered		30-day all-cause mortality in CDI group		Laboratory tests used	
			CDI group	Control group			EIA for toxins A and B	Culture
Hokkaido, tohoku	698	208,388	55	55	3 (5%)		+	+
	500	150,603	42	32	1 (2%)		+	+
	310	82,687	28	19	2 (7%)			+
	310	72,144	17	12	2 (12%)		+	+
	220	76,539	1	1	0 (0%)		+	+
Kanto, koshinetsu	780	238,420	124	121	15 (12%)		+	+
	455	151,622	36	36	3 (8%)		+	
	560	158,921	35	30	4 (11%)		+	+
	243	60,155	34	34	6 (18%)		+	+
	350	109,025	22	22	4 (18%)		+	+
	500	159,432	15	14	1 (7%)		+	
	510	166,668	4	4	0 (0%)		+	
	380	109,482	3	2	0 (0%)		+	+
	455	132,483	3	1	0 (0%)		+	
	429	104,802	0	0	— (—)		+	
Tokai, hokuriku	430	195,209	42	26	10 (24%)		+	+
	280	56,475	0	0	— (—)		+	
Kinki	316	103,677	24	22	1 (4%)		+	
	220	47,354	23	23	1 (4%)		+	+
	600	191,041	20	20	3 (15%)		+	
	494	70,455	15	15	6 (40%)		+	+
	520	145,299	13	9	1 (8%)		+	
	500	142,409	6	6	1 (17%)		+	
	180	55,721	3	3	1 (33%)		+	
	346	118,014	2	2	0 (0%)		+	
Chugoku, shikoku	370	94,722	0	0	— (—)		+	
	388	99,728	54	49	5 (9%)		+	+
	700	211,595	49	48	4 (8%)		+	+
	506	119,356	33	8	1 (3%)		+	+
	400	122,846	30	30	5 (17%)		+	
	401	108,303	26	0	2 (8%)		+	+
	250	80,558	21	21	0 (0%)		+	
	424	128,868	12	10	0 (0%)		+	
	365	125,645	10	10	3 (30%)		+	+
	300	87,061	0	0	— (—)			+
Kyushu, okinawa	459	66,454	0	0	— (—)		+	
	424	137,827	46	22	5 (11%)		+	
	702	239,448	38	37	1 (3%)		+	
	190	54,038	33	31	9 (27%)		+	
	550	189,417	27	26	3 (11%)		+	
	285	58,185	25	25	3 (12%)		+	
	500	140,371	24	23	2 (8%)		+	
	300	90,457	14	14	4 (29%)		+	
	320	103,315	6	5	1 (17%)		+	+
	280	79,580	4	4	2 (50%)		+	
	366	112,906	4	4	0 (0%)		+	
	368	89,195	3	2	2 (67%)		+	
Total	19,486	5,592,077	1,026	878	117 (11%)		45	20

Patient Grouping

A total of 1,026 CDI cases that met the study definitions were recorded at the various institutions. We were unable to collect clinical records regarding medical treatments for 1 case; therefore, this case was excluded from the case-control study, and the remaining 1,025 cases were analyzed. A total of 962 patients (93.9%) developed CDI within 48 hours after hospital admittance. The control group comprised 878 patients who were selected from 41 of the 42 facilities. In the cohort study, we analyzed the data from 924 of the 1,025 CDI group patients, excluding 101 patients with no available recent serum albumin level data (i.e., within 30 days prior to CDI development (Figure 1).

Case-Control Study of CDI Development

The mean ages of the CDI and control groups were 75.8 and 75.4 years, respectively. The majority of the subjects were of advanced age: 64.0% and 62.5% of the CDI and control group patients were aged ≥ 75 years, respectively. No significant differences were identified between the CDI and control groups in the univariate analysis of age distribution, sex differences, or underlying disease (Table 2). Among the medical treatments administered before CDI development, the following were significantly more prevalent in the CDI group than the control group: disruption of feeding (48.6% vs. 30.4%), parenteral nutrition (24.7% vs. 10.3%), and enteral feeding (24.8% vs. 9.1%). Antibiotics were used prior to CDI development in 85.8% of cases. The use of all types of intravenous antibiotics was significantly more prevalent in the CDI group. No significant differences were identified between the 2 groups with respect to oral antibiotic use. Meanwhile, in the univariate analysis, proton pump inhibitor use was significantly more prevalent in the CDI group than the control group (40.3% vs. 31.2%).

We used logistic regression analysis to determine the risk factors for CDI development. The following medical treatments prior to CDI development were identified as significant risk factors in comparison to the control group: disruption of feeding (odds ratio[OR], 1.31; 95% confidence interval[CI], 1.05 to 1.64), parenteral nutrition (OR, 1.63; 95%CI, 1.21 to

1 176 2.20) and enteral feeding (OR, 2.16; 95%CI, 1.60 to 2.92).The following intravenous antibiotics were also identified as
2
3
4 177 statistically significant risk factors for CDI development: first- and second-generation cepheems (OR, 1.44; 95%CI, 1.10 to
5
6
7 178 1.87), third- and fourth-generation cepheems (OR, 1.86; 95%CI, 1.48 to 2.33), and carbapenems (OR, 1.87; 95%CI, 1.44 to
8
9
10 179 2.42). However, penicillin (OR, 1.04; 95%CI, 0.82 to 1.33), fluoroquinolones (OR, 1.16; 95%CI, 0.74 to 1.83),
11
12
13 180 clindamycin/lincomycin (OR, 1.35; 95%CI, 0.81 to 2.26), and proton pump inhibitor use (OR, 1.17; 95%CI, 0.95 to 1.44)
14
15 181 were not identified as risk factors.
16
17
18 182

183 Table 2. Univariate and multivariate analyses of CDI development-related risk factors

Characteristics	CDI group	Control group	Univariate analysis	Multivariate analysis	
	%	%	P value	Odds ratio (95% CI)	P value
All	(1,025)	(878)	—	—	—
Age					
≤74 years	36.0 (369)	37.5 (329)	0.67	Ref.	—
75–84 years	37.0 (379)	37.2 (327)		1.02 (0.81 to 1.28)	0.88
≥85 years	27.0 (277)	25.3 (222)		1.09 (0.84 to 1.41)	0.52
Sex					
Women	43.0 (441)	42.6 (374)	0.85	1.11 (0.91 to 1.36)	0.28
Underlying disease					
Respiratory infections	15.8 (162)	17.5 (154)	0.14	—	—
Other infectious conditions	16.9 (173)	14.2 (125)		—	—
Gastrointestinal conditions	8.1 (83)	9.0 (79)		—	—
Malignant tumors	22.6 (232)	24.3 (213)		—	—
Cardiovascular conditions	7.7 (79)	9.8 (86)		—	—
Other conditions	28.9 (296)	25.2 (221)		—	—
Medical treatment prior to CDI development					
Disruption of feeding	48.6 (498)	30.4 (267)	<0.001	1.31 (1.05 to 1.64)	<0.05
Parenteral nutrition	24.7 (253)	10.3 (90)	<0.001	1.63 (1.21 to 2.20)	<0.01
Enteral feeding	24.8 (254)	9.1 (80)	<0.001	2.16 (1.60 to 2.92)	<0.001
Surgery with general anesthetic	18.2 (187)	15.6 (137)	0.14	0.89 (0.67 to 1.18)	0.41
Cancer drugs	11.3 (116)	14.2 (125)	0.06	0.86 (0.62 to 1.18)	0.35
Antibiotics use	85.8 (879)	66.5 (584)	<0.001	—	—
Intravenous					
Penicillins	27.6 (283)	21.0 (184)	<0.01	1.04 (0.82 to 1.33)	0.75
First/second-generation cepheims	22.7 (233)	15.6 (137)	<0.001	1.44 (1.10 to 1.87)	<0.01
Third/fourth-generation cepheims	35.2 (361)	19.9 (175)	<0.001	1.86 (1.48 to 2.33)	<0.001
Carbapenems	31.8 (326)	15.0 (132)	<0.001	1.87 (1.44 to 2.42)	<0.001
fluoroquinolones	7.5 (77)	4.0 (35)	<0.01	1.16 (0.74 to 1.83)	0.52
Clindamycin/lincomycin	6.5 (67)	2.8 (25)	<0.001	1.35 (0.81 to 2.26)	0.25
MRSA drugs	10.7 (110)	4.3 (38)	<0.001	1.10 (0.71 to 1.72)	0.66
Anti-fungal drugs	6.9 (71)	3.2 (28)	<0.001	1.01 (0.60 to 1.70)	0.96
Others(aminoglycosides, monobactam,etc.)	8.5 (87)	5.9 (52)	<0.05	1.19 (0.80 to 1.77)	0.39
Oral					
Cephems	5.6 (57)	4.4 (39)	0.29	1.49 (0.95 to 2.32)	0.08
fluoroquinolones	14.5 (149)	11.5 (101)	0.06	1.11 (0.82 to 1.51)	0.49
Others (macrolides, penicillins, etc.)	14.0 (144)	13.9 (122)	0.95	0.84 (0.63 to 1.13)	0.26
Proton pump inhibitors	40.3 (413)	31.2 (274)	<0.001	1.17 (0.95 to 1.44)	0.14

Cohort Study on Mortality among Patients with CDI

The cohort study examined mortality among the 924 patients from the 1,025 CDI group patients in the case-control study for whom serum albumin level data before CDI development were available.

Among the 924 patients, 102 (11.0%) died within 30 days of developing CDI. Among those cases, the cause of death was attributed to CDI in 11 cases (1.2%). Of 11 patients, a patient had gastrointestinal perforation, another patient had CDI-related surgery, and the others were not reported as severe complications. The toxic megacolon was reported in 2 patients however, they were not died within 30 days of CDI development. The mean age of the 102 patients who died during the study was 80.1 ± 8.3 years. Patients ≥ 75 years old were especially prevalent in this subgroup, accounting for 77.5% (79/102) of the cases.

Among the 714 cases in which CDI was treated directly, recurrence within 30 days was observed in 34 cases (4.8%).

The univariate analysis indicated that comorbidities of heart and respiratory failure were significantly more prevalent among CDI patients. In addition, lower serum albumin levels were significantly associated with mortality. Among CDI treatments, mortality was significantly lower among cases in which probiotics were administered.

A logistic regression analysis of the 102 cases in which the patients died within 30 days of CDI development was performed to identify the factors associated with the risk of mortality. Compared to patients ≤ 74 years old, the odds ratio of mortality among patients aged 75–84 years was 2.08 (95%CI, 1.19 to 3.62). Among underlying diseases, heart failure (OR, 2.12; 95%CI, 1.26 to 3.55) and respiratory failure (OR, 1.98; 95%CI, 1.19 to 3.32) were identified as risk factors for mortality within 30 days of CDI development. Regarding nutritional status, neither parenteral nutrition nor enteral nutrition was identified as a risk factor for mortality. However, low serum albumin level (i.e., ≤ 2.6 g/dL) was identified as a significant risk factor for mortality (OR, 3.50; 95%CI, 1.33 to 9.22). Among CDI treatments, probiotic use (OR, 0.66; 95%CI, 0.42 to 1.04) was not identified as a risk factor for mortality. However, compared to cases in which no anti-CDI drugs were administered, vancomycin administration yielded an odds ratio of 0.43 (95%CI, 0.25 to 0.75), indicating a

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

For peer review only

significantly lowered risk of mortality in the CDI group. Meanwhile, no such lowered mortality was observed in cases treated with metronidazole (OR, 0.85; 95%CI, 0.48 to 1.51).

211 Table 3. Univariate and multivariate analyses of all-cause mortality in CDI patients

Characteristics	All-cause mortality rate %	Univariate analysis P value	Multivariate analysis	
			Odds ratio (95% CI)	P value
All	11.0 (102/924)	—	—	—
Age				
≤74 years	7.1 (23/326)	<0.05	Ref.	
75–84 years	13.3 (47/353)		2.08 (1.19 to 3.62)	<0.05
≥85 years	13.1 (32/245)		1.86 (0.98 to 3.55)	0.06
Sex				
Men	12.2 (64/524)	0.21	Ref.	
Women	9.5 (38/400)		0.78 (0.49 to 1.24)	0.29
Underlying disease				
Non-infectious	10.3 (64/619)	0.37	Ref.	
Infectious	12.5 (38/305)		0.99 (0.60 to 1.62)	0.97
Comorbidities				
Malignant tumors				
Not present	10.6 (67/630)	0.57	Ref.	
Present	11.9 (35/294)		1.54 (0.94 to 2.53)	0.09
Diabetes				
Not present	11.6 (89/765)	0.27	Ref.	
Present	8.2 (13/159)		0.71 (0.37 to 1.35)	0.29
Renal failure				
Not present	10.7 (84/784)	0.46	Ref.	
Present	12.9 (18/140)		0.90 (0.49 to 1.65)	0.73
Heart failure				
Not present	9.3 (70/756)	<0.01	Ref.	
Present	19.0 (32/168)		2.12 (1.26 to 3.55)	<0.01
Respiratory failure				
Not present	9.2 (69/754)	<0.001	Ref.	
Present	19.4 (33/170)		1.98 (1.19 to 3.32)	<0.01
Cirrhosis				
Not present	11.2 (100/895)	0.76	Ref.	
Present	6.9 (2/29)		0.61 (0.13 to 2.83)	0.53
Indicators of nutritional status				
Parenteral nutrition or enteral feeding				
Not present	9.4 (53/563)	0.05	Ref.	
Present	13.6 (49/361)		1.16 (0.73 to 1.84)	0.53
Serum albumin (g/dL)				
≥3.5	4.0 (5/124)	<0.001	Ref.	
2.7–3.4	7.2 (27/376)		1.55 (0.57 to 4.21)	0.39
≤2.6	16.5 (70/424)		3.50 (1.33 to 9.22)	<0.05
CDI treatments				
Cessation of antibiotics				
Not present	12.5 (65/519)	0.11	Ref.	
Present	9.1 (37/405)		0.77 (0.48 to 1.22)	0.26
Probiotics (for intestine treatment)				
Not present	13.8 (52/378)	<0.05	Ref.	
Present	9.2 (50/546)		0.66 (0.42 to 1.04)	0.08
Anti-CDI drugs				
Not present	15.2 (32/210)	<0.05	Ref.	
Vancomycin alone	7.4 (32/433)		0.43 (0.25 to 0.75)	<0.01
Metronidazole alone	13.5 (32/237)		0.85 (0.48 to 1.51)	0.59
Vancomycin and metronidazole	13.6 (6/44)		0.75 (0.27 to 2.08)	0.57

Discussion

This is the first large-scale clinical study of CDI in Japan. This study examined 1,026 cases of CDI recorded over 1 year at the nationwide facilities of Japan's largest hospital group. The findings of this investigation are similar to those reported in previous studies conducted in Europe, North America, and Australia with respect to the identification of several risk factors for CDI development, including age, severity of the underlying condition, artificial feeding and mortality. Antibiotic use is a known risk factor for CDI development. [15] The present case-control study confirms that intravenous cepheems and carbapenems are important risk factors. Some studies report a low risk of CDI development owing to intravenous penicillin administration. [16, 17] Concordantly, penicillin use was not identified as a risk factor in the present study. The proton pump inhibitor use was discussed as a risk factor for CDI development in the previous studies. [18, 19, 20] In the present logistic regression analysis, it was not identified as a risk factor.

In this study, 11.0 % of CDI patients died within 30 days. In comparison, higher 30-day mortality rates have been reported in previous outbreaks: 24.8% in the ribotype 027 strain outbreak in Canada, and 36.7% in an examination of a single intensive care unit in the USA. [21, 22] However, reports of non-outbreak conditions indicate mortality rates of 13%, similar to the findings of the present study. [23] Some reports state that the CDI-associated mortality rate has increased 2.5 fold, possibly indicating that CDI cases are more severe and contribute more significantly to mortality than previously thought. [12, 23] The mortality rate of CDI patients is reported to increase with age. [24] Concordantly, the present study also found a significantly elevated risk of death in patients ≥ 75 years old.

The findings of this study indicate that the mortality risk of CDI patients was not reduced as a result of metronidazole treatment but was reduced with vancomycin treatment, corroborating the existing recommendation. [25] It is worth noting that metronidazole is less expensive than vancomycin, making it economically advantageous. a patient's condition must be carefully evaluated when selecting anti-CDI drugs. In particular, for patients in the present study who had conditions associated with a greater mortality risk, including advanced age (i.e., ≥ 75 years), heart or respiratory failure, or malnutrition

as determined by low serum albumin levels, the use of vancomycin rather than metronidazole for treatment appears to have provided better outcomes. The recurrence rate was low (4.8%) in this study compared to the previous studies. [11, 26] We did not investigate the patients neither after 30 days of CDI development nor the patients who discharge even if within 30 days of CDI development. Therefore, the recurrence rate might be underestimated.

Regardless, this study has also several methodological limitations. The most salient limitation is the low number of registered CDI cases from quite a few participants. In the definition of CDI, the times of diarrhea were not investigated. Another limitation of the case-control study phase is the existence of many confounding factors. In particular, probiotic use, which was recently discussed to be correlated with CDI prevention, was not included in the predictive model of this study. [10, 11, 27] When interpreting the findings of this study, it is necessary to consider the influence of confounding factors that were not included in the analytical models. Regarding antibiotic use, the present analyses included independent explanatory variables for each antibiotic. However, actual antibiotic use is more complicated. Therefore, it is difficult to clearly determine the roles of individual antibiotics as risk factors for CDI development. Concerning matching process, we tried to adopt 1 to 1 pair sampling matched with sex, age group and main diagnosis. Some hospital could not find appropriate control sample well matched with case sample. So total number of the control group was less than that of the case sample. In addition, although data for the control group were analyzed during the entire study period until hospital discharge, only data from the period prior to CDI development were analyzed in the CDI group. Therefore, the risks might be underestimated, because the control group had a longer period of exposure risk than the CDI group. Confounding factors that were not included in the present analyses also represent a limitation of the cohort study phase. Furthermore, issues of data quality among the facilities affect all aspects of this study. More than 40 different facilities participated in this study. While some facilities registered nearly all of their CDI patients, other facilities registered smaller proportions of patients. Only *C. difficile* culture but not toxin test was used for the laboratory test in two facilities.

Finally, there might have been differences with regard to individual researchers' understanding of the outcome definitions.

In order to ensure appropriate antibiotic use and control the incidence of CDI, it is important to create institutional measures such as infection control teams. The cost-effective treatment of CDI may necessitate the appropriate use of less-expensive metronidazole. However, in cases expected to become severe or life-threatening, the more expensive drug vancomycin should be administered. CDI is one of many issues concerning medicine and medical treatment costs. Accordingly, further and more proactive research into CDI epidemiology is needed.

1 277 Acknowledgements

2
3
4 278 The authors would like to express their sincere gratitude to Dr. Haru Kato and the Department of Bacteriology II,
5
6
7 279 National Institute of Infectious Diseases, Tokyo, Japan for their expert advice regarding CDI and the provision of CDI
8
9
10 280 training to the participating facilities.

11
12
13 281 We also wish to thank the participating institutions in the CD-NHO study Group for their collaboration with data and
14
15 282 sample collection: Hisaji Oshima (NHO Tokyo Medical Center); Hiroshi Miki (NHO Sendai Medical Center); Keisei
16
17
18 283 Shimoe (NHO Fukuyama Medical Center); Harumi Tominaga (NHO Kure Medical Center); Toyomitsu Sawai and Eisuke
19
20
21 284 Sasaki (NHO Ureshino Medical Center); Shie Nishijima and Naoko Maeda (NHO Shizuoka Medical Center); Masaru
22
23
24 285 Amishima (NHO Hokkaido Medical Center); Miki Odawara (NHO Kyushu Medical Center); Mitsuhiro Kamimura (NHO
25
26
27 286 National Disaster Medical Center); Hideaki Nagai (NHO Tokyo National Hospital); Kiyoshi Furuta (NHO Matsumoto
28
29
30 287 Medical Center, Matsumoto Hospital); Tohru Yamanaka (NHO Kumamoto Minami Hospital); Ikuko Mizouchi (NHO
31
32
33 288 Minimi-Okayama Medical Center); Yutaka Sato (NHO Kanmon Medical Center); Keita Ato and Hiroki Saito (NHO
34
35
36 289 Asahikawa Medical Center); Yoshio Haga (NHO Kumamoto Medical Center); Isao Murakami (NHO Higashihiroshima
37
38
39 290 Medical Center); Takeshi Yamaro (NHO Nagasaki Kawatana Medical Center); Hiroyuki Akiyama and Yukino Yoshikura
40
41
42 291 (NHO Minami Wakayama Medical Center); Akiko Muratake (NHO Beppu Medical Center); Masato Hasegawa (NHO
43
44
45 292 Higashi-Ohmi General Medical Center); Isamu Kamimaki (NHO Saitama National Hospital); Tomoaki Kosyoubu (NHO
46
47
48 293 Yonago Medical Center); Takao Odagaki (NHO Kyoto Medical Center); Nozomu Iwashiro (NHO Hakodate National
49
50
51 294 Hospital); Hiroyasu Ishida (NHO Mito Medical Center); Hiroshi Komatsu (NHO Maizuru Medical Center); Kaoru Nakama
52
53
54 295 (NHO Oita Medical Center); Yoshiko Yamamoto (NHO Osaka Minami Medical Center); Yoshihito Iwahara (NHO Kochi
55
56
57 296 National Hospital); Fumiko Okino (NHO Yamaguchi-Ube Medical Center); Daisuke Higuchi (NHO Okinawa National
58
59 297 Hospital); Kazuhiro Satonaka (NHO Hyogo-Chuo National Hospital); Takayoshi Soga and Haruko Ideguchi (NHO
60

Yokohama Medical Center); Mayuko Watanabe (NHO Kagoshima Medical Center); Kozaburo Hiramatsu (NHO Nagasaki National Hospital); Mitsugu Saito (NHO Awara National Hospital); Morio Sawamura (NHO Nishigunma National Hospital); Satoru Kaneda (NHO Chiba Medical Center); Kenji Okada (NHO Fukuoka National Hospital); Katsuhiro Suzuki (NHO Kinki-Chuo Chest Medical Center); Tetsuko Chiba and Keiji Chida (NHO Iwate National Hospital); Akihiko Tamura (NHO Tochigi Medical Center); Shunji Matsuda (NHO Ehime Medical Center); Takaya Maruyama (NHO Mie National Hospital); Shigeaki Kimura (NHO Tokushima National Hospital); Shin Oguri (NHO Minami Kyoto National Hospital)

Contributors

MT conceived the idea for the study, designed the study, developed the protocol, was responsible for study management and data collection, interpreted the findings, and drafted the paper. NM contributed to data analysis and interpretation of findings and drafted the paper. SB designed this study, developed the protocol, performed data analysis, and interpreted findings. and drafted the paper. All authors read and approved the final manuscript.

Funding

This study was supported by a grant from the National Hospital Organization (multi-center clinical studies for evidenced-based medicine).

Competing interests

None.

Ethics approval

1 319 The Central Ethics Committee of the NHO.

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

320

321 **Provenance and peer review**

322 Not commissioned; externally peer reviewed.

323

324 **Data sharing statement**

325 No additional data are available.

326

327

References

- 1 Honda H, Yamazaki A, Sato Y, *et al*. Incidence and mortality associated with *Clostridium difficile* infection at a Japanese tertiary care center. *Anaerobe* 2014;**25**:5-10.
- 2 Kato H, Ito Y, van den Berg RJ, *et al*. First isolation of *Clostridium difficile* 027 in Japan. *Euro Surveill* 2007;**12**:E070111 3.
- 3 Kato H, Kato N, Watanabe K, *et al*. Analysis of *Clostridium difficile* isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan. *J Clin Microbiol* 2001;**39**:1391-5.
- 4 Tagashira Y, Kato H, Senoh M, *et al*. Two cases of fulminant colitis due to binary toxin-positive *Clostridium difficile* that are not PCR ribotype 027 or type 078. *J Med Microbiol* 2013;**62**:1486-9.
- 5 Sawabe E, Kato H, Osawa K, *et al*. Molecular analysis of *Clostridium difficile* at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. *Eur J Clin Microbiol Infect Dis* 2007;**26**:695-703.
- 6 Iwashima Y, Nakamura A, Kato H, *et al*. A retrospective study of the epidemiology of *Clostridium difficile* infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. *J Infect Chemother* 2010;**16**:329-33.
- 7 Kato H, Ito Y, Akahane T, *et al*. Typing of *Clostridium difficile* isolates endemic in Japan by sequencing of *slpA* and its application to direct typing. *J Med Microbiol* 2010;**59**:556-62.
- 8 Collins DA, Hawkey PM, Riley TV. Epidemiology of *Clostridium difficile* infection in Asia. *Antimicrob Resist Infect Control* 2013;**2**:21.
- 9 Nakamura I, Yamaguchi T, Tsukimori A, *et al*. Fulminant colitis from *Clostridium difficile* infection, the epidemic strain ribotype 027, in Japan. *J Infect Chemother* 2014;**20**:380-3.
- 10 Rupnik M, Wilcox MH, Gerding DN. *Clostridium difficile* infection: new developments in epidemiology and pathogenesis. *Nat Rev Microbiol* 2009;**7**:526-36.
- 11 Cohen SH, Gerding DN, Johnson S, *et al*. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;**31**:431-55.
- 12 Mitchell BG, Gardner A. Mortality and *Clostridium difficile* infection: a review. *Antimicrob Resist Infect Control* 2012;**1**:20.
- 13 Freeman J, Bauer MP, Baines SD, *et al*. The changing epidemiology of *Clostridium difficile* infections. *Clin Microbiol Rev* 2010;**23**:529-49.
- 14 Bliss DZ, Johnson S, Savik K, *et al*. Acquisition of *Clostridium difficile* and *Clostridium difficile*-associated diarrhea in hospitalized patients receiving tube feeding. *Ann Intern Med* 1998;**129**:1012-9.
- 15 Owens RC, Jr., Donskey CJ, Gaynes RP, *et al*. Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clin Infect Dis* 2008;**46 Suppl 1**:S19-31.
- 16 Brown KA, Khanafer N, Daneman N, *et al*. Meta-analysis of antibiotics and the risk of community-associated *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2013;**57**:2326-32.
- 17 Deshpande A, Pasupuleti V, Thota P, *et al*. Community-associated *Clostridium difficile* infection and antibiotics: a meta-analysis. *J Antimicrob Chemother* 2013;**68**:1951-61.
- 18 Dial S, Delaney JA, Barkun AN, *et al*. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA* 2005;**294**:2989-95.
- 19 Kwok CS, Arthur AK, Anibueze CI, *et al*. Risk of *Clostridium difficile* infection with acid suppressing

369 drugs and antibiotics: meta-analysis. *Am J Gastroenterol* 2012;**107**:1011-9.

370 20 Tleyjeh IM, Bin Abdulhak AA, Riaz M, *et al.* Association between proton pump inhibitor therapy and

371 *Clostridium difficile* infection: a contemporary systematic review and meta-analysis. *PLoS One* 2012;**7**:e50836.

372 21 Loo VG, Poirier L, Miller MA, *et al.* A predominantly clonal multi-institutional outbreak of *Clostridium*

373 *difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005;**353**:2442-9.

374 22 Kenneally C, Rosini JM, Skrupky LP, *et al.* Analysis of 30-day mortality for *Clostridium*

375 *difficile*-associated disease in the ICU setting. *Chest* 2007;**132**:418-24.

376 23 Hensgens MP, Goorhuis A, Dekkers OM, *et al.* All-cause and disease-specific mortality in hospitalized

377 patients with *Clostridium difficile* infection: a multicenter cohort study. *Clin Infect Dis* 2013;**56**:1108-16.

378 24 Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in *Clostridium difficile*

379 infection in the general hospital population: a systematic review. *J Hosp Infect* 2012;**82**:1-12.

380 25 Zar FA, Bakkanagari SR, Moorthi KM, *et al.* A comparison of vancomycin and metronidazole for the

381 treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis*

382 2007;**45**:302-7.

383 26 Otete EH, Ahankari AS, Jones H, *et al.* Parameters for the mathematical modelling of *Clostridium*

384 *difficile* acquisition and transmission: a systematic review. *PloS one* 2013;**8**:e84224.

385 27 Johnston BC, Ma SS, Goldenberg JZ, *et al.* Probiotics for the prevention of *Clostridium*

386 *difficile*-associated diarrhea: a systematic review and meta-analysis. *Ann Intern Med* 2013;**157**:878-88.

387

388

Title

Multi-institution Case-control and Cohort Study of Risk Factors for the Development and Mortality of *Clostridium difficile*

Infections in Japan

Corresponding author

Masahiko Takahashi

Chief Director, Department of Gastroenterology

National Hospital Organization Tokyo Medical Center

2-5-1 Higashigaoka, Meguro-Ku, Tokyo 152-8902, Japan

Phone number: +81-3-3411-0111

Fax number: +81-3-3412-9811

matakaha@ntmc.hosp.go.jp

Authors

Masahiko Takahashi ^{1*}, Nobuaki Mori ², Seiji Bito ³.

Author Affiliations

¹ Chief Director of Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

² Medical staff of Department of General internal medicine and Infectious diseases physician, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

³ Chief Director of Department of General internal medicine and epidemiologist, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Abstract

Objective: To examine risk factors for *Clostridium difficile* infection (CDI) morbidity and mortality in Japan.

Design: Multi-method investigation including a case–control study and cohort study.

Setting: Forty-seven participating facilities of the National Hospital Organization (NHO).

Participants: One thousand twenty six CDI patients and 878 patients in control group over the age of 18 years admitted to the subject NHO facilities from November 2010 to October 2011.

Main Outcome Measures: In case-control study, we identify risk factors for CDI development. Next, in cohort study, we identify risk factors for all-cause mortality within 30 days following CDI onset.

Results: A total of 1,026 cases of CDI meeting the definitions of this investigation were identified, encompassing 878 patients at 42 of the 47 subject facilities. In the case–control study, we identified, compared with no antibiotics use, use of first- and second-generation cephem antibiotics (odds ratio[OR], 1.44; 95% confidence interval [CI], 1.10 to 1.87), use of third- and fourth-generation cephem antibiotics(OR, 1.86; 95%CI, 1.48 to 2.33), and use of carbapenem antibiotics (OR, 1.87; 95%CI, 1.44 to 2.42) were risk factors for CDI development. However, use of penicillin was not identified as risk factors. In the cohort study, sufficient data for analysis was available for 924 CDI cases; 102 of them (11.0%) resulted in death within 30 days of CDI onset. Compared with no anti-CDI drug use, use of vancomycin was associated with reduced risk of mortality (OR, 0.43; 95%CI, 0.25 to 0.75) whereas metronidazole was not.

Conclusions: The findings mirror those of previous studies from Europe and North America, identifying the administration of broad-spectrum antibiotics as a risk factor for CDI development. The use of vancomycin is associated with a decreased risk of mortality.

Strengths and limitations of this study

- This study is the first large-scale nationwide multi-center CDI investigation in Japan.
- Most of the epidemiological data of CDI has been limited in the North America and Europe. Our data plays a role of completion of the missing data in Asia.
- Use of β -lactam antibiotics except penicillin was the risk factor for CDI development in the first Japanese large-scale investigation. Appropriate antibiotic use is necessary in order to control the incidence of CDI.
- Vancomycin administration for CDI was associated with decreased risk of mortality. Although the cost-effective treatment of CDI may necessitate the appropriate use of less-expensive metronidazole, vancomycin should be administered in case expected to become severe or life-threatening.
- ~~• The most salient limitation of the case-control study phase is the existence of many confounding factors. In particular, probiotic use, which was recently shown to be correlated with CDI prevention, was not included in the predictive model of this study.~~
- The limitation of this study is the low number of registered CDI cases from quite a few participants and the existence of many confounding factors.

1 58 **Introduction**

2
3
4 59 *Clostridium difficile* is the main causative pathogen of antibiotic-associated colitis. Since 2000, outbreaks of
5
6
7 60 BI/NAP1/027 strain *C. difficile* infections (CDI) have been reported in North American and European hospitals and elder
8
9
10 61 care facilities. The numbers of CDI patients as well as severe and intractable cases have increased simultaneously.
11
12
13 62 Consequently, epidemiological surveillance systems have been set up in several countries. However, very few countries
14
15
16 63 have implemented such national-level measures.

17
18 64 ~~In Japan, the Ministry of Health, Welfare, and Labor's Japan Nosocomial Infection Surveillance program investigates the~~
19
20
21 65 ~~incidence rates of a variety of drug-resistant bacteria; however, this program does not monitor the incidence rate of *C.*~~
22
23
24 66 ~~*difficile* (<http://www.nih-janis.jp/index.asp>). Therefore, CDI epidemiological studies in Japan to date have been based on~~
25
26
27 67 scattered data from individual medical facilities. Consequently, the phenomenon of CDI in Japan is not sufficiently
28
29
30 68 understood, including *C. difficile* typing.[1, 2, 3, 4, 5, 6, 7, 8, 9] ~~Reports of BI/NAP1/027 infections are limited, and~~
31
32
33 69 ~~conditions in Japan possibly differ from those in Europe and North America.~~

34
35
36 70 Previous studies report that antibiotic administration is the largest risk factor for CDI development. Other risk factors
37
38
39 71 include advanced age and proton pump inhibitor use. [1, 2][10, 11] CDI mortality rates differ depending on the presence or
40
41
42 72 absence of an outbreak as well as the relevant definitions of epidemiological surveillance. Furthermore, it is especially
43
44
45 73 difficult to objectively determine precise CDI-related mortality rates because of factors such as underlying patient
46
47
48 74 conditions. [3][12]

49
50 75 This report documents a case-control study of CDI in Japan based on data from the National Hospital Organization
51
52
53 76 (NHO), which is Japan's largest group of hospitals and includes facilities located nationwide. In addition, a cohort
54
55
56 77 investigation of mortality among CDI cases was conducted.

58
59 78 **Materials and Methods**

Research Design

This multicenter study is a collaborative effort of the 47 facilities that met our facility standards from among the 143 NHO facilities in Japan. The study was planned as a part of the NHO's "National Hospital Organization Multi-Center Clinical Research for Evidence-Based Medicine" project. This study was conducted with the approval of the Central Ethics Committee of the NHO. The CDI group in this study included in principal all newly diagnosed CDI cases among patients hospitalized from November 1, 2010 to October 31, 2011; cases were registered continuously.

In the case-control study of CDI development, CDI cases newly diagnosed during the investigation period were registered in the CDI group; meanwhile, age-, sex-, and underlying disease-matched patients in the same facilities were registered to the control group. In addition, a prospective cohort study of CDI group patients who died within 30 days of CDI development was conducted. This investigation is a multi-method study using standard case-control and cohort study designs.

Definition of CDI

CDI was defined as the presence of any gastrointestinal symptoms accompanied by a clinical suspicion of CDI as well as a positive result for *C. difficile* toxins from rapid stool testing or *C. difficile* isolation from stool cultures or both. Final determinations were made by the attending physician or the facility's infection control team.

Enzyme immunoassay testing kits for *C. difficile* toxins A and B were used as the rapid testing method (Immunocard CD toxin A&B, Meridian Bioscience Inc., Cincinnati, OH, USA; C. Diff Quik Chek, Alere Medical Co. Ltd., Tokyo, Japan; Tox A/B Quik Chek, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan; X/pect Toxin A/B, Kanto Chemical Co Ltd., Tokyo, Japan). Cycloserine-cefoxitin mannitol agar (Nissui-pure-to CCMA baichi EX, Nissui Pharmaceutical Co. Ltd., Tokyo, Japan), cycloserine-cefoxitin fructose agar (CCFA baichi, Becton, Dickinson and Company Co. Ltd., Tokyo, Japan; Poamedhia[®] CCFA[®] kairyoubaichi, Eiken Chemical Co., Ltd., Tokyo, Japan), and brucella HK agar (RS) (brucella HK agar (RS),

1 100 Kyokuto Pharmaceutical Industrial Co. Ltd., Tokyo, Japan) were used in the *C. difficile* isolation cultures.

4 101 **Case–Control Study of CDI Development**

7 102 No additional information besides age, sex, and date of diagnosis was gathered when new patients were registered in the
10 103 CDI group. After the end of the study registration period, additional patient clinical data were gathered, including clinical
13 104 department, underlying diseases, dates of hospital admittance and discharge, and medical treatments administered for ≥ 3
16 105 days between admittance and CDI development. Recorded treatments included disruption of feeding, parenteral nutrition,
19 106 enteral feeding, surgery with general anesthetic, cancer drugs, antibiotics (excluding external-use antibiotics), proton pump
22 107 inhibitors (oral or intravenous). We also collected data regarding the use of intravenous antibiotics including penicillins,
25 108 first- and second-generation cepheems, third- and fourth-generation cepheems, carbapenems, fluoroquinolones,
28 109 clindamycin/lincomycin, anti–Methicillin-resistant *Staphylococcus aureus* (MRSA) drugs, and anti-fungal drugs, and others.
31 110 Finally, we collected data regarding the use of oral antibiotics including cepheems, fluoroquinolones, and others.

34 111 The control group was divided into three subgroups according to age: ≤ 74 , 75–84, and ≥ 85 years. The control patients
37 112 were selected from among patients at the same facilities who did not contract CDI and were matched to the CDI patients
40 113 with respect to age, sex, underlying disease, and hospital stays of ≥ 5 days within the same month as a counterpart’s CDI
43 114 diagnosis. The control group cases were selected regardless of gastrointestinal symptoms such as diarrhea. We strove to
46 115 ensure that the CDI and control groups were as matched as possible. The same data were collected from both groups. The
49 116 control patients were registered, and relevant patient data were gathered after the end of the CDI group study registration
52 117 period.

53 118 **Cohort Study on Mortality among CDI Patients**

56 119 The prospective cohort study of registered CDI group patients from the case–control study examined all-cause mortality
59 120 within 30 days as the primary outcome. Clinical outcomes of patients who discharged within 30 days of CDI

development were not investigated in this study. The following data were collected: whether the underlying disease was infectious and whether comorbidities were related to malignant tumors (i.e., gastrointestinal, respiratory, blood/lymph, gynecologic, urological, or other tumors including cancers of the ear, nose, and throat), diabetes, renal failure, heart failure, respiratory failure, or cirrhosis. We also considered patient nutritional status including whether the patient was subjected to parenteral nutrition or enteral feeding as well as serum albumin levels measured within 30 days prior to CDI development (i.e., ≥ 3.5 , 2.7–3.4, or ≤ 2.6 g/dL). In addition, we examined CDI treatment factors including whether antibiotic use was halted, probiotic use, and the type of anti-CDI drugs used (i.e., vancomycin and metronidazole). All patient data for the cohort investigation were collected after the end of the registration period.

Data Management and Statistical Analysis

~~The study coordinator established independent data management centers within the NHO facilities for data collection.~~ All input data were verified by a designated study data manager. Data from each facility were entered directly into a web-based case report form and subsequently encrypted for security. The data management center was responsible for confirming any missing data and directly inquiring the relevant facilities as necessary. ~~After the end of the study period, the data were finalized and subsequently transferred to the Research Coordinator's office.~~

During the case-control phase of the study, CDI development was treated as the outcome and odds ratios (ORs) were calculated from bivariate analysis comparing the use of different types of antibiotics as outcome causes. For each type of antibiotic, those used for ≥ 3 days were designated “used” while all others were designated “unused.” A dummy variable regression was subsequently performed. Statistical significance in the bivariate analysis was tested by the chi-square test. Logistic regression analysis was performed using the individual patient characteristics and other assumed confounding variables as independent variables. The 95% confidence intervals (CIs) for each variable were used to determine the relationships between the various predictive variables and outcomes.

1 142 In the cohort study, gastrointestinal perforations, toxic megacolon, CDI-related surgeries, and the all-cause in-hospital
2
3
4 143 mortality of patients within 30 days of CDI development were recorded. The clinical outcome of mortality within 30 days
5
6
7 144 was set as the dependent variable, and the relationships among the underlying diseases, nutritional status, probiotic use, and
8
9
10 145 types of anti-CDI drugs used were subjected to bivariate and multivariate analyses. Like the case-control phase, bivariate
11
12
13 146 analysis were conducted using the chi-square test, and the multivariate analysis was conducted using logistic regression.
14
15
16 147 The significance level for all analyses was set at $p < 0.05$. We used IBM SPSS Statistics version 20 for statistical analysis.
17

18 148 **Ethics Committee Approval and Informed Consent**

19
20
21 149 This study was conducted with the approval of the Central Ethics Committee of the NHO. In principle, individual patients
22
23
24 150 who met the inclusion criteria were not given direct explanations of the study, and no direct consent was sought.
25
26
27 151 Information about the study was made public through postings on facility notice boards and webpages. Patients and their
28
29
30 152 representative agents had the right to refuse study participation.
31
32

33 153
34
35
36 154 **Results**

37
38 155 **Participating Facilities**

39
40
41 156 Among the 47 facilities, a total of 1,026 CDI cases were registered at 42 facilities throughout Japan, from Hokkaido in
42
43
44 157 the north to Okinawa in the south. No CDI cases were recorded at the remaining 5 participating facilities, more than 280
45
46
47 158 patient beds (Table 1). ~~The regional locations of the 47 facilities were as follows: 5 in Hokkaido and Tohoku, 10 in Kanto~~
48
49
50 159 ~~and Koshinetsu, 2 in Tokai and Hokuriku, 9 in Kinki, 10 in Chugoku and Shikoku, and 11 in Kyushu and Okinawa.~~
51
52
53 160
54
55
56
57
58
59
60

Table 1. Number of registered cases of CDI and characteristics of hospitals included in the surveillance of CDI in the NHO (from november 2010 through october 2011)

Region	No. patient beds	No. patient days	No. patients registered		30-day all-cause mortality in CDI group	Bacteriological survey Laboratory tests used	
			CDI group	Control group		EIA detection- toxins A and B EIA for toxins A and B	Culture
Hokkaido, tohoku	698	208,388	55	55	3 (5%)	+	+
	500	150,603	42	32	1 (2%)	+	+
	310	82,687	28	19	2 (7%)		+
	310	72,144	17	12	2 (12%)	+	+
	220	76,539	1	1	0 (0%)	+	+
Kanto, koshinetsu	780	238,420	124	121	15 (12%)	+	+
	455	151,622	36	36	3 (8%)	+	
	560	158,921	35	30	4 (11%)	+	+
	243	60,155	34	34	6 (18%)	+	+
	350	109,025	22	22	4 (18%)	+	+
	500	159,432	15	14	1 (7%)	+	
	510	166,668	4	4	0 (0%)	+	
	380	109,482	3	2	0 (0%)	+	+
	455	132,483	3	1	0 (0%)	+	
Tokai, hokuriku	430	195,209	42	26	10 (24%)	+	+
	280	56,475	0	0	— (—)	+	
Kinki	316	103,677	24	22	1 (4%)	+	
	220	47,354	23	23	1 (4%)	+	+
	600	191,041	20	20	3 (15%)	+	
	494	70,455	15	15	6 (40%)	+	+
	520	145,299	13	9	1 (8%)	+	
	500	142,409	6	6	1 (17%)	+	
	180	55,721	3	3	1 (33%)	+	
	346	118,014	2	2	0 (0%)	+	
	370	94,722	0	0	— (—)	+	
Chugoku, shikoku	388	99,728	54	49	5 (9%)	+	+
	700	211,595	49	48	4 (8%)	+	+
	506	119,356	33	8	1 (3%)	+	+
	400	122,846	30	30	5 (17%)	+	
	401	108,303	26	0	2 (8%)	+	+
	250	80,558	21	21	0 (0%)	+	
	424	128,868	12	10	0 (0%)	+	
	365	125,645	10	10	3 (30%)	+	+
	300	87,061	0	0	— (—)		+
Kyushu, okinawa	459	66,454	0	0	— (—)	+	
	424	137,827	46	22	5 (11%)	+	
	702	239,448	38	37	1 (3%)	+	
	190	54,038	33	31	9 (27%)	+	
	550	189,417	27	26	3 (11%)	+	
	285	58,185	25	25	3 (12%)	+	
	500	140,371	24	23	2 (8%)	+	
	300	90,457	14	14	4 (29%)	+	
	320	103,315	6	5	1 (17%)	+	+
	280	79,580	4	4	2 (50%)	+	
Total	366	112,906	4	4	0 (0%)	+	
	368	89,195	3	2	2 (67%)	+	
Total	19,486	5,592,077	1,026	878	117 (11%)	45	20

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1 163 **Patient Grouping**

2
3
4 164 A total of 1,026 CDI cases that met the study definitions were recorded at the various institutions. We were unable to
5
6
7 165 collect clinical records regarding medical treatments for 1 case; therefore, this case was excluded from the case-control
8
9
10 166 study, and the remaining 1,025 cases were analyzed. A total of 962 patients (93.9%) developed CDI within 48 hours after
11
12
13 167 hospital admittance. The control group comprised 878 patients who were selected from 41 of the 42 facilities. In the cohort
14
15
16 168 study, we analyzed the data from 924 of the 1,025 CDI group patients, excluding 101 patients with no available recent
17
18
19 169 serum albumin level data (i.e., within 30 days prior to CDI development (Figure 1).

20
21 170 **Case-Control Study of CDI Development**

22
23
24 171 The mean ages of the CDI and control groups were 75.8 and 75.4 years, respectively. The majority of the subjects were of
25
26
27 172 advanced age: 64.0% and 62.5% of the CDI and control group patients were aged ≥ 75 years, respectively. No significant
28
29
30 173 differences were identified between the CDI and control groups in the univariate analysis of age distribution, sex differences,
31
32
33 174 or underlying disease (Table 2). Among the medical treatments administered before CDI development, the following were
34
35
36 175 significantly more prevalent in the CDI group than the control group: disruption of feeding (48.6% vs. 30.4%), parenteral
37
38
39 176 nutrition (24.7% vs. 10.3%), and enteral feeding (24.8% vs. 9.1%). Antibiotics were used prior to CDI development in
40
41
42 177 85.8% of cases. The use of all types of intravenous antibiotics was significantly more prevalent in the CDI group. No
43
44
45 178 significant differences were identified between the 2 groups with respect to oral antibiotic use. Meanwhile, in the univariate
46
47
48 179 analysis, proton pump inhibitor use was significantly more prevalent in the CDI group than the control group (40.3% vs.
49
50 180 31.2%).

51
52
53 181 We used logistic regression analysis to determine the risk factors for CDI development. The following medical treatments
54
55
56 182 prior to CDI development were identified as significant risk factors in comparison to the control group: disruption of
57
58
59 183 feeding (odds ratio[OR], 1.31; 95% confidence interval[CI], 1.05 to 1.64), parenteral nutrition (OR, 1.63; 95%CI, 1.21 to
60

2.20) and enteral feeding (OR, 2.16; 95%CI, 1.60 to 2.92).The following intravenous antibiotics were also identified as statistically significant risk factors for CDI development: first- and second-generation cepheems (OR, 1.44; 95%CI, 1.10 to 1.87), third- and fourth-generation cepheems (OR, 1.86; 95%CI, 1.48 to 2.33), and carbapenems (OR, 1.87; 95%CI, 1.44 to 2.42). However, penicillin (OR, 1.04; 95%CI, 0.82 to 1.33), fluoroquinolones (OR, 1.16; 95%CI, 0.74 to 1.83), clindamycin/lincomycin (OR, 1.35; 95%CI, 0.81 to 2.26), and proton pump inhibitor use (OR, 1.17; 95%CI, 0.95 to 1.44) were not identified as risk factors.

Table 2. Univariate and multivariate analyses of CDI development-related risk factors

Characteristics	CDI group	Control group	Univariate analysis	Multivariate analysis	
	%	%	P value	Odds ratio (95% CI)	P value
All	(1,025)	(878)	—	—	—
Age					
≤74 years	36.0 (369)	37.5 (329)	0.67	Ref.	—
75–84 years	37.0 (379)	37.2 (327)		1.02 (0.81 to 1.28)	0.88
≥85 years	27.0 (277)	25.3 (222)		1.09 (0.84 to 1.41)	0.52
Sex					
Women	43.0 (441)	42.6 (374)	0.85	1.11 (0.91 to 1.36)	0.28
Underlying disease					
Respiratory infections	15.8 (162)	17.5 (154)	0.14	—	—
Other infectious conditions	16.9 (173)	14.2 (125)		—	—
Gastrointestinal conditions	8.1 (83)	9.0 (79)		—	—
Malignant tumors	22.6 (232)	24.3 (213)		—	—
Cardiovascular conditions	7.7 (79)	9.8 (86)		—	—
Other conditions	28.9 (296)	25.2 (221)		—	—
Medical treatment prior to CDI development					
Disruption of feeding	48.6 (498)	30.4 (267)	<0.001	1.31 (1.05 to 1.64)	<0.05
Parenteral nutrition	24.7 (253)	10.3 (90)	<0.001	1.63 (1.21 to 2.20)	<0.01
Enteral feeding	24.8 (254)	9.1 (80)	<0.001	2.16 (1.60 to 2.92)	<0.001
Surgery with general anesthetic	18.2 (187)	15.6 (137)	0.14	0.89 (0.67 to 1.18)	0.41
Cancer drugs	11.3 (116)	14.2 (125)	0.06	0.86 (0.62 to 1.18)	0.35
Antibiotics use	85.8 (879)	66.5 (584)	<0.001	—	—
Intravenous					
Penicillins	27.6 (283)	21.0 (184)	<0.01	1.04 (0.82 to 1.33)	0.75
First/second-generation cephe	22.7 (233)	15.6 (137)	<0.001	1.44 (1.10 to 1.87)	<0.01
Third/fourth-generation cephe	35.2 (361)	19.9 (175)	<0.001	1.86 (1.48 to 2.33)	<0.001
Carbapenems	31.8 (326)	15.0 (132)	<0.001	1.87 (1.44 to 2.42)	<0.001
fluoroquinolones	7.5 (77)	4.0 (35)	<0.01	1.16 (0.74 to 1.83)	0.52
Clindamycin/lincomycin	6.5 (67)	2.8 (25)	<0.001	1.35 (0.81 to 2.26)	0.25
MRSA drugs	10.7 (110)	4.3 (38)	<0.001	1.10 (0.71 to 1.72)	0.66
Anti-fungal drugs	6.9 (71)	3.2 (28)	<0.001	1.01 (0.60 to 1.70)	0.96
Others(aminoglycosides, monobactam,etc.)	8.5 (87)	5.9 (52)	<0.05	1.19 (0.80 to 1.77)	0.39
Oral					
Cephems	5.6 (57)	4.4 (39)	0.29	1.49 (0.95 to 2.32)	0.08
fluoroquinolones	14.5 (149)	11.5 (101)	0.06	1.11 (0.82 to 1.51)	0.49
Others (macrolides, penicillins, etc.)	14.0 (144)	13.9 (122)	0.95	0.84 (0.63 to 1.13)	0.26
Proton pump inhibitors	40.3 (413)	31.2 (274)	<0.001	1.17 (0.95 to 1.44)	0.14

Cohort Study on Mortality among Patients with CDI

The cohort study examined mortality among the 924 patients from the 1,025 CDI group patients in the case-control study for whom serum albumin level data before CDI development were available.

Among the 924 patients, 102 (11.0%) died within 30 days of developing CDI. Among those cases, the cause of death was attributed to CDI in 11 cases (1.2%). Of 11 patients, a patient had gastrointestinal perforation, another patient had CDI-related surgery, and the others were not reported as severe complications. The toxic megacolon was reported in 2 patients however, they were not died within 30 days of CDI development. The mean age of the 102 patients who died during the study was 80.1 ± 8.3 years. Patients ≥ 75 years old were especially prevalent in this subgroup, accounting for 77.5% (79/102) of the cases.

~~Some patients developed severe complications within 30 days of CDI development, including gastrointestinal perforation in 1 patient (0.1%) and toxic megacolon in 2 patients (0.2%); 1 patient (0.1%) underwent a CDI-related surgery.~~ Among the 714 cases in which CDI was treated directly, recurrence within 30 days was observed in 34 cases (4.8%).

The univariate analysis indicated that comorbidities of heart and respiratory failure were significantly more prevalent among CDI patients. In addition, lower serum albumin levels were significantly associated with mortality. Among CDI treatments, mortality was significantly lower among cases in which probiotics were administered.

A logistic regression analysis of the 102 cases in which the patients died within 30 days of CDI development was performed to identify the factors associated with the risk of mortality. Compared to patients ≤ 74 years old, the odds ratio of mortality among patients aged 75–84 years was 2.08 (95%CI, 1.19 to 3.62). Among underlying diseases, heart failure (OR, 2.12; 95%CI, 1.26 to 3.55) and respiratory failure (OR, 1.98; 95%CI, 1.19 to 3.32) were identified as risk factors for mortality within 30 days of CDI development. Regarding nutritional status, neither parenteral nutrition nor enteral nutrition was identified as a risk factor for mortality. However, low serum albumin level (i.e., ≤ 2.6 g/dL) was identified as a significant risk factor for mortality (OR, 3.50; 95%CI, 1.33 to 9.22). Among CDI treatments, probiotic use (OR, 0.66;

1 216 95%CI, 0.42 to 1.04) was not identified as a risk factor for mortality. However, compared to cases in which no anti-CDI
2
3
4 217 drugs were administered, vancomycin administration yielded an odds ratio of 0.43 (95%CI, 0.25 to 0.75), indicating a
5
6
7 218 significantly lowered risk of mortality in the CDI group. Meanwhile, no such lowered mortality was observed in cases
8
9
10 219 treated with metronidazole (OR, 0.85; 95%CI, 0.48 to 1.51).
11
12 220

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2014-005665 on 3 September 2014. Downloaded from <http://bmjopen.bmj.com/> on April 10, 2024 by guest. Protected by copyright.

Table 3. Univariate and multivariate analyses of all-cause mortality in CDI patients

Characteristics	All-cause mortality rate %	Univariate analysis P value	Multivariate analysis	
			Odds ratio (95% CI)	P value
All	11.0 (102/924)	—	—	—
Age				
≤74 years	7.1 (23/326)	<0.05	Ref.	
75–84 years	13.3 (47/353)		2.08 (1.19 to 3.62)	<0.05
≥85 years	13.1 (32/245)		1.86 (0.98 to 3.55)	0.06
Sex				
Men	12.2 (64/524)	0.21	Ref.	
Women	9.5 (38/400)		0.78 (0.49 to 1.24)	0.29
Underlying disease				
Non-infectious	10.3 (64/619)	0.37	Ref.	
Infectious	12.5 (38/305)		0.99 (0.60 to 1.62)	0.97
Comorbidities				
Malignant tumors				
Not present	10.6 (67/630)	0.57	Ref.	
Present	11.9 (35/294)		1.54 (0.94 to 2.53)	0.09
Diabetes				
Not present	11.6 (89/765)	0.27	Ref.	
Present	8.2 (13/159)		0.71 (0.37 to 1.35)	0.29
Renal failure				
Not present	10.7 (84/784)	0.46	Ref.	
Present	12.9 (18/140)		0.90 (0.49 to 1.65)	0.73
Heart failure				
Not present	9.3 (70/756)	<0.01	Ref.	
Present	19.0 (32/168)		2.12 (1.26 to 3.55)	<0.01
Respiratory failure				
Not present	9.2 (69/754)	<0.001	Ref.	
Present	19.4 (33/170)		1.98 (1.19 to 3.32)	<0.01
Cirrhosis				
Not present	11.2 (100/895)	0.76	Ref.	
Present	6.9 (2/29)		0.61 (0.13 to 2.83)	0.53
Indicators of nutritional status				
Parenteral nutrition or enteral feeding				
Not present	9.4 (53/563)	0.05	Ref.	
Present	13.6 (49/361)		1.16 (0.73 to 1.84)	0.53
Serum albumin (g/dL)				
≥3.5	4.0 (5/124)	<0.001	Ref.	
2.7–3.4	7.2 (27/376)		1.55 (0.57 to 4.21)	0.39
≤2.6	16.5 (70/424)		3.50 (1.33 to 9.22)	<0.05
CDI treatments				
Cessation of antibiotics				
Not present	12.5 (65/519)	0.11	Ref.	
Present	9.1 (37/405)		0.77 (0.48 to 1.22)	0.26
Probiotics (for intestine treatment)				
Not present	13.8 (52/378)	<0.05	Ref.	
Present	9.2 (50/546)		0.66 (0.42 to 1.04)	0.08
Anti-CDI drugs				
Not present	15.2 (32/210)	<0.05	Ref.	
Vancomycin alone	7.4 (32/433)		0.43 (0.25 to 0.75)	<0.01
Metronidazole alone	13.5 (32/237)		0.85 (0.48 to 1.51)	0.59
Vancomycin and metronidazole	13.6 (6/44)		0.75 (0.27 to 2.08)	0.57

223 **Discussion**

224 This is the first large-scale clinical study of CDI in Japan. This study examined 1,026 cases of CDI recorded over 1 year

225 at the nationwide facilities of Japan's largest hospital group. The findings of this investigation are similar to those reported

226 in previous studies conducted in Europe, North America, and Australia with respect to the identification of several risk

227 factors for CDI development, including age, severity of the underlying condition, ~~and~~ artificial feeding ~~and~~ mortality. ~~[2, 4,~~

228 ~~5]~~ [11, 13, 14] Antibiotic use is a known risk factor for CDI development. ~~[6]~~ [15] The present case-control study confirms

229 that intravenous cepheems and carbapenems are important risk factors. Some studies report a low risk of CDI development

230 owing to intravenous penicillin administration. ~~[7, 8]~~ [16, 17] Concordantly, penicillin use was not identified as a risk factor

231 in the present study. ~~Although~~ The proton pump inhibitor use was discussed as a risk factor for CDI development in the

232 previous studies. ~~[9, 10].~~ [18, 19, 20] In the present logistic regression analysis, it was not identified as a risk factor. This

233 ~~finding might be influenced by the relatively high *Helicobacter pylori* infection rate in elderly Japanese people; proton~~

234 ~~pump inhibitors might produce smaller changes in pH levels in such patients than American and European patients. [11]~~

235 In this study, 11.0 % of CDI patients died within 30days. In comparison, higher 30-day mortality rates have been reported

236 in previous outbreaks: 24.8% in the ribotype 027 strain outbreak in Canada, and 36.7% in an examination of a single

237 intensive care unit in the USA. ~~[12, 13]~~ [21, 22] However, reports of non-outbreak conditions indicate mortality rates of 13%,

238 similar to the findings of the present study. ~~[14]~~ [23] Some reports state that the CDI-associated mortality rate has increased

239 2.5 fold, possibly indicating that CDI cases are more severe and contribute more significantly to mortality than previously

240 thought. ~~[3, 14]~~ [12, 23] The mortality rate of CDI patients is reported to increase with age. ~~[15]~~ [24] Concordantly, the

241 present study also found a significantly elevated risk of death in patients ≥ 75 years old.

242 The findings of this study indicate that the mortality risk of CDI patients was not reduced as a result of metronidazole

243 treatment but was reduced with vancomycin treatment, corroborating the existing recommendation. ~~[16]~~ [25] It is worth

244 noting that metronidazole is less expensive than vancomycin, making it economically advantageous. a patient's condition

must be carefully evaluated when selecting anti-CDI drugs. In particular, for patients in the present study who had conditions associated with a greater mortality risk, including advanced age (i.e., ≥ 75 years), heart or respiratory failure, or malnutrition as determined by low serum albumin levels, the use of vancomycin rather than metronidazole for treatment appears to have provided better outcomes. The recurrence rate was low (4.8%) in this study compared to the previous studies. [11, 26] We did not investigate the patients neither after 30 days of CDI development nor the patients who discharge even if within 30 days of CDI development. Therefore, the recurrence rate might be underestimated.

Regardless, this study has also several methodological limitations. The most salient limitation is the low number of registered CDI cases from quite a few participants. In the definition of CDI, the times of diarrhea were not investigated. The most salient-Another limitation of the case-control study phase is the existence of many confounding factors. In particular, probiotic use, which was recently discussed shown to be correlated with CDI prevention, was not included in the predictive model of this study. [17][10, 11, 27] When interpreting the findings of this study, it is necessary to consider the influence of confounding factors that were not included in the analytical models. Regarding antibiotic use, the present analyses included independent explanatory variables for each antibiotic. However, actual antibiotic use is more complicated. Therefore, it is difficult to clearly determine the roles of individual antibiotics as risk factors for CDI development. Concerning matching process, we tried to adopt 1 to 1 pair sampling matched with sex, age group and main diagnosis. Some hospital could not find appropriate control sample well matched with case sample. So total number of the control group was less than that of the case sample. In addition, although data for the control group were analyzed during the entire study period until hospital discharge, only data from the period prior to CDI development were analyzed in the CDI group. Therefore, the risks might be underestimated, because the control group had a longer period of exposure risk than the CDI group. Confounding factors that were not included in the present analyses also represent a

1 266 limitation of the cohort study phase. Furthermore, issues of data quality among the facilities affect all aspects of this study.
2
3
4 267 More than 40 different facilities participated in this study. While some facilities registered nearly all of their CDI patients,
5
6
7 268 other facilities registered smaller proportions of patients. ~~Only C. difficile culture but not toxin test was used for the~~
8
9
10 269 ~~laboratory test in two facilities.~~ Finally, there might have been differences with regard to individual researchers’
11
12
13 270 understanding of the outcome definitions.
14
15
16 271 ~~As the Japanese population continues to age, the number of elderly patients suffering from multiple ailments is increasing~~
17
18 272 ~~as well. As the number of patients requiring intravenous administration of broad-spectrum antibiotics has increased, close~~
19
20
21 273 ~~and careful monitoring of CDI epidemiology is necessary.~~ In order to ensure appropriate antibiotic use and control the
22
23
24 274 incidence of CDI, it is important to create institutional measures such as infection control teams ~~and to not limit such~~
25
26
27 275 ~~controls to the efforts of individual doctors.~~ The cost-effective treatment of CDI may necessitate the appropriate use of
28
29
30 276 less-expensive metronidazole. However, in cases expected to become severe or life-threatening, the more expensive drug
31
32
33 277 vancomycin should be administered. ~~In countries facing an aging population,~~ CDI is one of many issues concerning
34
35
36 278 medicine and medical treatment costs. Accordingly, further and more proactive research into CDI epidemiology is needed.
37
38
39 279

40
41 280 **Acknowledgements**

42
43
44 281 The authors would like to express their sincere gratitude to Dr. Haru Kato and the Department of Bacteriology II,
45
46
47 282 National Institute of Infectious Diseases, Tokyo, Japan for their expert advice regarding CDI and the provision of CDI
48
49
50 283 training to the participating facilities.
51
52

53 284 We also wish to thank the participating institutions in the CD-NHO study Group for their collaboration with data and
54
55
56 285 sample collection: Hisaji Oshima (NHO Tokyo Medical Center); Hiroshi Miki (NHO Sendai Medical Center); Keisei
57
58
59 286 Shimoe (NHO Fukuyama Medical Center); Harumi Tominaga (NHO Kure Medical Center); Toyomitsu Sawai and Eisuke
60

- 287 Sasaki (NHO Ureshino Medical Center); Shie Nishijima and Naoko Maeda (NHO Shizuoka Medical Center); Masaru
- 288 Amishima (NHO Hokkaido Medical Center); Miki Odawara (NHO Kyushu Medical Center); Mitsuhiro Kamimura (NHO
- 289 National Disaster Medical Center); Hideaki Nagai (NHO Tokyo National Hospital); Kiyoshi Furuta (NHO Matsumoto
- 290 Medical Center, Matsumoto Hospital); Tohru Yamanaka (NHO Kumamoto Minami Hospital); Ikuko Mizouchi (NHO
- 291 Minimi-Okayama Medical Center); Yutaka Sato (NHO Kanmon Medical Center); Keita Ato and Hiroki Saito (NHO
- 292 Asahikawa Medical Center); Yoshio Haga (NHO Kumamoto Medical Center); Isao Murakami (NHO Higashihiroshima
- 293 Medical Center); Takeshi Yarmayo (NHO Nagasaki Kawatana Medical Center); Hiroyuki Akiyama and Yukino Yoshikura
- 294 (NHO Minami Wakayama Medical Center); Akiko Muratake (NHO Beppu Medical Center); Masato Hasegawa (NHO
- 295 Higashi-Ohmi General Medical Center); Isamu Kamimaki (NHO Saitama National Hospital); Tomoaki Kosyoubu (NHO
- 296 Yonago Medical Center); Takao Odagaki (NHO Kyoto Medical Center); Nozomu Iwashiro (NHO Hakodate National
- 297 Hospital); Hiroyasu Ishida (NHO Mito Medical Center); Hiroshi Komatsu (NHO Maizuru Medical Center); Kaoru Nakama
- 298 (NHO Oita Medical Center); Yoshiko Yamamoto (NHO Osaka Minami Medical Center); Yoshihito Iwahara (NHO Kochi
- 299 National Hospital); Fumiko Okino (NHO Yamaguchi-Ube Medical Center); Daisuke Higuchi (NHO Okinawa National
- 300 Hospital); Kazuhiro Satonaka (NHO Hyogo-Chuo National Hospital); Takayoshi Soga and Haruko Ideguchi (NHO
- 301 Yokohama Medical Center); Mayuko Watanabe (NHO Kagoshima Medical Center); Kozaburo Hiramatsu (NHO Nagasaki
- 302 National Hospital); Mitsugu Saito (NHO Awara National Hospital); Morio Sawamura (NHO Nishigunma National
- 303 Hospital); Satoru Kaneda (NHO Chiba Medical Center); Kenji Okada (NHO Fukuoka National Hospital); Katsuhiro Suzuki
- 304 (NHO Kinki-Chuo Chest Medical Center); Tetsuko Chiba and Keiji Chida (NHO Iwate National Hospital); Akihiko Tamura
- 305 (NHO Tochigi Medical Center); Shunji Matsuda (NHO Ehime Medical Center); Takaya Maruyama (NHO Mie National
- 306 Hospital); Shigeaki Kimura (NHO Tokushima National Hospital); Shin Oguri (NHO Minami Kyoto National Hospital)

Contributors

MT conceived the idea for the study, designed the study, developed the protocol, was responsible for study management and data collection, interpreted the findings, and drafted the paper. NM contributed to data analysis and interpretation of findings and drafted the paper. SB designed this study, developed the protocol, performed data analysis, and interpreted findings, and drafted the paper. All authors read and approved the final manuscript.

Funding

This study was supported by a grant from the National Hospital Organization (multi-center clinical studies for evidenced-based medicine).

Competing interests

None.

Ethics approval

The Central Ethics Committee of the NHO.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data are available.

Contributorship Statement

All authors had full access to all of the data and can take responsibility for the integrity of the data and the accuracy of the data analysis. The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

References

1 Honda H, Yamazaki A, Sato Y, *et al*. Incidence and mortality associated with *Clostridium difficile* infection at a Japanese tertiary care center. *Anaerobe* 2014;**25**:5-10.

2 Kato H, Ito Y, van den Berg RJ, *et al*. First isolation of *Clostridium difficile* 027 in Japan. *Euro Surveill* 2007;**12**:E070111 3.

3 Kato H, Kato N, Watanabe K, *et al*. Analysis of *Clostridium difficile* isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan. *J Clin Microbiol* 2001;**39**:1391-5.

4 Tagashira Y, Kato H, Senoh M, *et al*. Two cases of fulminant colitis due to binary toxin-positive *Clostridium difficile* that are not PCR ribotype 027 or type 078. *J Med Microbiol* 2013;**62**:1486-9.

5 Sawabe E, Kato H, Osawa K, *et al*. Molecular analysis of *Clostridium difficile* at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. *Eur J Clin Microbiol Infect Dis* 2007;**26**:695-703.

6 Iwashima Y, Nakamura A, Kato H, *et al*. A retrospective study of the epidemiology of *Clostridium difficile* infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. *J Infect Chemother* 2010;**16**:329-33.

7 Kato H, Ito Y, Akahane T, *et al*. Typing of *Clostridium difficile* isolates endemic in Japan by sequencing of *slpA* and its application to direct typing. *J Med Microbiol* 2010;**59**:556-62.

8 Collins DA, Hawkey PM, Riley TV. Epidemiology of *Clostridium difficile* infection in Asia. *Antimicrob Resist Infect Control* 2013;**2**:21.

9 Nakamura I, Yamaguchi T, Tsukimori A, *et al*. Fulminant colitis from *Clostridium difficile* infection, the epidemic strain ribotype 027, in Japan. *J Infect Chemother* 2014;**20**:380-3.

10 Rupnik M, Wilcox MH, Gerding DN. *Clostridium difficile* infection: new developments in epidemiology and pathogenesis. *Nat Rev Microbiol* 2009;**7**:526-36.

11 Cohen SH, Gerding DN, Johnson S, *et al*. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;**31**:431-55.

12 Mitchell BG, Gardner A. Mortality and *Clostridium difficile* infection: a review. *Antimicrob Resist Infect Control* 2012;**1**:20.

13 Freeman J, Bauer MP, Baines SD, *et al*. The changing epidemiology of *Clostridium difficile* infections. *Clin Microbiol Rev* 2010;**23**:529-49.

14 Bliss DZ, Johnson S, Savik K, *et al*. Acquisition of *Clostridium difficile* and *Clostridium difficile*-associated diarrhea in hospitalized patients receiving tube feeding. *Ann Intern Med* 1998;**129**:1012-9.

15 Owens RC, Jr., Donskey CJ, Gaynes RP, *et al*. Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clin Infect Dis* 2008;**46 Suppl 1**:S19-31.

16 Brown KA, Khanafer N, Daneman N, *et al*. Meta-analysis of antibiotics and the risk of community-associated *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2013;**57**:2326-32.

17 Deshpande A, Pasupuleti V, Thota P, *et al*. Community-associated *Clostridium difficile* infection and antibiotics: a meta-analysis. *J Antimicrob Chemother* 2013;**68**:1951-61.

18 Dial S, Delaney JA, Barkun AN, *et al*. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA* 2005;**294**:2989-95.

19 Kwok CS, Arthur AK, Anibueze CI, *et al*. Risk of *Clostridium difficile* infection with acid suppressing

- drugs and antibiotics: meta-analysis. *Am J Gastroenterol* 2012;**107**:1011-9.
- 20 Tleyjeh IM, Bin Abdulhak AA, Riaz M, *et al.* Association between proton pump inhibitor therapy and *Clostridium difficile* infection: a contemporary systematic review and meta-analysis. *PLoS One* 2012;**7**:e50836.
- 11 Asaka M, Kimura T, Kudo M, *et al.* Relationship of *Helicobacter pylori* to serum pepsinogens in an asymptomatic Japanese population. *Gastroenterology* 1992;**102**:760-6.
- 1221 Loo VG, Poirier L, Miller MA, *et al.* A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005;**353**:2442-9.
- 1322 Kenneally C, Rosini JM, Skrupky LP, *et al.* Analysis of 30-day mortality for *Clostridium difficile*-associated disease in the ICU setting. *Chest* 2007;**132**:418-24.
- 1423 Hensgens MP, Goorhuis A, Dekkers OM, *et al.* All-cause and disease-specific mortality in hospitalized patients with *Clostridium difficile* infection: a multicenter cohort study. *Clin Infect Dis* 2013;**56**:1108-16.
- 1524 Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in *Clostridium difficile* infection in the general hospital population: a systematic review. *J Hosp Infect* 2012;**82**:1-12.
- 1625 Zar FA, Bakkanagari SR, Moorthi KM, *et al.* A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007;**45**:302-7.
- 1726 Otete EH, Ahankari AS, Jones H, *et al.* Parameters for the mathematical modelling of *Clostridium difficile* acquisition and transmission: a systematic review. *PloS one* 2013;**8**:e84224.
- 1827 Johnston BC, Ma SS, Goldenberg JZ, *et al.* Probiotics for the prevention of *Clostridium difficile*-associated diarrhea: a systematic review and meta-analysis. *Ann Intern Med* 2013;**157**:878-88.




Figure 1. Study populations for the analysis of patients with *Clostridium difficile* infection (CDI) and controls.

595x793mm (96 x 96 DPI)

TAKAHASHI et. al.

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls (b) For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how matching of cases and controls was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Other analyses	✓	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	✓8	Summarise key results with reference to study objectives
Limitations	✓19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	✓20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	✓21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	✓22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

TAKAHASHI et al.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	✓	Explain the scientific background and rationale for the investigation being reported
Objectives	✓	State specific objectives, including any prespecified hypotheses
Methods		
Study design	✓	Present key elements of study design early in the paper
Setting	✓	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	✓	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/measurement	✓	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Other analyses	✓17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	✓18	Summarise key results with reference to study objectives
Limitations	✓19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	✓20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	✓21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	✓22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Multi-institution Case-control and Cohort Study of Risk Factors for the Development and Mortality of Clostridium difficile Infections in Japan

Journal:	BMJ Open
Manuscript ID:	bmjopen-2014-005665.R2
Article Type:	Research
Date Submitted by the Author:	05-Aug-2014
Complete List of Authors:	Takahashi, Masahiko; NHO Tokyo Medical Center, Mori, Nobuaki; National Hospital Organization Tokyo Medical Center, General internal medicine Bito, Seiji; National Hospital Organization Tokyo Medical Center, General internal medicine
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Epidemiology
Keywords:	Gastrointestinal infections < GASTROENTEROLOGY, Epidemiology < INFECTIOUS DISEASES, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

11Title

22Multi-institution Case-control and Cohort Study of Risk Factors for the Development and Mortality of *Clostridium difficile*

33Infections in Japan

44

55Corresponding author

66Masahiko Takahashi

77Chief Director, Department of Gastroenterology

88National Hospital Organization Tokyo Medical Center

992-5-1 Higashigaoka, Meguro-Ku, Tokyo 152-8902, Japan

1010Phone number: +81-3-3411-0111

1111Fax number: +81-3-3412-9811

1212matakaha@ntmc.hosp.go.jp

1313Authors

1414Masahiko Takahashi ^{1*}, Nobuaki Mori ², Seiji Bito ³.

1515Author Affiliations

1616¹ Chief Director of Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo,

1717Japan

1818² Medical staff of Department of General internal medicine and Infectious diseases physician, National Hospital

1919Organization Tokyo Medical Center, Tokyo, Japan

2020³ Chief Director of Department of General internal medicine and epidemiologist, National Hospital Organization Tokyo

2121Medical Center, Tokyo, Japan

Abstract

Objective: To examine risk factors for *Clostridium difficile* infection (CDI) morbidity and mortality in Japan.

Design: Multi-method investigation including a case-control study and cohort study.

Setting: Forty-seven participating facilities of the National Hospital Organization (NHO).

Participants: One thousand twenty six CDI patients and 878 patients in control group over the age of 18 years admitted to the subject NHO facilities from November 2010 to October 2011.

Main Outcome Measures: In case-control study, we identify risk factors for CDI development. Next, in cohort study, we identify risk factors for all-cause mortality within 30 days following CDI onset.

Results: A total of 1,026 cases of CDI meeting the definitions of this investigation were identified, encompassing 878 patients at 42 of the 47 subject facilities. In the case-control study, we identified, compared with no antibiotics use, use of first- and second-generation cephem antibiotics (odds ratio[OR], 1.44; 95% confidence interval [CI], 1.10 to 1.87), use of third- and fourth-generation cephem antibiotics(OR, 1.86; 95%CI, 1.48 to 2.33), and use of carbapenem antibiotics (OR, 1.87; 95%CI, 1.44 to 2.42) were risk factors for CDI development. However, use of penicillin was not identified as risk factors. In the cohort study, sufficient data for analysis was available for 924 CDI cases; 102 of them (11.0%) resulted in death within 30 days of CDI onset. Compared with no anti-CDI drug use, use of vancomycin was associated with reduced risk of mortality (OR, 0.43; 95%CI, 0.25 to 0.75) whereas metronidazole was not.

Conclusions: The findings mirror those of previous studies from Europe and North America, identifying the administration of broad-spectrum antibiotics as a risk factor for CDI development. The use of vancomycin is associated with a decreased risk of mortality.

1 41
2
3 42
4 43
5
6 44
7
8 45
9 46
10 47
11 48
12 49
13 50
14 51
15 52
16 53
17
18
19
20
21 54
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This study is the first large-scale nationwide multi-center CDI investigation in Japan.
- Most of the epidemiological data of CDI has been limited in the North America and Europe. Our data plays a role of completion of the missing data in Asia.
- Use of β -lactam antibiotics except penicillin was the risk factor for CDI development in the first Japanese large-scale investigation. Appropriate antibiotic use is necessary in order to control the incidence of CDI.
- Vancomycin administration for CDI was associated with decreased risk of mortality. Although the cost-effective treatment of CDI may necessitate the appropriate use of less-expensive metronidazole, vancomycin should be administered in case expected to become severe or life-threatening.
- The limitation of this study is the low number of registered CDI cases from quite a few participants and the existence of many confounding factors.

Introduction

Clostridium difficile is the main causative pathogen of antibiotic-associated colitis. Since 2000, outbreaks of BI/NAP1/027 strain *C. difficile* infections (CDI) have been reported in North American and European hospitals and elder care facilities. The numbers of CDI patients as well as severe and intractable cases have increased simultaneously. Consequently, epidemiological surveillance systems have been set up in several countries. However, very few countries have implemented such national-level measures.

CDI epidemiological studies in Japan to date have been based on scattered data from individual medical facilities. Consequently, the phenomenon of CDI in Japan is not sufficiently understood.[1, 2, 3, 4, 5, 6, 7, 8, 9]

Previous studies report that antibiotic administration is the largest risk factor for CDI development. Other risk factors include advanced age and proton pump inhibitor use. [10, 11] CDI mortality rates differ depending on the presence or absence of an outbreak as well as the relevant definitions of epidemiological surveillance. Furthermore, it is especially difficult to objectively determine precise CDI-related mortality rates because of factors such as underlying patient conditions. [12]

This report documents a case-control study of CDI in Japan based on data from the National Hospital Organization (NHO), which is Japan's largest group of hospitals and includes facilities located nationwide. In addition, a cohort investigation of mortality among CDI cases was conducted.

Materials and Methods

Research Design

This multicenter study is a collaborative effort of the 47 facilities that met our facility standards from among the 143 NHO facilities in Japan. The study was planned as a part of the NHO's "National Hospital Organization Multi-Center Clinical Research for Evidence-Based Medicine" project. This study was conducted with the approval of the Central Ethics

76 Committee of the NHO. The CDI group in this study included in principal all newly diagnosed CDI cases among patients
77 hospitalized from November 1, 2010 to October 31, 2011; cases were registered continuously.

78 In the case-control study of CDI development, CDI cases newly diagnosed during the investigation period were
79 registered in the CDI group; meanwhile, age-, sex-, and underlying disease-matched patients in the same facilities were
80 registered to the control group. In addition, a prospective cohort study of CDI group patients who died within 30 days of
81 CDI development was conducted. This investigation is a multi-method study using standard case-control and cohort study
82 designs.

83 **Definition of CDI**

84 CDI was defined as the presence of any gastrointestinal symptoms accompanied by a clinical suspicion of CDI as well as
85 a positive result for *C. difficile* toxins from rapid stool testing or *C. difficile* isolation from stool cultures or both. Final
86 determinations were made by the attending physician or the facility's infection control team.

87 Enzyme immunoassay testing kits for *C. difficile* toxins A and B were used as the rapid testing method (Immunocard CD
88 toxin A&B, Meridian Bioscience Inc., Cincinnati, OH, USA; C. Diff Quik Chek, Alere Medical Co. Ltd., Tokyo, Japan; Tox
89 A/B Quik Chek, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan; X/pect Toxin A/B, Kanto Chemical Co Ltd., Tokyo, Japan).
90 Cycloserine-cefoxitin mannitol agar (Nissuipure-to CCMA baichi EX, Nissui Pharmaceutical Co. Ltd., Tokyo, Japan),
91 cycloserine-cefoxitin fructose agar (CCFA baichi, Becton, Dickinson and Company Co. Ltd., Tokyo, Japan; Poamedhia®
92 CCFA® kairyoubaichi, Eiken Chemical Co., Ltd., Tokyo, Japan), and brucella HK agar (RS) (brucella HK agar (RS),
93 Kyokuto Pharmaceutical Industrial Co. Ltd., Tokyo, Japan) were used in the *C. difficile* isolation cultures.

94 **Case-Control Study of CDI Development**

95 No additional information besides age, sex, and date of diagnosis was gathered when new patients were registered in the
96 CDI group. After the end of the study registration period, additional patient clinical data were gathered, including clinical

department, underlying diseases, dates of hospital admittance and discharge, and medical treatments administered for ≥ 3 days between admittance and CDI development. Recorded treatments included disruption of feeding, parenteral nutrition, enteral feeding, surgery with general anesthetic, cancer drugs, antibiotics (excluding external-use antibiotics), proton pump inhibitors (oral or intravenous). We also collected data regarding the use of intravenous antibiotics including penicillins, first- and second-generation cepheims, third- and fourth-generation cepheims, carbapenems, fluoroquinolones, clindamycin/lincomycin, anti-Methicillin-resistant *Staphylococcus aureus* (MRSA) drugs, and anti-fungal drugs, and others. Finally, we collected data regarding the use of oral antibiotics including cepheims, fluoroquinolones, and others.

The control group was divided into three subgroups according to age: ≤ 74 , 75–84, and ≥ 85 years. The control patients were selected from among patients at the same facilities who did not contract CDI and were matched to the CDI patients with respect to age, sex, underlying disease, and hospital stays of ≥ 5 days within the same month as a counterpart's CDI diagnosis. The control group cases were selected regardless of gastrointestinal symptoms such as diarrhea. We strove to ensure that the CDI and control groups were as matched as possible. The same data were collected from both groups. The control patients were registered, and relevant patient data were gathered after the end of the CDI group study registration period.

Cohort Study on Mortality among CDI Patients

The prospective cohort study of registered CDI group patients from the case-control study examined all-cause mortality within 30 days as the primary outcome. If the registered patients discharged within 30 days, clinical outcomes were not investigated after discharge in this study. The following data were collected: whether the underlying disease was infectious and whether comorbidities were related to malignant tumors (i.e., gastrointestinal, respiratory, blood/lymph, gynecologic, urological, or other tumors including cancers of the ear, nose, and throat), diabetes, renal failure, heart failure, respiratory failure, or cirrhosis. We also considered patient nutritional status including whether the patient was

1 118 subjected to parenteral nutrition or enteral feeding as well as serum albumin levels measured within 30 days prior to CDI
2
3
4 119 development (i.e., ≥ 3.5 , 2.7–3.4, or ≤ 2.6 g/dL). In addition, we examined CDI treatment factors including whether antibiotic
5
6
7 120 use was halted, probiotic use, and the type of anti-CDI drugs used (i.e., vancomycin and metronidazole). All patient data for
8
9
10 121 the cohort investigation were collected after the end of the registration period.

12 122 **Data Management and Statistical Analysis**

13
14
15 123 All input data were verified by a designated study data manager. Data from each facility were entered directly into a
16
17
18 124 web-based case report form and subsequently encrypted for security. The data management center was responsible for
19
20
21 125 confirming any missing data and directly inquiring the relevant facilities as necessary.

22
23
24 126 During the case-control phase of the study, CDI development was treated as the outcome and odds ratios (ORs) were
25
26
27 127 calculated from bivariate analysis comparing the use of different types of antibiotics as outcome causes. For each type of
28
29
30 128 antibiotic, those used for ≥ 3 days were designated “used” while all others were designated “unused.” A dummy variable
31
32
33 129 regression was subsequently performed. Statistical significance in the bivariate analysis was tested by the chi-square test.
34
35
36 130 Logistic regression analysis was performed using the individual patient characteristics and other assumed confounding
37
38
39 131 variables as independent variables. The 95% confidence intervals (CIs) for each variable were used to determine the
40
41
42 132 relationships between the various predictive variables and outcomes.

43
44 133 In cohort study, the definition of severe complications were gastrointestinal perforations, toxic megacolon, CDI-related
45
46
47 134 surgeries. Severe complications and the all-cause in-hospital mortality of patients within 30 days of CDI development were
48
49
50 135 recorded. The clinical outcome of mortality within 30 days was set as the dependent variable, and the relationships among
51
52
53 136 the underlying diseases, nutritional status, probiotic use, and types of anti-CDI drugs used were subjected to bivariate and
54
55
56 137 multivariate analyses. Like the case-control phase, bivariate analysis were conducted using the chi-square test, and the
57
58
59 138 multivariate analysis was conducted using logistic regression. The significance level for all analyses was set at $p < 0.05$. We
60

used IBM SPSS Statistics version 20 for statistical analysis.

Ethics Committee Approval and Informed Consent

This study was conducted with the approval of the Central Ethics Committee of the NHO. In principle, individual patients who met the inclusion criteria were not given direct explanations of the study, and no direct consent was sought. Information about the study was made public through postings on facility notice boards and webpages. Patients and their representative agents had the right to refuse study participation.

Results

Participating Facilities

Among the 47 facilities, a total of 1,026 CDI cases were registered at 42 facilities throughout Japan, from Hokkaido in the north to Okinawa in the south. No CDI cases were recorded at the remaining 5 participating facilities, more than 280 patient beds (Table 1).

152 Table 1. Number of registered cases of CDI and characteristics of hospitals included in the surveillance of
153 CDI in the NHO (from november 2010 through october 2011)

Region	No. patient beds	No. patient days	No. patients registered		30-day all-cause mortality in CDI group		Laboratory tests used	
			CDI group	Control group			EIA for toxins A and B	Culture
Hokkaido, tohoku	698	208,388	55	55	3 (5%)	+	+
	500	150,603	42	32	1 (2%)	+	+
	310	82,687	28	19	2 (7%)		+
	310	72,144	17	12	2 (12%)	+	+
	220	76,539	1	1	0 (0%)	+	+
Kanto, koshinetsu	780	238,420	124	121	15 (12%)	+	+
	455	151,622	36	36	3 (8%)	+	
	560	158,921	35	30	4 (11%)	+	+
	243	60,155	34	34	6 (18%)	+	+
	350	109,025	22	22	4 (18%)	+	+
	500	159,432	15	14	1 (7%)	+	
	510	166,668	4	4	0 (0%)	+	
	380	109,482	3	2	0 (0%)	+	+
	455	132,483	3	1	0 (0%)	+	
	429	104,802	0	0	— (—)	+	
Tokai, hokuriku	430	195,209	42	26	10 (24%)	+	+
	280	56,475	0	0	— (—)	+	
Kinki	316	103,677	24	22	1 (4%)	+	
	220	47,354	23	23	1 (4%)	+	+
	600	191,041	20	20	3 (15%)	+	
	494	70,455	15	15	6 (40%)	+	+
	520	145,299	13	9	1 (8%)	+	
	500	142,409	6	6	1 (17%)	+	
	180	55,721	3	3	1 (33%)	+	
	346	118,014	2	2	0 (0%)	+	
Chugoku, shikoku	370	94,722	0	0	— (—)	+	
	388	99,728	54	49	5 (9%)	+	+
	700	211,595	49	48	4 (8%)	+	+
	506	119,356	33	8	1 (3%)	+	+
	400	122,846	30	30	5 (17%)	+	
	401	108,303	26	0	2 (8%)	+	+
	250	80,558	21	21	0 (0%)	+	
	424	128,868	12	10	0 (0%)	+	
	365	125,645	10	10	3 (30%)	+	+
	300	87,061	0	0	— (—)		+
Kyushu, okinawa	459	66,454	0	0	— (—)	+	
	424	137,827	46	22	5 (11%)	+	
	702	239,448	38	37	1 (3%)	+	
	190	54,038	33	31	9 (27%)	+	
	550	189,417	27	26	3 (11%)	+	
	285	58,185	25	25	3 (12%)	+	
	500	140,371	24	23	2 (8%)	+	
	300	90,457	14	14	4 (29%)	+	
	320	103,315	6	5	1 (17%)	+	+
	280	79,580	4	4	2 (50%)	+	
	366	112,906	4	4	0 (0%)	+	
	368	89,195	3	2	2 (67%)	+	
Total	19,486	5,592,077	1,026	878	117 (11%)	45	20

Patient Grouping

A total of 1,026 CDI cases that met the study definitions were recorded at the various institutions. We were unable to collect clinical records regarding medical treatments for 1 case; therefore, this case was excluded from the case-control study, and the remaining 1,025 cases were analyzed. A total of 962 patients (93.9%) developed CDI within 48 hours after hospital admittance. The control group comprised 878 patients who were selected from 41 of the 42 facilities. In the cohort study, we analyzed the data from 924 of the 1,025 CDI group patients, excluding 101 patients with no available recent serum albumin level data (i.e., within 30 days prior to CDI development (Figure 1).

Case-Control Study of CDI Development

The mean ages of the CDI and control groups were 75.8 and 75.4 years, respectively. The majority of the subjects were of advanced age: 64.0% and 62.5% of the CDI and control group patients were aged ≥ 75 years, respectively. No significant differences were identified between the CDI and control groups in the univariate analysis of age distribution, sex differences, or underlying disease (Table 2). Among the medical treatments administered before CDI development, the following were significantly more prevalent in the CDI group than the control group: disruption of feeding (48.6% vs. 30.4%), parenteral nutrition (24.7% vs. 10.3%), and enteral feeding (24.8% vs. 9.1%). Antibiotics were used prior to CDI development in 85.8% of cases. The use of all types of intravenous antibiotics was significantly more prevalent in the CDI group. No significant differences were identified between the 2 groups with respect to oral antibiotic use. Meanwhile, in the univariate analysis, proton pump inhibitor use was significantly more prevalent in the CDI group than the control group (40.3% vs. 31.2%).

We used logistic regression analysis to determine the risk factors for CDI development. The following medical treatments prior to CDI development were identified as significant risk factors in comparison to the control group: disruption of feeding (odds ratio[OR], 1.31; 95% confidence interval[CI], 1.05 to 1.64), parenteral nutrition (OR, 1.63; 95%CI, 1.21 to

1 176 2.20) and enteral feeding (OR, 2.16; 95%CI, 1.60 to 2.92).The following intravenous antibiotics were also identified as
2
3
4 177 statistically significant risk factors for CDI development: first- and second-generation cepheems (OR, 1.44; 95%CI, 1.10 to
5
6
7 178 1.87), third- and fourth-generation cepheems (OR, 1.86; 95%CI, 1.48 to 2.33), and carbapenems (OR, 1.87; 95%CI, 1.44 to
8
9
10 179 2.42). However, penicillin (OR, 1.04; 95%CI, 0.82 to 1.33), fluoroquinolones (OR, 1.16; 95%CI, 0.74 to 1.83),
11
12
13 180 clindamycin/lincomycin (OR, 1.35; 95%CI, 0.81 to 2.26), and proton pump inhibitor use (OR, 1.17; 95%CI, 0.95 to 1.44)
14
15 181 were not identified as risk factors.
16
17
18 182

183 Table 2. Univariate and multivariate analyses of CDI development-related risk factors

Characteristics	CDI group	Control group	Univariate analysis	Multivariate analysis	
	%	%	P value	Odds ratio (95% CI)	P value
All	(1,025)	(878)	—	—	—
Age					
≤74 years	36.0 (369)	37.5 (329)	0.67	Ref.	—
75–84 years	37.0 (379)	37.2 (327)		1.02 (0.81 to 1.28)	0.88
≥85 years	27.0 (277)	25.3 (222)		1.09 (0.84 to 1.41)	0.52
Sex					
Women	43.0 (441)	42.6 (374)	0.85	1.11 (0.91 to 1.36)	0.28
Underlying disease					
Respiratory infections	15.8 (162)	17.5 (154)	0.14	—	—
Other infectious conditions	16.9 (173)	14.2 (125)		—	—
Gastrointestinal conditions	8.1 (83)	9.0 (79)		—	—
Malignant tumors	22.6 (232)	24.3 (213)		—	—
Cardiovascular conditions	7.7 (79)	9.8 (86)		—	—
Other conditions	28.9 (296)	25.2 (221)		—	—
Medical treatment prior to CDI development					
Disruption of feeding	48.6 (498)	30.4 (267)	<0.001	1.31 (1.05 to 1.64)	<0.05
Parenteral nutrition	24.7 (253)	10.3 (90)	<0.001	1.63 (1.21 to 2.20)	<0.01
Enteral feeding	24.8 (254)	9.1 (80)	<0.001	2.16 (1.60 to 2.92)	<0.001
Surgery with general anesthetic	18.2 (187)	15.6 (137)	0.14	0.89 (0.67 to 1.18)	0.41
Cancer drugs	11.3 (116)	14.2 (125)	0.06	0.86 (0.62 to 1.18)	0.35
Antibiotics use	85.8 (879)	66.5 (584)	<0.001	—	—
Intravenous					
Penicillins	27.6 (283)	21.0 (184)	<0.01	1.04 (0.82 to 1.33)	0.75
First/second-generation cepheims	22.7 (233)	15.6 (137)	<0.001	1.44 (1.10 to 1.87)	<0.01
Third/fourth-generation cepheims	35.2 (361)	19.9 (175)	<0.001	1.86 (1.48 to 2.33)	<0.001
Carbapenems	31.8 (326)	15.0 (132)	<0.001	1.87 (1.44 to 2.42)	<0.001
fluoroquinolones	7.5 (77)	4.0 (35)	<0.01	1.16 (0.74 to 1.83)	0.52
Clindamycin/lincomycin	6.5 (67)	2.8 (25)	<0.001	1.35 (0.81 to 2.26)	0.25
MRSA drugs	10.7 (110)	4.3 (38)	<0.001	1.10 (0.71 to 1.72)	0.66
Anti-fungal drugs	6.9 (71)	3.2 (28)	<0.001	1.01 (0.60 to 1.70)	0.96
Others(aminoglycosides, monobactam,etc.)	8.5 (87)	5.9 (52)	<0.05	1.19 (0.80 to 1.77)	0.39
Oral					
Cephems	5.6 (57)	4.4 (39)	0.29	1.49 (0.95 to 2.32)	0.08
fluoroquinolones	14.5 (149)	11.5 (101)	0.06	1.11 (0.82 to 1.51)	0.49
Others (macrolides, penicillins, etc.)	14.0 (144)	13.9 (122)	0.95	0.84 (0.63 to 1.13)	0.26
Proton pump inhibitors	40.3 (413)	31.2 (274)	<0.001	1.17 (0.95 to 1.44)	0.14

Cohort Study on Mortality among Patients with CDI

The cohort study examined mortality among the 924 patients from the 1,025 CDI group patients in the case-control study for whom serum albumin level data before CDI development were available.

Among the 924 patients, 102 (11.0%) died within 30 days of developing CDI. Among those cases, the cause of death was attributed to CDI in 11 cases (1.2%). Of 11 patients, a patient had gastrointestinal perforation, another patient had CDI-related surgery, and the others were not reported as severe complications. The toxic megacolon was reported in 2 patients however, they were not died within 30 days of CDI development. The mean age of the 102 patients who died during the study was 80.1 ± 8.3 years. Patients ≥ 75 years old were especially prevalent in this subgroup, accounting for 77.5% (79/102) of the cases.

Among the 714 cases in which CDI was treated directly, recurrence within 30 days was observed in 34 cases (4.8%).

The univariate analysis indicated that comorbidities of heart and respiratory failure were significantly more prevalent among CDI patients. In addition, lower serum albumin levels were significantly associated with mortality. Among CDI treatments, mortality was significantly lower among cases in which probiotics were administered.

A logistic regression analysis of the 102 cases in which the patients died within 30 days of CDI development was performed to identify the factors associated with the risk of mortality. Compared to patients ≤ 74 years old, the odds ratio of mortality among patients aged 75–84 years was 2.08 (95%CI, 1.19 to 3.62). Among underlying diseases, heart failure (OR, 2.12; 95%CI, 1.26 to 3.55) and respiratory failure (OR, 1.98; 95%CI, 1.19 to 3.32) were identified as risk factors for mortality within 30 days of CDI development. Regarding nutritional status, neither parenteral nutrition nor enteral nutrition was identified as a risk factor for mortality. However, low serum albumin level (i.e., ≤ 2.6 g/dL) was identified as a significant risk factor for mortality (OR, 3.50; 95%CI, 1.33 to 9.22). Among CDI treatments, probiotic use (OR, 0.66; 95%CI, 0.42 to 1.04) was not identified as a risk factor for mortality. However, compared to cases in which no anti-CDI drugs were administered, vancomycin administration yielded an odds ratio of 0.43 (95%CI, 0.25 to 0.75), indicating a

For peer review only

significantly lowered risk of mortality in the CDI group. Meanwhile, no such lowered mortality was observed in cases treated with metronidazole (OR, 0.85; 95%CI, 0.48 to 1.51).

211 Table 3. Univariate and multivariate analyses of all-cause mortality in CDI patients

Characteristics	All-cause mortality rate %	Univariate analysis P value	Multivariate analysis	
			Odds ratio (95% CI)	P value
All	11.0 (102/924)	—	—	—
Age				
≤74 years	7.1 (23/326)	<0.05	Ref.	
75–84 years	13.3 (47/353)		2.08 (1.19 to 3.62)	<0.05
≥85 years	13.1 (32/245)		1.86 (0.98 to 3.55)	0.06
Sex				
Men	12.2 (64/524)	0.21	Ref.	
Women	9.5 (38/400)		0.78 (0.49 to 1.24)	0.29
Underlying disease				
Non-infectious	10.3 (64/619)	0.37	Ref.	
Infectious	12.5 (38/305)		0.99 (0.60 to 1.62)	0.97
Comorbidities				
Malignant tumors				
Not present	10.6 (67/630)	0.57	Ref.	
Present	11.9 (35/294)		1.54 (0.94 to 2.53)	0.09
Diabetes				
Not present	11.6 (89/765)	0.27	Ref.	
Present	8.2 (13/159)		0.71 (0.37 to 1.35)	0.29
Renal failure				
Not present	10.7 (84/784)	0.46	Ref.	
Present	12.9 (18/140)		0.90 (0.49 to 1.65)	0.73
Heart failure				
Not present	9.3 (70/756)	<0.01	Ref.	
Present	19.0 (32/168)		2.12 (1.26 to 3.55)	<0.01
Respiratory failure				
Not present	9.2 (69/754)	<0.001	Ref.	
Present	19.4 (33/170)		1.98 (1.19 to 3.32)	<0.01
Cirrhosis				
Not present	11.2 (100/895)	0.76	Ref.	
Present	6.9 (2/29)		0.61 (0.13 to 2.83)	0.53
Indicators of nutritional status				
Parenteral nutrition or enteral feeding				
Not present	9.4 (53/563)	0.05	Ref.	
Present	13.6 (49/361)		1.16 (0.73 to 1.84)	0.53
Serum albumin (g/dL)				
≥3.5	4.0 (5/124)	<0.001	Ref.	
2.7–3.4	7.2 (27/376)		1.55 (0.57 to 4.21)	0.39
≤2.6	16.5 (70/424)		3.50 (1.33 to 9.22)	<0.05
CDI treatments				
Cessation of antibiotics				
Not present	12.5 (65/519)	0.11	Ref.	
Present	9.1 (37/405)		0.77 (0.48 to 1.22)	0.26
Probiotics (for intestine treatment)				
Not present	13.8 (52/378)	<0.05	Ref.	
Present	9.2 (50/546)		0.66 (0.42 to 1.04)	0.08
Anti-CDI drugs				
Not present	15.2 (32/210)	<0.05	Ref.	
Vancomycin alone	7.4 (32/433)		0.43 (0.25 to 0.75)	<0.01
Metronidazole alone	13.5 (32/237)		0.85 (0.48 to 1.51)	0.59
Vancomycin and metronidazole	13.6 (6/44)		0.75 (0.27 to 2.08)	0.57

Discussion

This is the first large-scale clinical study of CDI in Japan. This study examined 1,026 cases of CDI recorded over 1 year at the nationwide facilities of Japan's largest hospital group. The findings of this investigation are similar to those reported in previous studies conducted in Europe, North America, and Australia with respect to the identification of several risk factors for CDI development, including age, severity of the underlying condition, artificial feeding and mortality. Antibiotic use is a known risk factor for CDI development. [15] The present case-control study confirms that intravenous cepheems and carbapenems are important risk factors. Some studies report a low risk of CDI development owing to intravenous penicillin administration. [16, 17] Concordantly, penicillin use was not identified as a risk factor in the present study. The proton pump inhibitor use was discussed as a risk factor for CDI development in the previous studies. [18, 19, 20] In the present logistic regression analysis, it was not identified as a risk factor.

In this study, 11.0 % of CDI patients died within 30 days. In comparison, higher 30-day mortality rates have been reported in previous outbreaks: 24.8% in the ribotype 027 strain outbreak in Canada, and 36.7% in an examination of a single intensive care unit in the USA. [21, 22] However, reports of non-outbreak conditions indicate mortality rates of 13%, similar to the findings of the present study. [23] Some reports state that the CDI-associated mortality rate has increased 2.5 fold, possibly indicating that CDI cases are more severe and contribute more significantly to mortality than previously thought. [12, 23] The mortality rate of CDI patients is reported to increase with age. [24] Concordantly, the present study also found a significantly elevated risk of death in patients ≥ 75 years old.

The findings of this study indicate that the mortality risk of CDI patients was not reduced as a result of metronidazole treatment but was reduced with vancomycin treatment, corroborating the existing recommendation. [25] It is worth noting that metronidazole is less expensive than vancomycin, making it economically advantageous. a patient's condition must be carefully evaluated when selecting anti-CDI drugs. In particular, for patients in the present study who had conditions associated with a greater mortality risk, including advanced age (i.e., ≥ 75 years), heart or respiratory failure, or malnutrition

as determined by low serum albumin levels, the use of vancomycin was expected to reduce the mortality. The recurrence rate was low (4.8%) in this study compared to the previous studies. [11, 26] We did not investigate the patients neither after 30 days of CDI development nor the patients who discharge even if within 30 days of CDI development. Therefore, the recurrence rate might be underestimated.

Regardless, this study has also several methodological limitations. The most salient limitation is the low number of registered CDI cases from quite a few participants. In the definition of CDI, the times of diarrhea were not investigated. Another limitation of the case-control study phase is the existence of many confounding factors. In particular, probiotic use, which was recently discussed to be correlated with CDI prevention, was not included in the predictive model of this study. [10, 11, 27] When interpreting the findings of this study, it is necessary to consider the influence of confounding factors that were not included in the analytical models. Regarding antibiotic use, the present analyses included independent explanatory variables for each antibiotic. However, actual antibiotic use is more complicated. Therefore, it is difficult to clearly determine the roles of individual antibiotics as risk factors for CDI development. Concerning matching process, we tried to adopt 1 to 1 pair sampling matched with sex, age group and main diagnosis. Some hospital could not find appropriate control sample well matched with case sample. So total number of the control group was less than that of the case sample. In addition, although data for the control group were analyzed during the entire study period until hospital discharge, only data from the period prior to CDI development were analyzed in the CDI group. Therefore, the risks might be underestimated, because the control group had a longer period of exposure risk than the CDI group. Confounding factors that were not included in the present analyses also represent a limitation of the cohort study phase. Furthermore, issues of data quality among the facilities affect all aspects of this study. More than 40 different facilities participated in this study. While some facilities registered nearly all of their CDI patients, other facilities registered smaller proportions of patients. Only *C. difficile* culture but not toxin test was used for the laboratory test in two facilities.

Finally, there might have been differences with regard to individual researchers' understanding of the outcome definitions.

In order to ensure appropriate antibiotic use and control the incidence of CDI, it is important to create institutional measures such as infection control teams. The cost-effective treatment of CDI may necessitate the appropriate use of less-expensive metronidazole. However, in cases expected to become severe or life-threatening, the more expensive drug vancomycin should be administered. CDI is one of many issues concerning medicine and medical treatment costs. Accordingly, further and more proactive research into CDI epidemiology is needed.

Acknowledgements

The authors would like to express their sincere gratitude to Dr. Haru Kato and the Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan for their expert advice regarding CDI and the provision of CDI training to the participating facilities.

We also wish to thank the participating institutions in the CD-NHO study Group for their collaboration with data and sample collection: Hisaji Oshima (NHO Tokyo Medical Center); Hiroshi Miki (NHO Sendai Medical Center); Keisei Shimoe (NHO Fukuyama Medical Center); Harumi Tominaga (NHO Kure Medical Center); Toyomitsu Sawai and Eisuke Sasaki (NHO Ureshino Medical Center); Shie Nishijima and Naoko Maeda (NHO Shizuoka Medical Center); Masaru Amishima (NHO Hokkaido Medical Center); Miki Odawara (NHO Kyushu Medical Center); Mitsuhiro Kamimura (NHO National Disaster Medical Center); Hideaki Nagai (NHO Tokyo National Hospital); Kiyoshi Furuta (NHO Matsumoto Medical Center, Matsumoto Hospital); Tohru Yamanaka (NHO Kumamoto Minami Hospital); Ikuko Mizouchi (NHO Minimi-Okayama Medical Center); Yutaka Sato (NHO Kanmon Medical Center); Keita Ato and Hiroki Saito (NHO Asahikawa Medical Center); Yoshio Haga (NHO Kumamoto Medical Center); Isao Murakami (NHO Higashihiroshima Medical Center); Takeshi Yamaryo (NHO Nagasaki Kawatana Medical Center); Hiroyuki Akiyama and Yukino Yoshikura

1 277 (NHO Minami Wakayama Medical Center);Akiko Muratake (NHO Beppu Medical Center); Masato Hasegawa (NHO
2
3
4 278 Higashi-Ohmi General Medical Center); Isamu Kamimaki (NHO Saitama National Hospital); Tomoaki Kosyoubu (NHO
5
6
7 279 Yonago Medical Center); Takao Odagaki (NHO Kyoto Medical Center); Nozomu Iwashiro (NHO Hakodate National
8
9
10 280 Hospital); Hiroyasu Ishida (NHO Mito Medical Center); Hiroshi Komatsu (NHO Maizuru Medical Center); Kaoru Nakama
11
12
13 281 (NHO Oita Medical Center); Yoshiko Yamamoto (NHO Osaka Minami Medical Center); Yoshihito Iwahara (NHO Kochi
14
15
16 282 National Hospital); Fumiko Okino (NHO Yamaguchi-Ube Medical Center); Daisuke Higuchi (NHO Okinawa National
17
18
19 283 Hospital); Kazuhiro Satonaka (NHO Hyogo-Chuo National Hospital); Takayoshi Soga and Haruko Ideguchi (NHO
20
21
22 284 Yokohama Medical Center); Mayuko Watanabe (NHO Kagoshima Medical Center); Kozaburo Hiramatsu (NHO Nagasaki
23
24
25 285 National Hospital); Mitsugu Saito (NHO Awara National Hospital); Morio Sawamura (NHO Nishigunma National
26
27
28 286 Hospital); Satoru Kaneda (NHO Chiba Medical Center); Kenji Okada (NHO Fukuoka National Hospital); Katsuhiro Suzuki
29
30
31 287 (NHO Kinki-Chuo Chest Medical Center); Tetsuko Chiba and Keiji Chida (NHO Iwate National Hospital); Akihiko Tamura
32
33
34 288 (NHO Tochigi Medical Center); Shunji Matsuda (NHO Ehime Medical Center); Takaya Maruyama (NHO Mie National
35
36
37 289 Hospital); Shigeaki Kimura (NHO Tokushima National Hospital); Shin Oguri (NHO Minami Kyoto National Hospital)
38
39 290
40
41

42 291 **Contributors**

43
44 292 MT conceived the idea for the study, designed the study, developed the protocol, was responsible for study management
45
46
47 293 and data collection, interpreted the findings, and drafted the paper. NM contributed to data analysis and interpretation of
48
49
50 294 findings and drafted the paper. SB designed this study, developed the protocol, performed data analysis, and interpreted
51
52
53 295 findings. and drafted the paper. All authors read and approved the final manuscript.

54 296

55
56
57
58
59 297 **Funding**
60

This study was supported by a grant from the National Hospital Organization (multi-center clinical studies for evidenced-based medicine).

Competing interests

None.

Ethics approval

The Central Ethics Committee of the NHO.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data are available.

Contributorship Statement

All authors had full access to all of the data and can take responsibility for the integrity of the data and the accuracy of the data analysis. The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

1 318 **References**

2

3 319 1 Honda H, Yamazaki A, Sato Y, *et al.* Incidence and mortality associated with *Clostridium difficile*

4 320 infection at a Japanese tertiary care center. *Anaerobe* 2014;**25**:5-10.

5

6 321 2 Kato H, Ito Y, van den Berg RJ, *et al.* First isolation of *Clostridium difficile* 027 in Japan. *Euro Surveill*

7 322 2007;**12**:E070111 3.

8

9 323 3 Kato H, Kato N, Watanabe K, *et al.* Analysis of *Clostridium difficile* isolates from nosocomial outbreaks

10 324 at three hospitals in diverse areas of Japan. *J Clin Microbiol* 2001;**39**:1391-5.

11

12 325 4 Tagashira Y, Kato H, Senoh M, *et al.* Two cases of fulminant colitis due to binary toxin-positive

13 326 *Clostridium difficile* that are not PCR ribotype 027 or type 078. *J Med Microbiol* 2013;**62**:1486-9.

14

15 327 5 Sawabe E, Kato H, Osawa K, *et al.* Molecular analysis of *Clostridium difficile* at a university teaching

16 328 hospital in Japan: a shift in the predominant type over a five-year period. *Eur J Clin Microbiol Infect Dis*

17 329 2007;**26**:695-703.

18

19 330 6 Iwashima Y, Nakamura A, Kato H, *et al.* A retrospective study of the epidemiology of *Clostridium*

20 331 *difficile* infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics

21 332 of the patients. *J Infect Chemother* 2010;**16**:329-33.

22

23 333 7 Kato H, Ito Y, Akahane T, *et al.* Typing of *Clostridium difficile* isolates endemic in Japan by sequencing

24 334 of *slpA* and its application to direct typing. *J Med Microbiol* 2010;**59**:556-62.

25

26 335 8 Collins DA, Hawkey PM, Riley TV. Epidemiology of *Clostridium difficile* infection in Asia. *Antimicrob*

27 336 *Resist Infect Control* 2013;**2**:21.

28

29 337 9 Nakamura I, Yamaguchi T, Tsukimori A, *et al.* Fulminant colitis from *Clostridium difficile* infection, the

30 338 epidemic strain ribotype 027, in Japan. *J Infect Chemother* 2014;**20**:380-3.

31

32 339 10 Rupnik M, Wilcox MH, Gerding DN. *Clostridium difficile* infection: new developments in epidemiology

33 340 and pathogenesis. *Nat Rev Microbiol* 2009;**7**:526-36.

34

35 341 11 Cohen SH, Gerding DN, Johnson S, *et al.* Clinical practice guidelines for *Clostridium difficile* infection in

36 342 adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases

37 343 society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;**31**:431-55.

38

39 344 12 Mitchell BG, Gardner A. Mortality and *Clostridium difficile* infection: a review. *Antimicrob Resist Infect*

40 345 *Control* 2012;**1**:20.

41

42 346 13 Freeman J, Bauer MP, Baines SD, *et al.* The changing epidemiology of *Clostridium difficile* infections.

43 347 *Clin Microbiol Rev* 2010;**23**:529-49.

44

45 348 14 Bliss DZ, Johnson S, Savik K, *et al.* Acquisition of *Clostridium difficile* and *Clostridium*

46 349 *difficile*-associated diarrhea in hospitalized patients receiving tube feeding. *Ann Intern Med* 1998;**129**:1012-9.

47

48 350 15 Owens RC, Jr., Donskey CJ, Gaynes RP, *et al.* Antimicrobial-associated risk factors for *Clostridium*

49 351 *difficile* infection. *Clin Infect Dis* 2008;**46 Suppl 1**:S19-31.

50

51 352 16 Brown KA, Khanafer N, Daneman N, *et al.* Meta-analysis of antibiotics and the risk of

52 353 community-associated *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2013;**57**:2326-32.

53

54 354 17 Deshpande A, Pasupuleti V, Thota P, *et al.* Community-associated *Clostridium difficile* infection and

55 355 antibiotics: a meta-analysis. *J Antimicrob Chemother* 2013;**68**:1951-61.

56

57 356 18 Dial S, Delaney JA, Barkun AN, *et al.* Use of gastric acid-suppressive agents and the risk of

58 357 community-acquired *Clostridium difficile*-associated disease. *JAMA* 2005;**294**:2989-95.

59

60 358 19 Kwok CS, Arthur AK, Anibueze CI, *et al.* Risk of *Clostridium difficile* infection with acid suppressing

- drugs and antibiotics: meta-analysis. *Am J Gastroenterol* 2012;**107**:1011-9.
- 20 Tleyjeh IM, Bin Abdulhak AA, Riaz M, *et al*. Association between proton pump inhibitor therapy and *Clostridium difficile* infection: a contemporary systematic review and meta-analysis. *PLoS One* 2012;**7**:e50836.
- 21 Loo VG, Poirier L, Miller MA, *et al*. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005;**353**:2442-9.
- 22 Kenneally C, Rosini JM, Skrupky LP, *et al*. Analysis of 30-day mortality for *Clostridium difficile*-associated disease in the ICU setting. *Chest* 2007;**132**:418-24.
- 23 Hensgens MP, Goorhuis A, Dekkers OM, *et al*. All-cause and disease-specific mortality in hospitalized patients with *Clostridium difficile* infection: a multicenter cohort study. *Clin Infect Dis* 2013;**56**:1108-16.
- 24 Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in *Clostridium difficile* infection in the general hospital population: a systematic review. *J Hosp Infect* 2012;**82**:1-12.
- 25 Zar FA, Bakkanagari SR, Moorthi KM, *et al*. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007;**45**:302-7.
- 26 Otete EH, Ahankari AS, Jones H, *et al*. Parameters for the mathematical modelling of *Clostridium difficile* acquisition and transmission: a systematic review. *PloS one* 2013;**8**:e84224.
- 27 Johnston BC, Ma SS, Goldenberg JZ, *et al*. Probiotics for the prevention of *Clostridium difficile*-associated diarrhea: a systematic review and meta-analysis. *Ann Intern Med* 2013;**157**:878-88.

BMJ Open: first published as 10.1136/bmjopen-2014-005665 on 3 September 2014. Downloaded from <http://bmjopen.bmj.com/> on April 10, 2024 by guest. Protected by copyright.

1 **Title**

2

3

4 2 Multi-institution Case-control and Cohort Study of Risk Factors for the Development and Mortality of *Clostridium difficile*

5

6

7 3 Infections in Japan

8

9

10 4

11

12 5 **Corresponding author**

13

14

15 6 Masahiko Takahashi

16

17

18 7 Chief Director, Department of Gastroenterology

19

20

21 8 National Hospital Organization Tokyo Medical Center

22

23

24 9 2-5-1 Higashigaoka, Meguro-Ku, Tokyo 152-8902, Japan

25

26

27 10 Phone number: +81-3-3411-0111

28

29

30 11 Fax number: +81-3-3412-9811

31

32

33 12 matakaha@ntmc.hosp.go.jp

34

35

36 13 **Authors**

37

38

39 14 Masahiko Takahashi ^{1*}, Nobuaki Mori ², Seiji Bito ³.

40

41

42 15 **Author Affiliations**

43

44 16 ¹ Chief Director of Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo,

45

46

47 17 Japan

48

49

50 18 ² Medical staff of Department of General internal medicine and Infectious diseases physician, National Hospital

51

52

53 19 Organization Tokyo Medical Center, Tokyo, Japan

54

55

56 20 ³ Chief Director of Department of General internal medicine and epidemiologist, National Hospital Organization Tokyo

57

58

59 21 Medical Center, Tokyo, Japan

Abstract

Objective: To examine risk factors for *Clostridium difficile* infection (CDI) morbidity and mortality in Japan.

Design: Multi-method investigation including a case-control study and cohort study.

Setting: Forty-seven participating facilities of the National Hospital Organization (NHO).

Participants: One thousand twenty six CDI patients and 878 patients in control group over the age of 18 years admitted to the subject NHO facilities from November 2010 to October 2011.

Main Outcome Measures: In case-control study, we identify risk factors for CDI development. Next, in cohort study, we identify risk factors for all-cause mortality within 30 days following CDI onset.

Results: A total of 1,026 cases of CDI meeting the definitions of this investigation were identified, encompassing 878 patients at 42 of the 47 subject facilities. In the case-control study, we identified, compared with no antibiotics use, use of first- and second-generation cephem antibiotics (odds ratio[OR], 1.44; 95% confidence interval [CI], 1.10 to 1.87), use of third- and fourth-generation cephem antibiotics(OR, 1.86; 95%CI, 1.48 to 2.33), and use of carbapenem antibiotics (OR, 1.87; 95%CI, 1.44 to 2.42) were risk factors for CDI development. However, use of penicillin was not identified as risk factors. In the cohort study, sufficient data for analysis was available for 924 CDI cases; 102 of them (11.0%) resulted in death within 30 days of CDI onset. Compared with no anti-CDI drug use, use of vancomycin was associated with reduced risk of mortality (OR, 0.43; 95%CI, 0.25 to 0.75) whereas metronidazole was not.

Conclusions: The findings mirror those of previous studies from Europe and North America, identifying the administration of broad-spectrum antibiotics as a risk factor for CDI development. The use of vancomycin is associated with a decreased risk of mortality.

1 41
2
3 42
4 43
5
6 44
7
8 45
9 46
10 47
11 48
12 49
13 50
14 51
15 52
16 53
17
18
19
20
21 54
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This study is the first large-scale nationwide multi-center CDI investigation in Japan.
- Most of the epidemiological data of CDI has been limited in the North America and Europe. Our data plays a role of completion of the missing data in Asia.
- Use of β -lactam antibiotics except penicillin was the risk factor for CDI development in the first Japanese large-scale investigation. Appropriate antibiotic use is necessary in order to control the incidence of CDI.
- Vancomycin administration for CDI was associated with decreased risk of mortality. Although the cost-effective treatment of CDI may necessitate the appropriate use of less-expensive metronidazole, vancomycin should be administered in case expected to become severe or life-threatening.
- The limitation of this study is the low number of registered CDI cases from quite a few participants and the existence of many confounding factors.

Introduction

Clostridium difficile is the main causative pathogen of antibiotic-associated colitis. Since 2000, outbreaks of BI/NAP1/027 strain *C. difficile* infections (CDI) have been reported in North American and European hospitals and elder care facilities. The numbers of CDI patients as well as severe and intractable cases have increased simultaneously. Consequently, epidemiological surveillance systems have been set up in several countries. However, very few countries have implemented such national-level measures.

CDI epidemiological studies in Japan to date have been based on scattered data from individual medical facilities. Consequently, the phenomenon of CDI in Japan is not sufficiently understood, ~~including *C. difficile* typing~~. [1, 2, 3, 4, 5, 6, 7, 8, 9]

Previous studies report that antibiotic administration is the largest risk factor for CDI development. Other risk factors include advanced age and proton pump inhibitor use. [10, 11] CDI mortality rates differ depending on the presence or absence of an outbreak as well as the relevant definitions of epidemiological surveillance. Furthermore, it is especially difficult to objectively determine precise CDI-related mortality rates because of factors such as underlying patient conditions. [12]

This report documents a case-control study of CDI in Japan based on data from the National Hospital Organization (NHO), which is Japan's largest group of hospitals and includes facilities located nationwide. In addition, a cohort investigation of mortality among CDI cases was conducted.

Materials and Methods

Research Design

This multicenter study is a collaborative effort of the 47 facilities that met our facility standards from among the 143 NHO facilities in Japan. The study was planned as a part of the NHO's "National Hospital Organization Multi-Center

1 76 Clinical Research for Evidence-Based Medicine” project. This study was conducted with the approval of the Central Ethics
2
3
4 77 Committee of the NHO. The CDI group in this study included in principal all newly diagnosed CDI cases among patients
5
6
7 78 hospitalized from November 1, 2010 to October 31, 2011; cases were registered continuously.
8

9
10 79 In the case-control study of CDI development, CDI cases newly diagnosed during the investigation period were
11
12
13 80 registered in the CDI group; meanwhile, age-, sex-, and underlying disease-matched patients in the same facilities were
14
15
16 81 registered to the control group. In addition, a prospective cohort study of CDI group patients who died within 30 days of
17
18
19 82 CDI development was conducted. This investigation is a multi-method study using standard case-control and cohort study
20
21
22 83 designs.
23

24 84 **Definition of CDI**

25
26
27 85 CDI was defined as the presence of any gastrointestinal symptoms accompanied by a clinical suspicion of CDI as well as
28
29
30 86 a positive result for *C. difficile* toxins from rapid stool testing or *C. difficile* isolation from stool cultures or both. Final
31
32
33 87 determinations were made by the attending physician or the facility’s infection control team.
34

35
36 88 Enzyme immunoassay testing kits for *C. difficile* toxins A and B were used as the rapid testing method (Immunocard CD
37
38
39 89 toxin A&B, Meridian Bioscience Inc., Cincinnati, OH, USA; C. Diff Quik Chek, Alere Medical Co. Ltd., Tokyo, Japan; Tox
40
41
42 90 A/B Quik Chek, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan; X/pect Toxin A/B, Kanto Chemical Co Ltd., Tokyo, Japan).
43
44
45 91 Cycloserine-cefoxitin mannitol agar (Nissui-pure-to CCMA baichi EX, Nissui Pharmaceutical Co. Ltd., Tokyo, Japan),
46
47
48 92 cycloserine-cefoxitin fructose agar (CCFA baichi, Becton, Dickinson and Company Co. Ltd., Tokyo, Japan; Poamedhia®
49
50
51 93 CCFA® kairyoubaiichi, Eiken Chemical Co., Ltd., Tokyo, Japan), and brucella HK agar (RS) (brucella HK agar (RS),
52
53
54 94 Kyokuto Pharmaceutical Industrial Co. Ltd., Tokyo, Japan) were used in the *C. difficile* isolation cultures.
55

56 95 **Case-Control Study of CDI Development**

57
58
59 96 No additional information besides age, sex, and date of diagnosis was gathered when new patients were registered in the
60

CDI group. After the end of the study registration period, additional patient clinical data were gathered, including clinical department, underlying diseases, dates of hospital admittance and discharge, and medical treatments administered for ≥ 3 days between admittance and CDI development. Recorded treatments included disruption of feeding, parenteral nutrition, enteral feeding, surgery with general anesthetic, cancer drugs, antibiotics (excluding external-use antibiotics), proton pump inhibitors (oral or intravenous). We also collected data regarding the use of intravenous antibiotics including penicillins, first- and second-generation cepheems, third- and fourth-generation cepheems, carbapenems, fluoroquinolones, clindamycin/lincomycin, anti-Methicillin-resistant *Staphylococcus aureus* (MRSA) drugs, and anti-fungal drugs, and others. Finally, we collected data regarding the use of oral antibiotics including cepheems, fluoroquinolones, and others.

The control group was divided into three subgroups according to age: ≤ 74 , 75–84, and ≥ 85 years. The control patients were selected from among patients at the same facilities who did not contract CDI and were matched to the CDI patients with respect to age, sex, underlying disease, and hospital stays of ≥ 5 days within the same month as a counterpart's CDI diagnosis. The control group cases were selected regardless of gastrointestinal symptoms such as diarrhea. We strove to ensure that the CDI and control groups were as matched as possible. The same data were collected from both groups. The control patients were registered, and relevant patient data were gathered after the end of the CDI group study registration period.

Cohort Study on Mortality among CDI Patients

The prospective cohort study of registered CDI group patients from the case-control study examined all-cause mortality within 30 days as the primary outcome. ~~Clinical outcomes of patients who discharged within 30 days of CDI development were not investigated in this study.~~ If the registered patients discharged within 30 days, ~~clinical outcomes were not investigated after discharge in this study.~~ The following data were collected: whether the underlying disease was infectious and whether comorbidities were related to malignant tumors (i.e., gastrointestinal,

1 118 respiratory, blood/lymph, gynecologic, urological, or other tumors including cancers of the ear, nose, and throat), diabetes,
2
3
4 119 renal failure, heart failure, respiratory failure, or cirrhosis. We also considered patient nutritional status including whether
5
6
7 120 the patient was subjected to parenteral nutrition or enteral feeding as well as serum albumin levels measured within 30 days
8
9
10 121 prior to CDI development (i.e., ≥ 3.5 , 2.7–3.4, or ≤ 2.6 g/dL). In addition, we examined CDI treatment factors including
11
12
13 122 whether antibiotic use was halted, probiotic use, and the type of anti-CDI drugs used (i.e., vancomycin and metronidazole).
14
15
16 123 All patient data for the cohort investigation were collected after the end of the registration period.

17
18 124 **Data Management and Statistical Analysis**

19
20
21 125 All input data were verified by a designated study data manager. Data from each facility were entered directly into a
22
23
24 126 web-based case report form and subsequently encrypted for security. The data management center was responsible for
25
26
27 127 confirming any missing data and directly inquiring the relevant facilities as necessary.

28
29
30 128 During the case-control phase of the study, CDI development was treated as the outcome and odds ratios (ORs) were
31
32
33 129 calculated from bivariate analysis comparing the use of different types of antibiotics as outcome causes. For each type of
34
35
36 130 antibiotic, those used for ≥ 3 days were designated “used” while all others were designated “unused.” A dummy variable
37
38
39 131 regression was subsequently performed. Statistical significance in the bivariate analysis was tested by the chi-square test.
40
41
42 132 Logistic regression analysis was performed using the individual patient characteristics and other assumed confounding
43
44
45 133 variables as independent variables. The 95% confidence intervals (CIs) for each variable were used to determine the
46
47
48 134 relationships between the various predictive variables and outcomes.

49
50 135 ~~In the cohort study, gastrointestinal perforations, toxic megacolon, CDI-related surgeries, and the all-cause in-hospital~~
51
52
53 136 ~~mortality of patients within 30 days of CDI development were recorded.~~ In cohort study, the definition of severe
54
55
56 137 complications were gastrointestinal perforations, toxic megacolon, CDI-related surgeries. Severe complications and the
57
58
59 138 all-cause in-hospital mortality of patients within 30 days of CDI development were recorded. The clinical outcome of

mortality within 30 days was set as the dependent variable, and the relationships among the underlying diseases, nutritional status, probiotic use, and types of anti-CDI drugs used were subjected to bivariate and multivariate analyses. Like the case-control phase, bivariate analysis were conducted using the chi-square test, and the multivariate analysis was conducted using logistic regression. The significance level for all analyses was set at $p < 0.05$. We used IBM SPSS Statistics version 20 for statistical analysis.

Ethics Committee Approval and Informed Consent

This study was conducted with the approval of the Central Ethics Committee of the NHO. In principle, individual patients who met the inclusion criteria were not given direct explanations of the study, and no direct consent was sought. Information about the study was made public through postings on facility notice boards and webpages. Patients and their representative agents had the right to refuse study participation.

Results

Participating Facilities

Among the 47 facilities, a total of 1,026 CDI cases were registered at 42 facilities throughout Japan, from Hokkaido in the north to Okinawa in the south. No CDI cases were recorded at the remaining 5 participating facilities, more than 280 patient beds (Table 1).

156 Table 1. Number of registered cases of CDI and characteristics of hospitals included in the surveillance of
157 CDI in the NHO (from november 2010 through october 2011)

Region	No. patient beds	No. patient days	No. patients registered		30-day all-cause mortality in CDI group		Laboratory tests used	
			CDI group	Control group			EIA for toxins A and B	Culture
Hokkaido, tohoku	698	208,388	55	55	3 (5%)		+	+
	500	150,603	42	32	1 (2%)		+	+
	310	82,687	28	19	2 (7%)			+
	310	72,144	17	12	2 (12%)		+	+
	220	76,539	1	1	0 (0%)		+	+
Kanto, koshinetsu	780	238,420	124	121	15 (12%)		+	+
	455	151,622	36	36	3 (8%)		+	
	560	158,921	35	30	4 (11%)		+	+
	243	60,155	34	34	6 (18%)		+	+
	350	109,025	22	22	4 (18%)		+	+
	500	159,432	15	14	1 (7%)		+	
	510	166,668	4	4	0 (0%)		+	
	380	109,482	3	2	0 (0%)		+	+
	455	132,483	3	1	0 (0%)		+	
	429	104,802	0	0	— (—)		+	
Tokai, hokuriku	430	195,209	42	26	10 (24%)		+	+
	280	56,475	0	0	— (—)		+	
Kinki	316	103,677	24	22	1 (4%)		+	
	220	47,354	23	23	1 (4%)		+	+
	600	191,041	20	20	3 (15%)		+	
	494	70,455	15	15	6 (40%)		+	+
	520	145,299	13	9	1 (8%)		+	
	500	142,409	6	6	1 (17%)		+	
	180	55,721	3	3	1 (33%)		+	
	346	118,014	2	2	0 (0%)		+	
Chugoku, shikoku	370	94,722	0	0	— (—)		+	
	388	99,728	54	49	5 (9%)		+	+
	700	211,595	49	48	4 (8%)		+	+
	506	119,356	33	8	1 (3%)		+	+
	400	122,846	30	30	5 (17%)		+	
	401	108,303	26	0	2 (8%)		+	+
	250	80,558	21	21	0 (0%)		+	
	424	128,868	12	10	0 (0%)		+	
	365	125,645	10	10	3 (30%)		+	+
	300	87,061	0	0	— (—)			+
Kyushu, okinawa	459	66,454	0	0	— (—)		+	
	424	137,827	46	22	5 (11%)		+	
	702	239,448	38	37	1 (3%)		+	
	190	54,038	33	31	9 (27%)		+	
	550	189,417	27	26	3 (11%)		+	
	285	58,185	25	25	3 (12%)		+	
	500	140,371	24	23	2 (8%)		+	
	300	90,457	14	14	4 (29%)		+	
	320	103,315	6	5	1 (17%)		+	+
	280	79,580	4	4	2 (50%)		+	
Total	366	112,906	4	4	0 (0%)		+	
	368	89,195	3	2	2 (67%)		+	
Total	19,486	5,592,077	1,026	878	117 (11%)		45	20

Patient Grouping

A total of 1,026 CDI cases that met the study definitions were recorded at the various institutions. We were unable to collect clinical records regarding medical treatments for 1 case; therefore, this case was excluded from the case-control study, and the remaining 1,025 cases were analyzed. A total of 962 patients (93.9%) developed CDI within 48 hours after hospital admittance. The control group comprised 878 patients who were selected from 41 of the 42 facilities. In the cohort study, we analyzed the data from 924 of the 1,025 CDI group patients, excluding 101 patients with no available recent serum albumin level data (i.e., within 30 days prior to CDI development (Figure 1).

Case-Control Study of CDI Development

The mean ages of the CDI and control groups were 75.8 and 75.4 years, respectively. The majority of the subjects were of advanced age: 64.0% and 62.5% of the CDI and control group patients were aged ≥ 75 years, respectively. No significant differences were identified between the CDI and control groups in the univariate analysis of age distribution, sex differences, or underlying disease (Table 2). Among the medical treatments administered before CDI development, the following were significantly more prevalent in the CDI group than the control group: disruption of feeding (48.6% vs. 30.4%), parenteral nutrition (24.7% vs. 10.3%), and enteral feeding (24.8% vs. 9.1%). Antibiotics were used prior to CDI development in 85.8% of cases. The use of all types of intravenous antibiotics was significantly more prevalent in the CDI group. No significant differences were identified between the 2 groups with respect to oral antibiotic use. Meanwhile, in the univariate analysis, proton pump inhibitor use was significantly more prevalent in the CDI group than the control group (40.3% vs. 31.2%).

We used logistic regression analysis to determine the risk factors for CDI development. The following medical treatments prior to CDI development were identified as significant risk factors in comparison to the control group: disruption of feeding (odds ratio[OR], 1.31; 95% confidence interval[CI], 1.05 to 1.64), parenteral nutrition (OR, 1.63; 95%CI, 1.21 to

1 180 2.20) and enteral feeding (OR, 2.16; 95%CI, 1.60 to 2.92).The following intravenous antibiotics were also identified as
2
3
4 181 statistically significant risk factors for CDI development: first- and second-generation cepheems (OR, 1.44; 95%CI, 1.10 to
5
6
7 182 1.87), third- and fourth-generation cepheems (OR, 1.86; 95%CI, 1.48 to 2.33), and carbapenems (OR, 1.87; 95%CI, 1.44 to
8
9
10 183 2.42). However, penicillin (OR, 1.04; 95%CI, 0.82 to 1.33), fluoroquinolones (OR, 1.16; 95%CI, 0.74 to 1.83),
11
12
13 184 clindamycin/lincomycin (OR, 1.35; 95%CI, 0.81 to 2.26), and proton pump inhibitor use (OR, 1.17; 95%CI, 0.95 to 1.44)
14
15 185 were not identified as risk factors.
16
17
18 186

187 Table 2. Univariate and multivariate analyses of CDI development-related risk factors

Characteristics	CDI group	Control group	Univariate analysis	Multivariate analysis	
	%	%	P value	Odds ratio (95% CI)	P value
All	(1,025)	(878)	—	—	—
Age					
≤74 years	36.0 (369)	37.5 (329)	0.67	Ref.	—
75–84 years	37.0 (379)	37.2 (327)		1.02 (0.81 to 1.28)	0.88
≥85 years	27.0 (277)	25.3 (222)		1.09 (0.84 to 1.41)	0.52
Sex					
Women	43.0 (441)	42.6 (374)	0.85	1.11 (0.91 to 1.36)	0.28
Underlying disease					
Respiratory infections	15.8 (162)	17.5 (154)	0.14	—	—
Other infectious conditions	16.9 (173)	14.2 (125)		—	—
Gastrointestinal conditions	8.1 (83)	9.0 (79)		—	—
Malignant tumors	22.6 (232)	24.3 (213)		—	—
Cardiovascular conditions	7.7 (79)	9.8 (86)		—	—
Other conditions	28.9 (296)	25.2 (221)		—	—
Medical treatment prior to CDI development					
Disruption of feeding	48.6 (498)	30.4 (267)	<0.001	1.31 (1.05 to 1.64)	<0.05
Parenteral nutrition	24.7 (253)	10.3 (90)	<0.001	1.63 (1.21 to 2.20)	<0.01
Enteral feeding	24.8 (254)	9.1 (80)	<0.001	2.16 (1.60 to 2.92)	<0.001
Surgery with general anesthetic	18.2 (187)	15.6 (137)	0.14	0.89 (0.67 to 1.18)	0.41
Cancer drugs	11.3 (116)	14.2 (125)	0.06	0.86 (0.62 to 1.18)	0.35
Antibiotics use	85.8 (879)	66.5 (584)	<0.001	—	—
Intravenous					
Penicillins	27.6 (283)	21.0 (184)	<0.01	1.04 (0.82 to 1.33)	0.75
First/second-generation cepheims	22.7 (233)	15.6 (137)	<0.001	1.44 (1.10 to 1.87)	<0.01
Third/fourth-generation cepheims	35.2 (361)	19.9 (175)	<0.001	1.86 (1.48 to 2.33)	<0.001
Carbapenems	31.8 (326)	15.0 (132)	<0.001	1.87 (1.44 to 2.42)	<0.001
fluoroquinolones	7.5 (77)	4.0 (35)	<0.01	1.16 (0.74 to 1.83)	0.52
Clindamycin/lincomycin	6.5 (67)	2.8 (25)	<0.001	1.35 (0.81 to 2.26)	0.25
MRSA drugs	10.7 (110)	4.3 (38)	<0.001	1.10 (0.71 to 1.72)	0.66
Anti-fungal drugs	6.9 (71)	3.2 (28)	<0.001	1.01 (0.60 to 1.70)	0.96
Others(aminoglycosides, monobactam,etc.)	8.5 (87)	5.9 (52)	<0.05	1.19 (0.80 to 1.77)	0.39
Oral					
Cephems	5.6 (57)	4.4 (39)	0.29	1.49 (0.95 to 2.32)	0.08
fluoroquinolones	14.5 (149)	11.5 (101)	0.06	1.11 (0.82 to 1.51)	0.49
Others (macrolides, penicillins, etc.)	14.0 (144)	13.9 (122)	0.95	0.84 (0.63 to 1.13)	0.26
Proton pump inhibitors	40.3 (413)	31.2 (274)	<0.001	1.17 (0.95 to 1.44)	0.14

Cohort Study on Mortality among Patients with CDI

The cohort study examined mortality among the 924 patients from the 1,025 CDI group patients in the case-control study for whom serum albumin level data before CDI development were available.

Among the 924 patients, 102 (11.0%) died within 30 days of developing CDI. Among those cases, the cause of death was attributed to CDI in 11 cases (1.2%). Of 11 patients, a patient had gastrointestinal perforation, another patient had CDI-related surgery, and the others were not reported as severe complications. The toxic megacolon was reported in 2 patients however, they were not died within 30 days of CDI development. The mean age of the 102 patients who died during the study was 80.1 ± 8.3 years. Patients ≥ 75 years old were especially prevalent in this subgroup, accounting for 77.5% (79/102) of the cases.

Among the 714 cases in which CDI was treated directly, recurrence within 30 days was observed in 34 cases (4.8%).

The univariate analysis indicated that comorbidities of heart and respiratory failure were significantly more prevalent among CDI patients. In addition, lower serum albumin levels were significantly associated with mortality. Among CDI treatments, mortality was significantly lower among cases in which probiotics were administered.

A logistic regression analysis of the 102 cases in which the patients died within 30 days of CDI development was performed to identify the factors associated with the risk of mortality. Compared to patients ≤ 74 years old, the odds ratio of mortality among patients aged 75–84 years was 2.08 (95%CI, 1.19 to 3.62). Among underlying diseases, heart failure (OR, 2.12; 95%CI, 1.26 to 3.55) and respiratory failure (OR, 1.98; 95%CI, 1.19 to 3.32) were identified as risk factors for mortality within 30 days of CDI development. Regarding nutritional status, neither parenteral nutrition nor enteral nutrition was identified as a risk factor for mortality. However, low serum albumin level (i.e., ≤ 2.6 g/dL) was identified as a significant risk factor for mortality (OR, 3.50; 95%CI, 1.33 to 9.22). Among CDI treatments, probiotic use (OR, 0.66; 95%CI, 0.42 to 1.04) was not identified as a risk factor for mortality. However, compared to cases in which no anti-CDI drugs were administered, vancomycin administration yielded an odds ratio of 0.43 (95%CI, 0.25 to 0.75), indicating a

significantly lowered risk of mortality in the CDI group. Meanwhile, no such lowered mortality was observed in cases treated with metronidazole (OR, 0.85; 95%CI, 0.48 to 1.51).

For peer review only

215 Table 3. Univariate and multivariate analyses of all-cause mortality in CDI patients

Characteristics	All-cause mortality rate %	Univariate analysis P value	Multivariate analysis	
			Odds ratio (95% CI)	P value
All	11.0 (102/924)	—	—	—
Age				
≤74 years	7.1 (23/326)	<0.05	Ref.	
75–84 years	13.3 (47/353)		2.08 (1.19 to 3.62)	<0.05
≥85 years	13.1 (32/245)		1.86 (0.98 to 3.55)	0.06
Sex				
Men	12.2 (64/524)	0.21	Ref.	
Women	9.5 (38/400)		0.78 (0.49 to 1.24)	0.29
Underlying disease				
Non-infectious	10.3 (64/619)	0.37	Ref.	
Infectious	12.5 (38/305)		0.99 (0.60 to 1.62)	0.97
Comorbidities				
Malignant tumors				
Not present	10.6 (67/630)	0.57	Ref.	
Present	11.9 (35/294)		1.54 (0.94 to 2.53)	0.09
Diabetes				
Not present	11.6 (89/765)	0.27	Ref.	
Present	8.2 (13/159)		0.71 (0.37 to 1.35)	0.29
Renal failure				
Not present	10.7 (84/784)	0.46	Ref.	
Present	12.9 (18/140)		0.90 (0.49 to 1.65)	0.73
Heart failure				
Not present	9.3 (70/756)	<0.01	Ref.	
Present	19.0 (32/168)		2.12 (1.26 to 3.55)	<0.01
Respiratory failure				
Not present	9.2 (69/754)	<0.001	Ref.	
Present	19.4 (33/170)		1.98 (1.19 to 3.32)	<0.01
Cirrhosis				
Not present	11.2 (100/895)	0.76	Ref.	
Present	6.9 (2/29)		0.61 (0.13 to 2.83)	0.53
Indicators of nutritional status				
Parenteral nutrition or enteral feeding				
Not present	9.4 (53/563)	0.05	Ref.	
Present	13.6 (49/361)		1.16 (0.73 to 1.84)	0.53
Serum albumin (g/dL)				
≥3.5	4.0 (5/124)	<0.001	Ref.	
2.7–3.4	7.2 (27/376)		1.55 (0.57 to 4.21)	0.39
≤2.6	16.5 (70/424)		3.50 (1.33 to 9.22)	<0.05
CDI treatments				
Cessation of antibiotics				
Not present	12.5 (65/519)	0.11	Ref.	
Present	9.1 (37/405)		0.77 (0.48 to 1.22)	0.26
Probiotics (for intestine treatment)				
Not present	13.8 (52/378)	<0.05	Ref.	
Present	9.2 (50/546)		0.66 (0.42 to 1.04)	0.08
Anti-CDI drugs				
Not present	15.2 (32/210)	<0.05	Ref.	
Vancomycin alone	7.4 (32/433)		0.43 (0.25 to 0.75)	<0.01
Metronidazole alone	13.5 (32/237)		0.85 (0.48 to 1.51)	0.59
Vancomycin and metronidazole	13.6 (6/44)		0.75 (0.27 to 2.08)	0.57

Discussion

This is the first large-scale clinical study of CDI in Japan. This study examined 1,026 cases of CDI recorded over 1 year at the nationwide facilities of Japan's largest hospital group. The findings of this investigation are similar to those reported in previous studies conducted in Europe, North America, and Australia with respect to the identification of several risk factors for CDI development, including age, severity of the underlying condition, artificial feeding and mortality. Antibiotic use is a known risk factor for CDI development. [15] The present case-control study confirms that intravenous cepheems and carbapenems are important risk factors. Some studies report a low risk of CDI development owing to intravenous penicillin administration. [16, 17] Concordantly, penicillin use was not identified as a risk factor in the present study. The proton pump inhibitor use was discussed as a risk factor for CDI development in the previous studies. [18, 19, 20] In the present logistic regression analysis, it was not identified as a risk factor.

In this study, 11.0 % of CDI patients died within 30 days. In comparison, higher 30-day mortality rates have been reported in previous outbreaks: 24.8% in the ribotype 027 strain outbreak in Canada, and 36.7% in an examination of a single intensive care unit in the USA. [21, 22] However, reports of non-outbreak conditions indicate mortality rates of 13%, similar to the findings of the present study. [23] Some reports state that the CDI-associated mortality rate has increased 2.5 fold, possibly indicating that CDI cases are more severe and contribute more significantly to mortality than previously thought. [12, 23] The mortality rate of CDI patients is reported to increase with age. [24] Concordantly, the present study also found a significantly elevated risk of death in patients ≥ 75 years old.

The findings of this study indicate that the mortality risk of CDI patients was not reduced as a result of metronidazole treatment but was reduced with vancomycin treatment, corroborating the existing recommendation. [25] It is worth noting that metronidazole is less expensive than vancomycin, making it economically advantageous. a patient's condition must be carefully evaluated when selecting anti-CDI drugs. In particular, for patients in the present study who had conditions associated with a greater mortality risk, including advanced age (i.e., ≥ 75 years), heart or respiratory failure, or malnutrition

1 239 as determined by low serum albumin levels, ~~the use of vancomycin rather than metronidazole for treatment appears to have~~
2
3
4 240 ~~provided better outcomes.~~ the use of vancomycin was expected to reduce the mortality. The recurrence rate was low
5
6
7 241 (4.8%) in this study compared to the previous studies. [11, 26] We did not investigate the patients neither after
8
9
10 242 30 days of CDI development nor the patients who discharge even if within 30 days of CDI development. Therefore,
11
12
13 243 the recurrence rate might be underestimated.
14
15 244 Regardless, this study has also several methodological limitations. The most salient limitation is the low number of
16
17
18 245 registered CDI cases from quite a few participants. In the definition of CDI, the times of diarrhea were not investigated.
19
20
21 246 Another limitation of the case-control study phase is the existence of many confounding factors. In particular, probiotic use,
22
23
24 247 which was recently discussed to be correlated with CDI prevention, was not included in the predictive model of this study.
25
26
27 248 [10, 11, 27] When interpreting the findings of this study, it is necessary to consider the influence of confounding factors that
28
29
30 249 were not included in the analytical models. Regarding antibiotic use, the present analyses included independent explanatory
31
32
33 250 variables for each antibiotic. However, actual antibiotic use is more complicated. Therefore, it is difficult to clearly
34
35
36 251 determine the roles of individual antibiotics as risk factors for CDI development. Concerning matching process, we
37
38
39 252 tried to adopt 1 to 1 pair sampling matched with sex, age group and main diagnosis. Some hospital could not
40
41
42 253 find appropriate control sample well matched with case sample. So total number of the control group was
43
44
45 254 less than that of the case sample. In addition, although data for the control group were analyzed during the entire study
46
47
48 255 period until hospital discharge, only data from the period prior to CDI development were analyzed in the CDI group.
49
50
51 256 Therefore, the risks might be underestimated, because the control group had a longer period of exposure risk than the CDI
52
53
54 257 group. Confounding factors that were not included in the present analyses also represent a limitation of the cohort study
55
56
57 258 phase. Furthermore, issues of data quality among the facilities affect all aspects of this study. More than 40 different
58
59 259 facilities participated in this study. While some facilities registered nearly all of their CDI patients, other facilities registered

smaller proportions of patients. Only *C. difficile* culture but not toxin test was used for the laboratory test in two facilities.

Finally, there might have been differences with regard to individual researchers' understanding of the outcome definitions.

In order to ensure appropriate antibiotic use and control the incidence of CDI, it is important to create institutional measures such as infection control teams. The cost-effective treatment of CDI may necessitate the appropriate use of less-expensive metronidazole. However, in cases expected to become severe or life-threatening, the more expensive drug vancomycin should be administered. CDI is one of many issues concerning medicine and medical treatment costs. Accordingly, further and more proactive research into CDI epidemiology is needed.

Acknowledgements

The authors would like to express their sincere gratitude to Dr. Haru Kato and the Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan for their expert advice regarding CDI and the provision of CDI training to the participating facilities.

We also wish to thank the participating institutions in the CD-NHO study Group for their collaboration with data and sample collection: Hisaji Oshima (NHO Tokyo Medical Center); Hiroshi Miki (NHO Sendai Medical Center); Keisei Shimoe (NHO Fukuyama Medical Center); Harumi Tominaga (NHO Kure Medical Center); Toyomitsu Sawai and Eisuke Sasaki (NHO Ureshino Medical Center); Shie Nishijima and Naoko Maeda (NHO Shizuoka Medical Center); Masaru Amishima (NHO Hokkaido Medical Center); Miki Odawara (NHO Kyushu Medical Center); Mitsuhiro Kamimura (NHO National Disaster Medical Center); Hideaki Nagai (NHO Tokyo National Hospital); Kiyoshi Furuta (NHO Matsumoto Medical Center, Matsumoto Hospital); Tohru Yamanaka (NHO Kumamoto Minami Hospital); Ikuko Mizouchi (NHO Minimi-Okayama Medical Center); Yutaka Sato (NHO Kanmon Medical Center); Keita Ato and Hiroki Saito (NHO Asahikawa Medical Center); Yoshio Haga (NHO Kumamoto Medical Center); Isao Murakami (NHO Higashihiroshima

1 281 Medical Center); Takeshi Yamyaro (NHO Nagasaki Kawatana Medical Center); Hiroyuki Akiyama and Yukino Yoshikura
2
3
4 282 (NHO Minami Wakayama Medical Center);Akiko Muratake (NHO Beppu Medical Center); Masato Hasegawa (NHO
5
6
7 283 Higashi-Ohmi General Medical Center); Isamu Kamimaki (NHO Saitama National Hospital); Tomoaki Kosyoubu (NHO
8
9
10 284 Yonago Medical Center); Takao Odagaki (NHO Kyoto Medical Center); Nozomu Iwashiro (NHO Hakodate National
11
12
13 285 Hospital); Hiroyasu Ishida (NHO Mito Medical Center); Hiroshi Komatsu (NHO Maizuru Medical Center); Kaoru Nakama
14
15 286 (NHO Oita Medical Center); Yoshiko Yamamoto (NHO Osaka Minami Medical Center); Yoshihito Iwahara (NHO Kochi
16
17
18 287 National Hospital); Fumiko Okino (NHO Yamaguchi-Ube Medical Center); Daisuke Higuchi (NHO Okinawa National
19
20
21 288 Hospital); Kazuhiro Satonaka (NHO Hyogo-Chuo National Hospital); Takayoshi Soga and Haruko Ideguchi (NHO
22
23
24 289 Yokohama Medical Center); Mayuko Watanabe (NHO Kagoshima Medical Center); Kozaburo Hiramatsu (NHO Nagasaki
25
26
27 290 National Hospital); Mitsugu Saito (NHO Awara National Hospital); Morio Sawamura (NHO Nishigunma National
28
29
30 291 Hospital); Satoru Kaneda (NHO Chiba Medical Center); Kenji Okada (NHO Fukuoka National Hospital); Katsuhiro Suzuki
31
32
33 292 (NHO Kinki-Chuo Chest Medical Center); Tetsuko Chiba and Keiji Chida (NHO Iwate National Hospital); Akihiko Tamura
34
35
36 293 (NHO Tochigi Medical Center); Shunji Matsuda (NHO Ehime Medical Center); Takaya Maruyama (NHO Mie National
37
38
39 294 Hospital); Shigeaki Kimura (NHO Tokushima National Hospital); Shin Oguri (NHO Minami Kyoto National Hospital)
40
41
42 295
43

44 296 **Contributors**

45
46
47 297 MT conceived the idea for the study, designed the study, developed the protocol, was responsible for study management
48
49
50 298 and data collection, interpreted the findings, and drafted the paper. NM contributed to data analysis and interpretation of
51
52
53 299 findings and drafted the paper. SB designed this study, developed the protocol, performed data analysis, and interpreted
54
55
56 300 findings. and drafted the paper. All authors read and approved the final manuscript.
57
58
59 301
60

Funding

This study was supported by a grant from the National Hospital Organization (multi-center clinical studies for evidenced-based medicine).

Competing interests

None.

Ethics approval

The Central Ethics Committee of the NHO.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data are available.

Contributorship Statement

All authors had full access to all of the data and can take responsibility for the integrity of the data and the accuracy of the data analysis. The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

References

1 Honda H, Yamazaki A, Sato Y, *et al.* Incidence and mortality associated with *Clostridium difficile* infection at a Japanese tertiary care center. *Anaerobe* 2014;**25**:5-10.

2 Kato H, Ito Y, van den Berg RJ, *et al.* First isolation of *Clostridium difficile* 027 in Japan. *Euro Surveill* 2007;**12**:E070111 3.

3 Kato H, Kato N, Watanabe K, *et al.* Analysis of *Clostridium difficile* isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan. *J Clin Microbiol* 2001;**39**:1391-5.

4 Tagashira Y, Kato H, Senoh M, *et al.* Two cases of fulminant colitis due to binary toxin-positive *Clostridium difficile* that are not PCR ribotype 027 or type 078. *J Med Microbiol* 2013;**62**:1486-9.

5 Sawabe E, Kato H, Osawa K, *et al.* Molecular analysis of *Clostridium difficile* at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. *Eur J Clin Microbiol Infect Dis* 2007;**26**:695-703.

6 Iwashima Y, Nakamura A, Kato H, *et al.* A retrospective study of the epidemiology of *Clostridium difficile* infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. *J Infect Chemother* 2010;**16**:329-33.

7 Kato H, Ito Y, Akahane T, *et al.* Typing of *Clostridium difficile* isolates endemic in Japan by sequencing of *slpA* and its application to direct typing. *J Med Microbiol* 2010;**59**:556-62.

8 Collins DA, Hawkey PM, Riley TV. Epidemiology of *Clostridium difficile* infection in Asia. *Antimicrob Resist Infect Control* 2013;**2**:21.

9 Nakamura I, Yamaguchi T, Tsukimori A, *et al.* Fulminant colitis from *Clostridium difficile* infection, the epidemic strain ribotype 027, in Japan. *J Infect Chemother* 2014;**20**:380-3.

10 Rupnik M, Wilcox MH, Gerding DN. *Clostridium difficile* infection: new developments in epidemiology and pathogenesis. *Nat Rev Microbiol* 2009;**7**:526-36.

11 Cohen SH, Gerding DN, Johnson S, *et al.* Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;**31**:431-55.

12 Mitchell BG, Gardner A. Mortality and *Clostridium difficile* infection: a review. *Antimicrob Resist Infect Control* 2012;**1**:20.

13 Freeman J, Bauer MP, Baines SD, *et al.* The changing epidemiology of *Clostridium difficile* infections. *Clin Microbiol Rev* 2010;**23**:529-49.

14 Bliss DZ, Johnson S, Savik K, *et al.* Acquisition of *Clostridium difficile* and *Clostridium difficile*-associated diarrhea in hospitalized patients receiving tube feeding. *Ann Intern Med* 1998;**129**:1012-9.

15 Owens RC, Jr., Donskey CJ, Gaynes RP, *et al.* Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clin Infect Dis* 2008;**46 Suppl 1**:S19-31.

16 Brown KA, Khanafer N, Daneman N, *et al.* Meta-analysis of antibiotics and the risk of community-associated *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2013;**57**:2326-32.

17 Deshpande A, Pasupuleti V, Thota P, *et al.* Community-associated *Clostridium difficile* infection and antibiotics: a meta-analysis. *J Antimicrob Chemother* 2013;**68**:1951-61.

18 Dial S, Delaney JA, Barkun AN, *et al.* Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA* 2005;**294**:2989-95.

19 Kwok CS, Arthur AK, Anibueze CI, *et al.* Risk of *Clostridium difficile* infection with acid suppressing

- drugs and antibiotics: meta-analysis. *Am J Gastroenterol* 2012;**107**:1011-9.
- 20 Tleyjeh IM, Bin Abdulhak AA, Riaz M, *et al.* Association between proton pump inhibitor therapy and *Clostridium difficile* infection: a contemporary systematic review and meta-analysis. *PLoS One* 2012;**7**:e50836.
- 21 Loo VG, Poirier L, Miller MA, *et al.* A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005;**353**:2442-9.
- 22 Kenneally C, Rosini JM, Skrupky LP, *et al.* Analysis of 30-day mortality for *Clostridium difficile*-associated disease in the ICU setting. *Chest* 2007;**132**:418-24.
- 23 Hensgens MP, Goorhuis A, Dekkers OM, *et al.* All-cause and disease-specific mortality in hospitalized patients with *Clostridium difficile* infection: a multicenter cohort study. *Clin Infect Dis* 2013;**56**:1108-16.
- 24 Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in *Clostridium difficile* infection in the general hospital population: a systematic review. *J Hosp Infect* 2012;**82**:1-12.
- 25 Zar FA, Bakkanagari SR, Moorthi KM, *et al.* A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007;**45**:302-7.
- 26 Otete EH, Ahankari AS, Jones H, *et al.* Parameters for the mathematical modelling of *Clostridium difficile* acquisition and transmission: a systematic review. *PloS one* 2013;**8**:e84224.
- 27 Johnston BC, Ma SS, Goldenberg JZ, *et al.* Probiotics for the prevention of *Clostridium difficile*-associated diarrhea: a systematic review and meta-analysis. *Ann Intern Med* 2013;**157**:878-88.




Figure 1. Study populations for the analysis of patients with *Clostridium difficile* infection (CDI) and controls.

90x119mm (300 x 300 DPI)

TAKAHASHI et. al.

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls (b) For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how matching of cases and controls was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Other analyses	✓	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	✓8	Summarise key results with reference to study objectives
Limitations	✓19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	✓20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	✓21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	✓22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

TAKAHASHI et al.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	✓	Explain the scientific background and rationale for the investigation being reported
Objectives	✓	State specific objectives, including any prespecified hypotheses
Methods		
Study design	✓	Present key elements of study design early in the paper
Setting	✓	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	✓	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	✓	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	✓	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Other analyses	✓17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	✓18	Summarise key results with reference to study objectives
Limitations	✓19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	✓20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	✓21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	✓22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.